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A B S T R A C T
Background
The glycaemic index (GI) is a physiological measure of the ability of a carbohydrate to affect blood glucose. Interest is growing in this
area for the clinical management of people at risk of, or with, established cardiovascular disease. There is a need to review the current
evidence from randomised controlled trials (RCTs) in this area. This is an update of the original review published in 2008.
Objectives
To assess the effect of the dietary GI on total mortality, cardiovascular events, and cardiovascular risk factors (blood lipids, blood
pressure) in healthy people or people who have established cardiovascular disease or related risk factors, using all eligible randomised
controlled trials.
Search methods
We searched CENTRAL, MEDLINE, Embase and CINAHL in July 2016. We also checked reference lists of relevant articles. No
language restrictions were applied.
Selection criteria
We selectedRCTs that assessed the effects of lowGI diets compared to diets with a similar composition but a higher GI on cardiovascular
disease and related risk factors. Minimum trial duration was 12 weeks. Participants included were healthy adults or those at increased risk
of cardiovascular disease, or previously diagnosed with cardiovascular disease. Studies in people with diabetes mellitus were excluded.
Data collection and analysis
Two reviewers independently screened and selected studies. Two review authors independently assessed risk of bias, evaluated the overall
quality of the evidence using GRADE, and extracted data following the Cochrane Handbook for Systematic Reviews of Interventions. We
contacted trial authors for additional information. Analyses were checked by a second reviewer. Continuous outcomes were synthesized
using mean differences and adverse events were synthesized narratively.
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Main results
Twenty-one RCTs were included, with a total of 2538 participants randomised to low GI intervention (1288) or high GI (1250). All 21
included studies reported the effect of low GI diets on risk factors for cardiovascular disease, including blood lipids and blood pressure.
Twenty RCTs (18 of which were newly included in this version of the review) included primary prevention populations (healthy
individuals or those at high risk of CVD, with mean age range from 19 to 69 years) and one RCT was in those diagnosed with pre-
existing CVD (a secondary prevention population, with mean age 26.9 years). Most of the studies did not have an intervention duration
of longer than six months. Difference in GI intake between comparison groups varied widely from 0.6 to 42.
None of the included studies reported the effect of low GI dietary intake on cardiovascular mortality and cardiovascular events such
as fatal and nonfatal myocardial infarction, unstable angina, coronary artery bypass graft surgery, percutaneous transluminal coronary
angioplasty, and stroke. The unclear risk of bias of most of the included studies makes overall interpretation of the data difficult. Only
two of the included studies (38 participants) reported on adverse effects and did not observe any harms (low-quality evidence).
Authors’ conclusions
There is currently no evidence available regarding the effect of low GI diets on cardiovascular disease events. Moreover, there is currently
no convincing evidence that low GI diets have a clear beneficial effect on blood lipids or blood pressure parameters.
P L A I N L A N G U A G E S U M M A R Y
Low glycaemic index diets for cardiovascular disease
Background
The glycaemic index (GI) is a measure of the ability of a carbohydrate (for example sugar or starch) to affect blood sugar levels.
Study characteristics
In this review update, we examined 21 randomised studies that assessed the effects of low GI diets compared to diets with a similar
composition but a higher GI on cardiovascular disease events and levels of cholesterol in the blood or blood pressure (major risk factors
for cardiovascular disease, such as heart attacks or stroke). Studies were included up to July 2016.
Results
Participants were adults with a mean age of between 19 and 69 years. In most studies, participants had cardiovascular risk factors such
as overweight or obesity or abnormal blood fat levels, and one study included participants with existing heart disease. The diets were
followed for at least 12 weeks but most studies had unclear of bias and some of the compared diets only had small differences in GI.
Cardiovascular disease events were not reported and no evidence of differences in effects of the diets on blood cholesterol and blood
pressure were seen. Most studies did not report harms but the two that did found no harmful effects of the diets, however the evidence
was poor.
Conclusions
There was insufficient evidence from randomised controlled trials to recommend consumption of low GI diets for the purpose of
improving blood lipids or blood pressure.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Low GI versus high GI for the primary prevention of cardiovascular disease
Patient or population: Overweight or obese adults
Settings: Unclear and research centre
Intervention: Low GI
Control: High GI
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
High GI Low GI
Total and cardiovascu-
lar mortality
See comment See comment See comment See comment See comment No trials reported total
and CVD mortality for
the primary prevent ion
of CVD
Fatal and nonfatal my-
ocardial infarction
See comment See comment See comment See comment See comment No trials reported fa-
tal and nonfatal myocar-
dial infarct ion for the pri-
mary prevent ion of CVD
Unstable angina See comment See comment See comment See comment See comment No trials reported unsta-
ble angina for the pri-
mary prevent ion of CVD
Coronary artery bypass
graft surgery
See comment See comment See comment See comment See comment No trials reported coro-
nary artery bypass graf t
surgery for the primary
prevent ion of CVD
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Percutaneous translu-
minal coronary angio-
plasty
See comment See comment See comment See comment See comment No trials reported per-
cutaneous transluminal
coronary angioplasty for
the primary prevent ion
of CVD
Stroke See comment See comment See comment See comment See comment No trials reported stroke
for the primary preven-
t ion of CVD
Adverse events
Measurement unclear
Follow-up: 6 months
No adverse events No adverse events - 38
(2 studies)
⊕⊕©©
lowa
See Appendix 2 adverse
events checklist for the
primary prevent ion of
CVD
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
a Downgraded by one level because of serious risk of bias and one level for serious imprecision (see Appendix 2)
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B A C K G R O U N D
This was an update of the original review published in 2004 (Kelly
2004).
Description of the condition
Cardiovascular diseases (CVD) are a group of conditions that af-
fect the heart and blood vessels and include coronary heart dis-
ease, cerebrovascular disease, andperipheral arterial disease (WHO
2013). One of the main mechanisms thought to cause CVD is
atherosclerosis, where the arteries become clogged by atheromas
or plaques (NHS 2012). CVD occurs when the arteries are com-
pletely blocked or when blood flow is restricted by a narrowed
artery, limiting the amount of blood and oxygen delivered to or-
gans or tissue (BHF 2014). Arteries may naturally become harder
and narrower with age, although this process may be accelerated
by such factors as a sedentary lifestyle, obesity, diet, diabetes, eth-
nicity, smoking, high cholesterol, and high blood pressure (NHS
2012). Another cause of CVD is unstable plaque rupturing. It is
thought that unstable plaques activate an inflammatory response
in the body that causes the structure of atherosclerotic plaque
to weaken and rupture, leading to the formation of blood clots
(Spagnoli 2007).
CVD is the number one cause of death and disability (WHO
2013) globally. Around 30% of total global deaths can be at-
tributed to CVD (WHO 2013), and it is estimated to cause 17
million deaths per year (Bovet 2012). The World Health Orga-
nization (WHO) reports that by 2030, CVDs will account for
almost 23.3 million deaths per year (WHO 2013). This burden
is set to increase as a consequence of ageing populations and in-
creasing levels of sedentary lifestyles, and obesity.
One key public health priority in the prevention of CVD is tar-
geting modifiable risk factors. One such risk factor is diet, which
plays a major role in the aetiology of many chronic conditions,
including CVD. A number of dietary factors are thought to lower
CVD risk, such as a low sodium intake (Aburto 2013), a low-car-
bohydrate diet (Hu 2014), intake of whole grains (Ye 2012), and a
high consumption of fruits and vegetables (Oude 2010). Such risk
factors are important, not only because they have been linked to
CVD development, but also because they can be modified, which
makes them one of the main targets for interventions aimed at
primary prevention and management of CVD.
Description of the intervention
An association between cardiovascular disease and dietary fat in-
take is well-documented (e.g. Vafeiadou 2012) but the role of di-
etary carbohydrate in cardiovascular disease is not. There is increas-
ing evidence from observational nonrandomised studies that the
glycaemic index (GI) of dietary carbohydrates may be important
in disease prevention and control (Brand-Miller 2002; Frost 2000;
Leeds 2002; Rizkalla 2002). A 2008 meta-analysis of 37 prospec-
tive cohort studies (Barclay 2008) investigating the association be-
tween GI and chronic diseases (including diabetes, colorectal can-
cer, cardiovascular disease, and eye diseases) found a positive asso-
ciation between GI and chronic disease (relative risk for coronary
heart disease 1.25, 95%CI 1.00 to 1.56; relative risk for all diseases
combined 1.14, 95%CI 1.09 to 1.19). TheWorldHealth Organ-
isation (WHO) recommended in 1997 that dietary carbohydrates
be classified according to their GI and that the methodology for
assessing the GI should be standardised (FAO/WHO 1997). In
2007, theWHOpublished a scientific update on carbohydrates in
nutrition, where it was acknowledged that the GI can be a useful
means to choose carbohydrate food, but that this should always
be considered in the context of other nutritional indicators and
should not be based solely on the basis of the GI (FAO/WHO
2007a; FAO/WHO 2007b).
The concept of GI was first proposed in 1981 (Jenkins 1981). The
GI of a dietary carbohydrate is an assessment of its postprandial
effect on blood glucose. The lower the GI, the smaller the effect
of the carbohydrate on postprandial glucose levels. The GI classi-
fication is a standardised comparison of the 2-hour postprandial
glucose response to 50g of a carbohydrate with that of 50g of white
bread or glucose, calculated from the area under the glucose re-
sponse curve. The GI of white bread and of glucose is 100 and all
other carbohydrate foods have a GI between 0 and 100. The GI of
a carbohydrate depends on its rate of intestinal absorption, which
can be influenced by its composition and ease of digestion (Frost
2000). Low GI carbohydrates have lower 2-hour areas under the
glucose curve than white bread.
Cooking and food preparation canmodify theGI of foods. Highly
processed convenience foods tend to have a highGI. Cooked pulse
vegetables (legumes, e.g. lentils, peas, kidney beans) have a low GI
as their cell walls are resistant to cooking. The intact cereal grains
of rye and granary bread all have low GIs. However, when granary
bread is processed to wholemeal bread, the grains are disrupted,
resulting in a higher GI. Some examples of GI of common carbo-
hydrate foods are given in Table 1 (Frost 2000).
In 1995, the first international tables of GI of individual foods
were published (Foster-Powell 1995) and updated in 2002 (Foster-
Powell 2002) and 2008 (Atkinson 2008), and the methodology
on their derivation has also been reported (Jenkins 1981; Wolever
1990). TheGI of amixedmeal can be calculated from the different
proportions of each of the carbohydrate-containing foods and their
individualGI values. For example, whenbread andbeans aremixed
in equal quantities, the resulting glycaemic response is midway
between that of bread alone and beans alone (Wolever 1985;
Wolever 1986). The addition of fat to a mixed meal reduces the
glycaemic response (Bornet 1987; Coulston 1987;Wolever 1988),
but the relative response of one carbohydrate to another remains.
Another measure often used is the glycaemic load which puts the
GI in relation to the total amount of carbohydrate actually con-
sumed. The glycaemic load of a food is calculated as the carbo-
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hydrate content (g) multiplied by the GI value of the food and
divided by 100 (Ebbeling 2003). So for example, a watermelon
is a high GI food but has a low glycaemic load for the amount
typically consumed.
How the intervention might work
Lower GI foods cause lower peaks and fewer fluctuations in post-
prandial blood glucose levels than foods with high GI values. In-
creases in fasting and postprandial glucose concentrations pro-
mote oxidative stress, inflammation and endothelial dysfunction
thereby predisposing to cardiovascular disease and type 2 diabetes
(Blaak 2012). Type 2 diabetes is also associated with increased car-
diovascular risk and there is a suggestion that low GI foods may
play a role in the prevention of type 2 diabetes and also improve the
blood glucose control in people with type 2 diabetes (Du 2006).
Abnormal levels of serum lipids also represent a risk factor for
cardiovascular disease and two cross-sectional studies found a sig-
nificant negative correlation between dietary GI and high density
lipoprotein (HDL) cholesterol concentrations (Ford 2001; Frost
1999). Two systematic reviews also suggested that low glycaemic
index diets can significantly lower total and low density lipopro-
tein (LDL) cholesterol levels (Fleming 2013; Goff 2013). Obesity
is also a risk factor for cardiovascular disease. Diets based on low
GI foods produced greater weight loss in overweight or obese pop-
ulations than did diets based on high GI foods (Thomas 2007).
One hypothesis is that low GI diets lead to increased satiety and
decreased sensations of hunger, thus leading to a lower energy in-
take. However, results from studies were inconsistent. While some
short-term studies reported a reduction in satiety with low GI di-
ets, this did not lead to a long term reduction in energy intake
(Bornet 2007; Niwano 2009).
Why it is important to do this review
Three recent meta-analyses summarised the effects of GI and gly-
caemic load on coronary heart disease or cardiovascular events or
both (Dong 2012; Ma 2012; Mirrahimi 2012). The studies sum-
marised between eight and 14 prospective cohort studies (large
overlap between reviews) involving between 229,213 and 240,936
participants. Cohorts were followed for six to 25 years and the
dietary GI and glycaemic load were largely assessed using food fre-
quency questionnaires. GI and glycaemic load levels were divided
into categories and cardiovascular events compared between the
highest and the lowest categories. Mirrahimi 2012 reported di-
etary composition in their review of ten studies and both carbohy-
drate and fibre content tended to be higher in the higher glycaemic
load categories. All three reviews agreed that the evidence showed
that women in the highest GI and glycaemic load categories had
a significantly higher risk of cardiovascular or coronary heart dis-
ease (or both) events than women in the lowest categories, but
this effect was not shown for men. Dong 2012 also found that the
unfavourable effects of high GI or glycaemic load may be more
pronounced in overweight and obese participants.
As described, recent meta-analyses examining GI and CVD events
included only prospective cohort studies. There is evidence that
high GI diets may contribute to a greater risk of CVD. There ap-
pears to be suggestive evidence of benefit of low GI diets on CVD
risk factors (Augustin 2015); however, evidence has largely been
from observational studies which may be prone to confounding
and other biases. We undertook this systematic review to exam-
ine evidence on the effects of GI on CVD from randomised con-
trolled trials. An update was necessary to include newly published
relevant RCTs and to distinguish the review from other relevant
Cochrane reviews.
O B J E C T I V E S
To assess the effect of the dietary GI on total mortality, cardiovas-
cular events, and cardiovascular risk factors (blood lipids, blood
pressure) in healthy people or people who have established cardio-
vascular disease or related risk factors, using all eligible randomised
controlled trials.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled studies (RCTs). Cross-over trials were eli-
gible but only the first half was used before cross-over took place,
treating it as a parallel group design. Minimum study duration
was 12 weeks.
Types of participants
Free-living adults (age≥18 years) were eligible for inclusion if they
were healthy, had established cardiovascular disease, or one ormore
of the following risk factors: abnormal blood lipid levels (high and
low density lipoprotein (HDL, LDL) cholesterol, triglycerides and
total cholesterol), raised blood pressure/hypertension, overweight
(body mass index (BMI) > 25 kg/m2), or obesity (BMI > 30 kg/
m2).
A separate Cochrane review is concerned with the effects of lowGI
diets in people with diabetes mellitus (Thomas 2009) and another
Cochrane review has focused on low GI diets in overweight and
obesity (Thomas 2007). Hence, we excluded studies in people
with type 2 diabetes and studies which only focused on weight
loss if they did not also measure other cardiovascular risk factors.
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Types of interventions
Interventions were eligible if they were advice on diet or dietary
carbohydrate or a prescribed diet. Diets with a lower GI had to
be compared with a diet with a higher GI and the GI of the diets
had to be reported. Compared diets had to have similar overall
energy levels and levels of carbohydrate, fat, and protein. Studies
manipulating any other components of the diet were included if
this was similar for the low and high GI groups.
Types of outcome measures
Primary outcomes
1. Total and cardiovascular mortality
2. Cardiovascular events (e.g. fatal and nonfatal myocardial
infarction, unstable angina, coronary artery bypass graft surgery,
percutaneous transluminal coronary angioplasty, stroke)
3. Adverse events (e.g. bloating, nausea, weight gain, difficulty
in eating out)
Secondary outcomes
1. Blood lipid levels (total cholesterol, HDL cholesterol, LDL
cholesterol, triglycerides) (mmol/L)
2. Systolic and diastolic blood pressure (mmHg)
3. Quality of life (using validated instruments)
4. Attitudes to diets, satisfaction, appetite, satiety, or similar
(as reported by the studies, using validated instruments)
Weight (Kg) and BMI (Kg/m2) were recorded as additional poten-
tially effect-modifying parameters. Studies had to report at least
one of the outcomes of interest to be eligible for inclusion.
Search methods for identification of studies
Electronic searches
For this update, the searches from the previously published review
(Kelly 2004) were updated (to adjust for the broadened inclusion
criteria) and re-run on 31 July 2016. Searches were conducted in
the Cochrane Central Register of Controlled Trials (CENTRAL,
Issue 7 of 12, 2016) in the Cochrane Library, MEDLINE (Ovid,
1946 to 31 July 2016) and Embase Classic and Embase (Ovid,
1947 to 30 July 2016) and CINAHL (EBSCO, 1937 to 31 July
2016).
See Appendix 1 for details of search strategies. The sensitivity-max-
imising version of the Cochrane RCT filter (Lefebvre 2011) was
applied toMEDLINE and adaptations of it to the other databases,
except CENTRAL. No language restrictions were applied.
Searching other resources
The reference lists of all relevant studies were checked. Relevant
published reviews were also sought as a source of RCTs. We con-
tacted authors of potentially relevant publications for further stud-
ies.
Data collection and analysis
Selection of studies
The titles and abstracts of retrieved records were scanned inde-
pendently by two reviewers (CC, NF, LH, SK, LA-K) and were
only rejected if the reviewer could determine that they definitely
did not meet the inclusion criteria. Full texts were obtained for
any that could not be rejected with certainty. Each paper was then
assessed independently by two reviewers (CC, RG, SK, LA-K). An
in/out form was used to assess the inclusion (or otherwise) of full
papers into the review. If a trial was excluded after the full paper
has been obtained, a record of the study and reason for exclusion
was recorded. Differences in selection of the final full text articles
were resolved by discussion or by consulting a third reviewer (KR).
Data extraction and management
Original reports of trial results were extracted by one reviewer (CC,
EL, LA-K) and checked by a second reviewer (KR, EL, SK).
Data were extracted as follows and are reported in the character-
istics of included studies table:
1. General information: published/unpublished, title, authors,
source, country, year of publication, trial dates, additional
publications;
2. Trial characteristics: design, setting, duration,
randomisation (and method), allocation concealment (and
method), blinding (outcome assessors), check of blinding,
funding/conflict of interest;
3. Participants: inclusion criteria, exclusion criteria, total
number and number in comparison groups, sex/age, ethnicity,
BMI, lipid levels, blood pressure, similarity of groups at baseline,
withdrawals/losses to follow-up, assessment of adherence,
medications used, smoking status, when provided;
4. Intervention: dietary information/diet provided, length of
intervention, comparison interventions, macronutrient
composition of diets and GI;
5. Outcomes: outcomes as specified above, the main outcome
assessed in the study, other events, length of follow-up;
6. Results: for outcomes and times of assessment.
Assessment of risk of bias in included studies
We assessed risk of bias according to the Cochrane Handbook
(Higgins 2011). We categorised risk of bias as ’low’, ’unclear’ or
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’high’. The risk of bias was assessed by one reviewer (CC, LA-K)
and checked by a second (EL, SK, KR).
Studies were not excluded on the basis of a high ’risk of bias’ score.
In particular, the following factors were examined:
1. Method of randomisation;
2. Allocation concealment;
3. Blinding of outcome assessment (detection bias);
4. Incomplete outcome data (attrition bias);
5. Intention-to-treat analysis;
6. Selective reporting (reporting bias);
7. Groups comparable at baseline;
8. Other (e.g. power analysis, analysis issues).
Measures of treatment effect
We processed data in accordance with the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We expressed
dichotomous outcomes as hazard ratios (HRs), with 95% confi-
dence intervals (CIs). For continuous outcomes, we compared net
changes (i.e. intervention group minus control group differences)
and calculated a mean difference (MD) and standard deviation
difference for each study.
Where necessary, we imputed standard deviation differences from
baseline to follow-up, as these datawere not available in the papers.
To do this, we followed the guidelines in the Cochrane Handbook
of obtaining standard deviations from standard errors (Higgins
2011, chapter 7.3.3) and we used a correlation coefficient of 0.5 in
these calculations, as recommended by Follman (Follman 1992).
We included studies reporting multiple comparison groups in this
review. In studies that found a difference between groups, we used
the data for the control group for each intervention group com-
parison and reduced the weight assigned to the control group by
dividing the number of participants in the control group by the
number of intervention groups (Higgins 2011, chapter 7.7.3).
Three studies reported results as medians and interquartile range
(Philippou 2008; RISCK 2010 highMUFA; RISCK 2010 low fat,
Juanola-Falgarona 2014) - these data could not be converted to
means and standard deviations and could therefore not be included
in the meta-analyses, but were included in the narrative summary
of the results.
We included cluster-randomised trials in this review by using the
unit of randomisation (cluster) as the number of observations.
Where necessary, we utilised individual level means and standard
deviations adjusted for clustering together with the number of
clusters in the denominator, in order to weight the trials appro-
priately.
We entered data presented as a scale with a consistent direction of
effect, with the exception of HDL cholesterol where an increase
in this outcome was a positive finding.
Assessment of heterogeneity
For each outcome, we conducted tests of heterogeneity using the
Chi2 test of heterogeneity and the I2 statistic. Where there was
no heterogeneity, we performed a fixed-effect meta-analysis. If
substantial heterogeneity was detected (I2 = 50% or greater), we
looked for possible explanations for this (e.g. difference in GI
between study groups, study duration, weight loss versus weight
maintenance interventions) and used a random-effectsmodel with
appropriate cautious interpretation.
Data synthesis
We carried out statistical analysis using Cochrane’s statistical soft-
ware, Review Manager 2014. We entered continuous data as the
change in means and standard deviations from baseline to follow-
up measurements.
Studies in primary prevention populations (healthy individuals or
those at high risk of CVD) or secondary prevention populations
(defined as those with a pre-existing diagnosis of CVD) were anal-
ysed separately.
Data were pooled using a fixed-effect model and the results for the
longest follow-up. Data were pooled for the studies categorised
as primary prevention. Only one study in a secondary prevention
population was included and this was reported in the narrative
synthesis only.
Studies reported results either as absolute values at the endpoint
or as change from baseline. For the pooled analysis, change from
baseline values were reported. Where papers did not report results
as change from baseline, we calculated this and for the standard
deviation differences, we followed the methods presented in the
Cochrane Handbook for Systematic Reviews of Interventions for im-
puting these (16.1.3.2 Imputing standard deviations for changes
from baseline Higgins 2011), and assumed a correlation of 0.5 be-
tween baseline and follow-up measures, as suggested by Follman
(Follman 1992).
Quality of evidence
We presented the overall quality of the evidence for each pri-
mary outcome (Summary of findings for the main comparison;
Summary of findings 2) according to the Grading of Recommen-
dations Assessment, Development and Evaluation (GRADE) ap-
proach, which takes into account issues not only related to inter-
nal validity (risk of bias, inconsistency, imprecision, publication
bias) but also to external validity such as directness of results. Two
review authors (LA, KR) rated the quality for each outcome. We
presented summaries of the evidence in ’Summary of findings’ ta-
bles, which provide key information about the best estimate of the
magnitude of the effect, in relative terms for each relevant compar-
ison of alternative management strategies, numbers of participants
and trials addressing each important outcome, and the rating of
the overall confidence in effect estimates for each outcome. We
created the ’Summary of findings’ tables based on the methods
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described in the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011). We presented results on the outcomes
as described in Types of outcome measures.
In addition, we established an appendix ’Checklist to aid con-
sistency and reproducibility of GRADE assessments’ (Meader
2014) to help with standardisation of ’Summary of findings’ tables
(Appendix 2).
R E S U L T S
Description of studies
Results of the search
The study flow is shown in Figure 1. The searches resulted in the
identificationof 18614potentially relevant records. 18036 of these
were excluded based on titles and abstracts as clearly not relevant
and 578 full text articles were assessed for eligibility. Twelve addi-
tional records were identified through screening reference lists of
systematic reviews, other potentially relevant articles and contact-
ing authors; of these, nine studies were excluded and three were
included. In total, five studies are awaiting classification, one study
is ongoing and 21 studies were included in the analysis of this
review. Three of these had been included in the previous version
of this review (Frost 2004; Raatz 2005; Wolever 2002); the other
RCTs included in the previous version of the review no longer
fulfilled the updated inclusion criteria. Nineteen studies could be
included in the meta-analysis. Four studies included four eligible
comparison groups (DiOGenes 2011a high protein; DiOGenes
2011 low protein; Ghani 2014a high insulin; Ghani 2014 low
insulin; McMillan-Price 2006 high CHO; McMillan-Price 2006
high protein; RISCK 2010 high MUFA; RISCK 2010 low fat)
with different cointerventions and therefore two independent
comparisons per study could be included in the analysis. How-
ever, the RISCK study (RISCK 2010 high MUFA; RISCK 2010
low fat) only reported medians and interquartile range and could
therefore not be included in the pooled analysis. The pooled anal-
yses therefore included up to 17 comparisons.
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Figure 1. Ongoing: 1 study (3 records)Awaiting classification: 5 studies (5 records)Study flow diagram.
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Included studies
Detailed study characteristics are shown in Characteristics of
included studies.
Study design
All included studies were parallel group RCTs. Most used indi-
vidual randomisation, while one randomised Weight Watchers
classes (Bellisle 2007) and one randomised families (DiOGenes
2011a high protein; DiOGenes 2011 low protein). Most RCTs
were single centre studies, while two were multicentre studies
(DiOGenes 2011a high protein; DiOGenes 2011 low protein;
RISCK 2010 high MUFA; RISCK 2010 low fat). One multicen-
tre study was carried out in eight European countries; five came
from the UK, four from the USA, and one each from Australia,
NewZealand, Brazil, Canada, France, Italy,Germany, andMexico.
Nine studies had a duration of 12 weeks (Bellisle 2007; Buscemi
2013; Frost 2004; Juanola-Falgarona 2014; McMillan-Price 2006
high CHO; McMillan-Price 2006 high protein; Melanson 2012;
Philippou 2008; Shikany 2005; Solomon 2010), two of four
months (Philippou 2009a; Wolever 2002), six of between 24
weeks and 6 months (Armendariz-Anguiano 2011; DiOGenes
2011a high protein; DiOGenes 2011 low protein; Hönemann
2010; Juanola-Falgarona 2014; Philippou 2009; RISCK 2010
highMUFA; RISCK 2010 low fat), one of 36 weeks (Raatz 2005),
one of one year (Ghani 2014a high insulin; Ghani 2014 low
insulin) and two of 18 months (Sichieri 2007; Venn 2010). Most
of the studies did not report on postintervention follow-up pe-
riods. One study mentioned a 12-month weight maintenance
phase after the main intervention, but results were not reported
(Buscemi 2013). One study reported an extension up to one year
in two of the eight centres taking part in themain six-month study
(DiOGenes 2011a high protein; DiOGenes 2011 low protein).
Types of participants
The included studies had a total of 2538 participants (n = 2233
included in meta-analysis). Sample sizes ranged between 18 and
773, with more than half of the studies having fewer than 100 par-
ticipants (median 60). Sample sizes per comparison group ranged
from 6 to 159.
The inclusion criterion for over half of the studies was overweight
or obesity, or both. Four studies included participants who were
overweight or obese and had additional cardiovascular risk fac-
tors or the metabolic syndrome (Buscemi 2013; Ghani 2014a
high insulin; Ghani 2014 low insulin; RISCK 2010 high MUFA;
RISCK 2010 low fat; Solomon 2010). Two studies included par-
ticipants with at least one recognised heart disease risk factor
(Philippou 2008; Philippou 2009). One study included partic-
ipants with hyperlipidaemia (Shikany 2005), and one included
participants with impaired glucose tolerance (Wolever 2002). One
study included participants with coronary heart disease (Frost
2004).
Where reported (15 studies), the mean age of participants was
between 30 and 67 years. One study did not report on the sex of
participants, four included only women, one only men, the rest
included between 12% and 88.5% men.
At baseline, the mean BMI of participants ranged from 26.7 kg/
m2 to 36.5 kg/m2 (reported by 19 studies). Mean total choles-
terol was between 4.1 and 6.1 mmol/L and between 6.1 and 6.3
mmol/L in the study restricted to hyperlipidaemic participants
(reported by 19 studies). Mean HDL cholesterol levels were be-
tween 1.1 and 1.9 mmol/L (reported by 20 studies) and mean
LDL cholesterol levels between 2.4 and 4.4 mmol/L (reported by
19 studies). Mean systolic blood pressure was between 112 and
141 mmHg and mean diastolic blood pressure between 71 and 84
mmHg (reported by 13 studies). Medication use was not reported
by twelve studies, participants in five studies used no medication
for cardiovascular disorders (Bellisle 2007; McMillan-Price 2006
high CHO; McMillan-Price 2006 high protein; Melanson 2012;
Philippou 2009), and four studies reported on medication use for
cardiovascular disorders (Buscemi 2013; Frost 2004; RISCK 2010
high MUFA; RISCK 2010 low fat; Wolever 2002).
Types of interventions
Recommendations regarding high or low GI diets were gener-
ally based on standard tables or on specific high or low GI
food groups. In some trials, relevant foods were provided to the
participants (McMillan-Price 2006 high CHO; McMillan-Price
2006 high protein; Randolph 2014; RISCK 2010 high MUFA;
RISCK 2010 low fat; Solomon 2010; Wolever 2002), and/or par-
ticipants received prescribed diets or eating plans (Armendariz-
Anguiano 2011; Buscemi 2013;McMillan-Price 2006 highCHO;
McMillan-Price 2006 high protein; Sichieri 2007), and/or menu
lists and recipes (Armendariz-Anguiano 2011; DiOGenes 2011a
high protein; DiOGenes 2011 low protein; Juanola-Falgarona
2014; Melanson 2012; Raatz 2005; Shikany 2005; Venn 2010).
In one trial (Raatz 2005), a feeding phase with diet prepared
by a metabolic kitchen (12 weeks) was followed by a 12 week
phase where participants prepared their own meals. In the DiO-
Genes trial (DiOGenes 2011a high protein; DiOGenes 2011
low protein), a lab-based shop system was used in two of eight
centres. Trials also included written information (information
booklets/instructions) (Bellisle 2007; Ghani 2014a high insulin;
Ghani 2014 low insulin; Hönemann 2010; Juanola-Falgarona
2014; Melanson 2012; Philippou 2009a; RISCK 2010 high
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MUFA; RISCK 2010 low fat; Shikany 2005; Venn 2010;Wolever
2002), dietary counselling or staff being available for ques-
tions (Armendariz-Anguiano 2011; Buscemi 2013; Frost 2004;
McMillan-Price 2006 high CHO; McMillan-Price 2006 high
protein; Melanson 2012; Philippou 2008; Philippou 2009; Raatz
2005; Shikany 2005; Sichieri 2007; Solomon 2010; Venn 2010),
cooking and behavioural advice (DiOGenes 2011a high protein;
DiOGenes 2011 low protein), cooking classes (Venn 2010), re-
minders (Armendariz-Anguiano 2011), and group instructions
(Shikany 2005). Two trials were based on the Weight Watch-
ers programme (Bellisle 2007; Melanson 2012). Several trials
specifically based their recommendations on current healthy eat-
ing guidelines (Frost 2004; Philippou 2009a; Shikany 2005;
Venn 2010), in one trial, a Mediterranean diet was followed
(Buscemi 2013), one trial was based on a traditional Mexican diet
(Armendariz-Anguiano 2011), and one was based one a low GI
diet of wholegrains and pulses (Venn 2010). Melanson 2012 com-
pared a low GI diet with a portion control group (with similar
nutritional composition) and a high carbohydrate diet was used
in the trial by Wolever 2002.
In most trials, the diet was energy-reduced in all participants
(Armendariz-Anguiano 2011; Bellisle2007; Buscemi 2013;Ghani
2014a high insulin; Ghani 2014 low insulin; Juanola-Falgarona
2014; McMillan-Price 2006 high CHO; McMillan-Price 2006
high protein; Philippou 2008; Philippou 2009; Raatz 2005;
Randolph 2014; Sichieri 2007) or in participants with a BMI
above a certain level (Frost 2004). Several trials did not specifically
report that the diet was energy-reduced, but the energy content of
the actual intervention diets consumed was lower than the energy
content of the baseline diets (Melanson 2012; Shikany 2005; Venn
2010). Other studies specifically used a weight-maintenance diet
(DiOGenes 2011a high protein; DiOGenes 2011 low protein;
Philippou 2009a; RISCK 2010 high MUFA; RISCK 2010 low
fat; Solomon 2010; Wolever 2002).
Two studies included a weight loss phase before randomisation
and randomisation was based on a defined level of weight loss
during that phase (DiOGenes 2011a high protein; DiOGenes
2011 low protein; Philippou 2009a). Of the trials with multiple
dietary interventions, the DiOGenes trial (DiOGenes 2011a high
protein; DiOGenes 2011 low protein) compared high and low
GI groups receiving concomitant high or low protein diets, and
other trials compared high and low GI diets in the context of
high carbohydrate and low protein diets (McMillan-Price 2006
high CHO; McMillan-Price 2006 high protein), or low fat and
highmonounsaturated fatty acid diets (RISCK 2010 highMUFA;
RISCK 2010 low fat).
One trial included exercise sessions (Solomon 2010) and others
recommended increased physical activity (Bellisle 2007; Philippou
2009a; Venn 2010; RISCK 2010 high MUFA; RISCK 2010 low
fat). Dietary adherence was generally checked using food records
or food diaries (e.g. 3-day food records) (Armendariz-Anguiano
2011; Buscemi 2013; DiOGenes 2011a high protein; DiOGenes
2011 low protein; Frost 2004; Ghani 2014a high insulin; Ghani
2014 low insulin; Juanola-Falgarona 2014; McMillan-Price 2006
high CHO; McMillan-Price 2006 high protein; Melanson 2012;
Philippou 2008; Philippou 2009; Raatz 2005; Randolph 2014;
RISCK 2010 high MUFA; RISCK 2010 low fat; Shikany 2005;
Venn 2010; Wolever 2002); some trials used food choice check-
lists (Bellisle 2007), a computer-based check of consumption
(Hönemann 2010), or food-container weigh-backs (Solomon
2010).
Where reported (20 studies, see Analysis 1.1), daily energy intake
of the intervention diets varied widely between 5335 and 14,000
kJ per day. Despite aiming for a similar energy content of diets,
the low GI diet in the trial by Frost 2004 had a significantly higher
energy content than the highGI diet (8506 (SE 473) kJ/day versus
7360 (SE 331) kJ/day, P = 0.04). Carbohydrate content of diets
varied between 143 g and 258 g per day (7 studies) or 40% and
62% of energy (15 studies), fat content between 32 g and 73 g per
day (7 studies) or 19% and 39.6% of energy (15 studies), protein
content between 57 g and 95 g per day (7 studies) or 15% and
28% of energy (13 studies), and fibre content between 8 g and
44.5 g per day (14 studies).
GI was clearly reported for 19 studies (see Analysis 1.1). Mean
GI ranged between 30 and 71 in the low GI groups (mean 49)
and between 47 and 81 in the high GI groups (mean 63). The
GI difference between groups varied widely between 0.6 and 42
(mean 13.5).
Types of outcomes
None of the studies reported on mortality (total or cardiovascular)
or cardiovascular events. All studies reportedweight, BMI, or both.
Most studies reported on blood lipids (total cholesterol, HDL
cholesterol, LDL cholesterol, triglycerides). A range of studies re-
ported systolic anddiastolic bloodpressure (Bellisle 2007; Buscemi
2013; DiOGenes 2011a high protein; DiOGenes 2011 low
protein; Frost 2004;Hönemann 2010;Melanson 2012; Philippou
2009; Randolph 2014; RISCK 2010 high MUFA; RISCK 2010
low fat; Solomon 2010; Venn 2010). Only a small number of
studies reported on adverse events (Armendariz-Anguiano 2011;
Raatz 2005), satisfaction (Bellisle 2007; DiOGenes 2011a high
protein; DiOGenes 2011 low protein), hunger/satiety (Bellisle
2007; Juanola-Falgarona 2014;Melanson 2012; Philippou 2009a;
Sichieri 2007), or appetite/desire to eat (Bellisle 2007; Philippou
2009a).
Most studies also reported on variables related to blood glu-
cose values and insulin sensitivity (Armendariz-Anguiano 2011;
Bellisle 2007; Frost 2004; Ghani 2014a high insulin; Ghani
2014 low insulin; Hönemann 2010; Juanola-Falgarona 2014;
McMillan-Price 2006 high CHO; McMillan-Price 2006 high
protein; Melanson 2012; Philippou 2008; Philippou 2009;
Philippou 2009a; Raatz 2005; Randolph 2014; RISCK 2010 high
MUFA;RISCK2010 low fat; Shikany 2005; Solomon 2010;Venn
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2010; Wolever 2002), but these outcomes are not reported here.
Buscemi 2013 also reported flow-mediated dilatation and carotid
intima thickness.
Funding
Nine studies reported noncommercial funding (Ghani 2014a
high insulin; Ghani 2014 low insulin; Hönemann 2010; Juanola-
Falgarona 2014; Philippou 2009; Raatz 2005; Shikany 2005;
Sichieri 2007; Solomon 2010; Venn 2010). Four studies had
both noncommercial and commercial funding (the latter partially
for sponsoring of food products)(DiOGenes 2011a high protein;
DiOGenes 2011 low protein; RISCK 2010 high MUFA; RISCK
2010 low fat; Wolever 2002; McMillan-Price 2006 high CHO;
McMillan-Price 2006 high protein). One study was sponsored by
WeightWatchers International (Bellisle 2007), one study reported
that a slimming product used in the weight loss phase was provided
by the manufacturer (Philippou 2009a) and one study was funded
by the United States Potato Board (Randolph 2014). Four studies
did not report the source of funding (Armendariz-Anguiano 2011;
Frost 2004; Melanson 2012; Philippou 2008) and one reported
that there was no specific funding (Buscemi 2013).
Excluded studies
Reasons for study exclusion (Figure 1) included: the study was
not an RCT, study duration was less than 12 weeks, not relevant
intervention, not relevant participants (participants with diabetes
or of children or adolescents), or the study reported no eligible
outcomes. The Characteristics of excluded studies table includes
both excluded studies from this version of the review and of the
previous version of this review.
Ongoing studies
The PREVIEW study (Brand-Miller 2013) is an ongoing 3-
year RCT that includes 2500 adults and children who are over-
weight (BMI≥ 25.0 kg/m2) and prediabetic. The study compares
high-protein, low-glycaemic index diet to a high-carbohydrate,
medium-glycaemic index diet in combination with moderate or
high intensity physical activity on the incidence of type 2 diabetes
and CVDoutcomes. There was insufficient information about the
intervention and study completion is in 2018 (Characteristics of
ongoing studies).
Studies awaiting classification
Five studies are awaiting classification (Characteristics of studies
awaiting classification). Three studies did not clearly report if
CVD outcomes were collected (Boyadjieva 2015; Giroux 2015;
Karl 2015), and the diet composition was not clear in one study
(Cayanan 2015). The authors of the three studies were con-
tacted for further details but the authors did not respond (Studies
awaiting classification). The library could not track down one
study (Weinhold 2015).
Risk of bias in included studies
Risk of bias was generally unclear (see Figure 2 and Figure
3). Three studies were at high risk of bias for at least three
domains (Armendariz-Anguiano 2011; Hönemann 2010; Raatz
2005) while eight studies were at low risk of bias for at least
three domains (DiOGenes 2011a high protein; DiOGenes 2011
low protein; Ghani 2014a high insulin; Ghani 2014 low insulin;
Juanola-Falgarona 2014; McMillan-Price 2006 high CHO;
McMillan-Price 2006 high protein; Randolph 2014; RISCK 2010
high MUFA; RISCK 2010 low fat; Sichieri 2007; Venn 2010).
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
15Low glycaemic index diets for the prevention of cardiovascular disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Allocation
Nine of 21 studies reported an adequate method of randomisation
(Buscemi 2013; DiOGenes 2011a high protein; DiOGenes 2011
low protein; Frost 2004; Ghani 2014a high insulin; Ghani 2014
low insulin; Juanola-Falgarona 2014; Randolph 2014; RISCK
2010 high MUFA; RISCK 2010 low fat; Sichieri 2007; Wolever
2002), while none of the studies clearly reported allocation con-
cealment.
Blinding
Adequate blinding of outcome assessment was only reported by
four of the 21 trials (Buscemi 2013; Ghani 2014a high insulin;
Ghani 2014 low insulin; Juanola-Falgarona 2014; Randolph
2014) and were at low risk of bias. The other trials did not report
whether outcome assessment was blinded.
Incomplete outcome data
Many studies had high levels of dropouts or losses to follow-up
(reported by 19 studies). The attrition rate ranged between 0 and
41.5% (mean 23.8%) in the low GI groups and between 0 and
70.4% (mean 26.6%) in the high GI groups.
Five trials reported an intention-to-treat analysis (low risk of bias:
DiOGenes 2011a high protein; DiOGenes 2011 low protein;
McMillan-Price 2006 high CHO; McMillan-Price 2006 high
protein; Juanola-Falgarona 2014; Sichieri 2007; Venn 2010),
while 12 trials clearly included only participants completing the
trial in the analysis (high risk of bias: Armendariz-Anguiano
2011; Bellisle 2007; Buscemi 2013; Frost 2004;Hönemann 2010;
Melanson 2012; Philippou 2009a; Raatz 2005; Randolph 2014;
Shikany 2005; Solomon 2010; Wolever 2002).
Selective reporting
In the study by Raatz 2005, there was only very limited report-
ing of outcomes for the second phase of their trial (i.e. the phase
where participants prepared their ownmeals, after the initial phase
where food was obtained from a metabolic kitchen). The study
by Juanola-Falgarona 2014 did not report postintervention blood
pressure parameters.Most other studies appeared to report all out-
comes as intended, however, not enough information was avail-
able to check (protocols were not available) and these have been
judged as at unclear risk of bias.
Other potential sources of bias
Comparability at baseline
Differences at baseline are indicative of selection bias. In most
trials, comparison groups were similar at baseline, although in a
number of studies, baseline characteristics were reported only for
participants that completed the study. In the study by Frost 2004,
significantly fewer participants took a statin or aspirin in the low
GI group than in the high GI group. In the study by Hönemann
2010, triglycerides were significantly lower at baseline in the low
GI group than in the control group. Melanson 2012 reported a
significantly higher level of triglycerides, a significantly lower fibre
intake and significantly lower blood glucose in the low GI group
compared to the portion control group at baseline. Philippou
2009a did not report age or sex and the RISCK (RISCK 2010
high MUFA; RISCK 2010 low fat) trial only reported baseline
data for men versus women, but not for the different comparison
groups. Raatz 2005 reported that baseline characteristics between
comparison groupswere similar, but only limited datawere shown.
Power analysis
Seven studies reported a power analysis and the study was ade-
quately powered (Bellisle 2007; Buscemi 2013; Ghani 2014a high
insulin; Ghani 2014 low insulin; Hönemann 2010; Randolph
2014; RISCK 2010 high MUFA; RISCK 2010 low fat; Venn
2010). However, some of these studies did not base their power
analyses on outcomes relevant for the present review, so it was
unclear if they were adequately powered for measuring these out-
comes (Buscemi 2013; Ghani 2014a high insulin; Ghani 2014
low insulin; Randolph 2014; RISCK 2010 high MUFA; RISCK
2010 low fat).
Six studies reported a power analysis but the study was underpow-
ered - this was partially due to an underestimation of dropouts
(Armendariz-Anguiano 2011; DiOGenes 2011a high protein;
DiOGenes 2011 low protein; McMillan-Price 2006 high CHO;
McMillan-Price 2006 high protein; Sichieri 2007; Venn 2010;
Wolever 2002). Three studies reported a power analysis but it
was unclear if the study was adequately powered (Frost 2004;
Juanola-Falgarona 2014; Melanson 2012). Six studies reported
no power analysis (Philippou 2008; Philippou 2009; Philippou
2009a; Raatz 2005; Shikany 2005; Solomon 2010).
Other
The study by Bellisle 2007 was cluster randomised but this does
not appear to have been taken account of in the analysis.
Effects of interventions
See: Summary of findings for the main comparison Low GI
versus highGI for theprimary prevention of cardiovascular disease;
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Summary of findings 2 Low GI versus high GI for the secondary
prevention of cardiovascular disease
Results are reported separately for primary prevention studies and
the secondary prevention study.
Primary outcomes
Total and cardiovascular mortality:
None of the included studies reported on total cardiovascular mor-
tality.
Cardiovascular disease events - fatal and nonfatal myocardial
infarction:
None of the included studies reported on fatal and nonfatal my-
ocardial infarction.
Cardiovascular disease events - unstable angina:
None of the included studies reported on unstable angina.
Cardiovascular disease events - coronary artery bypass graft
surgery:
None of the included studies reported on coronary artery bypass
graft surgery.
Cardiovascular disease events - percutaneous transluminal
coronary angioplasty:
None of the included studies reported on percutaneous translu-
minal coronary angioplasty.
Cardiovascular disease events - stroke:
None of the included studies reported on stroke.
Adverse events
Two trials reported adverse effects (Armendariz-Anguiano 2011;
Raatz 2005), low-quality evidence (Summary of findings for the
main comparison). In one study (Armendariz-Anguiano 2011)
no side effects were observed with the diets (0/24). In another
study (Raatz 2005) no participant withdrew due to side effects or
health complications (0/14). The remaining trials did not report
on adverse events.
Secondary outcomes
Blood lipids
Primary Prevention Studies
Pooled summaries for the effects of low GI diets on blood lipids
are shown in Analysis 1.1 to Analysis 1.4. Studies in the analyses
are sorted by magnitude of GI difference between study groups,
with the study with the largest GI difference listed first and the
studies with an unclearly reported GI difference listed last.
Total cholesterol
Seventeen studies reported total cholesterol and 14 of these could
be summarised in a meta-analysis (17 comparisons). Including
all studies reporting this outcome, the change in total cholesterol
from baseline to study end varied between -0.80 and +1.5 mmol/
L in the low GI groups and between -0.67 and +1.5 mmol/L in
the control groups.
The pooled analysis showed no evidence for a difference between
comparison groups (mean difference (MD) -0.12 mmol/L, 95%
CI -0.26 to 0.02, P = 0.10, 1277 participants, 14 studies, 17 com-
parisons, Analysis 1.1).However, therewas substantial heterogene-
ity (I2 = 61%), but no evidence for an effect of the magnitude of
the difference in GI between comparison diets, of study duration
or of weight loss versus weight maintenance studies could be seen.
Of the trials that could not be included in the pooled analysis, the
RISCK trial (RISCK 2010 highMUFA; RISCK 2010 low fat) did
not show evidence for a difference in total cholesterol between the
low and high GI groups after 24 weeks of intervention. Similarly,
there was no evidence for a difference in total cholesterol between
the low and high GI groups after 12 weeks of intervention in the
trial by Philippou 2008, after 4 months in the trial by Wolever
2002, and after one year in a subgroup of participants of the
DiOGenes trial (DiOGenes 2011a high protein; DiOGenes 2011
low protein). Melanson 2012 reported a significant reduction in
total cholesterol in all comparison groups over 12 weeks (P <
0.001), but there was no evidence for a difference between groups,
and numeric values were not reported.
HDL cholesterol
Seventeen studies reportedHDL cholesterol and 14 of these could
be summarised in a meta-analysis (17 comparisons). Including all
studies reporting this outcome, the change in HDL cholesterol
from baseline to study end varied between -0.6 and +0.4 mmol/L
in the low GI groups and between -0.7 and +0.6 mmol/L in the
control groups.
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The pooled analysis showed no evidence for a difference between
comparison groups (MD -0.00 mmol/L, 95% CI -0.03 to 0.02,
P = 0.69, 1329 participants, 14 studies, 17 comparisons, Analysis
1.2). No evidence for an effect of the magnitude of the difference
in GI between comparison diets, of study duration or of weight
loss versus weight maintenance studies could be seen. There was
no substantial heterogeneity (I2= 0%).
Of the trials that could not be included in the pooled analysis,
the RISCK trial (RISCK 2010 high MUFA; RISCK 2010 low
fat) did not show evidence of a difference in HDL cholesterol
between the lowandhighGI groups after 24weeks of intervention.
Similarly, there was no evidence of a difference inHDL cholesterol
between the low and highGI groups after 12 weeks of intervention
in the trial by Philippou 2008, after 4 months in the trial by
Wolever 2002, and after one year in a subgroup of participants of
the DiOGenes trial (DiOGenes 2011a high protein; DiOGenes
2011 low protein). Melanson 2012 reported a significant overall
reduction in HDL cholesterol over 12 weeks (P < 0.001), but
there was no evidence of a difference between groups, and numeric
values were not reported.
LDL cholesterol.
Seventeen studies reported LDL cholesterol and 14 of these could
be summarised in a meta-analysis (17 comparisons). Including all
studies reporting this outcome, the change in LDL cholesterol
from baseline to study end varied between -0.45 and +0.5 mmol/
L in the low GI groups and between -0.44 and +0.52 mmol/L in
the control groups.
The pooled analysis showed no evidence for a difference between
comparison groups (MD -0.03 mmol/L, 95% CI -0.10 to 0.04,
P = 0.46, 1274 participants, 14 studies, 17 comparisons, Analysis
1.3). No evidence of an effect of the magnitude of the difference
in GI between comparison diets, of study duration or of weight
loss versus weight maintenance studies could be seen. There was
no substantial heterogeneity (I2= 4%).
Of the trials that could not be included in the pooled analysis, the
RISCK trial (RISCK 2010 highMUFA; RISCK 2010 low fat) did
not find a significant difference in LDL cholesterol between the
low and high GI groups after 24 weeks of intervention. Similarly,
there was no significant difference in LDL cholesterol between
the low and high GI groups after 12 weeks of intervention in the
trial by Philippou 2008, after 4 months in the trial by Wolever
2002, and after one year in a subgroup of participants of the
DiOGenes trial (DiOGenes 2011a high protein; DiOGenes 2011
low protein). Melanson 2012 reported a significant reduction in
LDL cholesterol in all comparison groups after 12 weeks (P <
0.001), but no significant difference between groups, and numeric
values were not reported.
Triglycerides
Seventeen studies reported triglyceride levels and 13 of these could
be summarised in a meta-analysis (16 comparisons). Including all
studies reporting this outcome, the change in triglycerides from
baseline to study end varied between -0.61 and +0.28 mmol/L in
the low GI groups and between -2.34 and +0.36 mmol/L in the
control groups.
The pooled analysis showed no evidence for a difference between
comparison groups (MD 0.03 mmol/L, 95% CI -0.03 to 0.09, P
= 0.32, 1252 participants, 13 studies, 16 comparisons, Analysis
1.4). No effect of the magnitude of the difference in GI between
comparison diets, of study duration or of weight loss versus weight
maintenance studies could be seen. There was no substantial het-
erogeneity (I2 = 9%).
Of the trials that could not be included in the pooled analysis,
the RISCK trial (RISCK 2010 high MUFA; RISCK 2010 low
fat) did not show evidence of a difference in triglycerides between
the low and high GI groups after 24 weeks of intervention. Simi-
larly, there was no evidence of a difference in triglycerides between
the low and high GI groups after 12 weeks of intervention in the
trial by Philippou 2008, after 4 months in the trial by Wolever
2002, and after one year in a subgroup of participants of the DiO-
Genes trial (DiOGenes 2011a high protein; DiOGenes 2011 low
protein). One study (Juanola-Falgarona 2014) reported change in
triglyceride levels as median and interquartile range (IQR); there
was a nonsignificant difference (P = 0.516) between low (median
0.27 mmol/L, 41 participants) and high GI groups (median -0.26
mmol/L, 40 participants) after six months.
Secondary Prevention study
In the one study (Frost 2004) including participants with CHD,
there were no evidence of differences seen between groups in the
change from baseline values for total cholesterol (MD -0.10, 95%
CI -0.59 to 0.39, 55 participants, 1 study, 1 comparison, Analysis
2.1);HDL cholesterol (MD -0.03mmol/L, 95%CI -0.18 to 0.12,
55 participants, 1 study, 1 comparison, Analysis 2.2); LDL choles-
terol (MD -0.06 mmol/L, 95% CI -0.47 to 0.35, 55 participants,
1 study, 1 comparison, Analysis 2.3); and triglycerides (MD -0.29
mmol/L, 95% CI -0.73 to 0.15, 55 participants, 1 study, 1 com-
parison, Analysis 2.4).
Blood pressure
Primary Prevention studies
Eleven studies reported blood pressure and nine of these could
be summarised in a meta-analysis (10 comparisons). Including
all studies reporting this outcome, the change in systolic blood
pressure from baseline to study end varied between -10 and +4.5
mmHg (mean -3.44 mmHg) in the low GI groups and between
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-14 and +5.1 mmHg (mean -4.14 mmHg) in the control groups.
The change in diastolic blood pressure from baseline to study end
varied between -8 and+1.9mmHg (mean -1.85mmHg) in the low
GI groups and between -8 and +3.6 mmHg (mean -2.37 mmHg)
in the control groups.
The pooled analysis showed no evidence of a difference between
comparison groups in systolic blood pressure (MD 0.52 mmHg,
95% CI -1.21 to 2.25, P = 0.55, 786 participants, 9 studies, 10
comparisons, Analysis 1.5) with no substantial heterogeneity (I2 =
7%). The pooled analysis showed no evidence of a difference be-
tween comparison groups in diastolic blood pressure (MD -0.23
mmHg, 95% CI -1.42 to 0.96, P = 0.71, 786 participants, 9 stud-
ies, 10 comparisons, Analysis 1.6) where there was moderate het-
erogeneity (I2 = 38%). No evidence of an effect of the magnitude
of the difference in GI between comparison diets, of study dura-
tion or of weight loss versus weight maintenance studies could be
seen.
Of the trials that could not be included in the pooled analysis,
the RISCK trial (RISCK 2010 high MUFA; RISCK 2010 low
fat) did not show evidence of a difference in systolic or diastolic
blood pressure between the low and high GI groups after 24 weeks
of intervention. Similarly, there was no evidence of a difference
in systolic or diastolic blood pressure between the low and high
GI groups after one year in a subgroup of participants of the
DiOGenes trial (DiOGenes 2011a high protein; DiOGenes 2011
low protein) and no evidence of a difference in diastolic blood
pressure after four months of intervention in the trial by Wolever
2002.
Secondary Prevention study
In the one study (Frost 2004) including participants with CHD,
there was no evidence of any differences seen between groups in
systolic blood pressure (MD -2.00 mmHg, 95% CI -14.97 to
10.97, 55 participants, 1 study, 1 comparison, Analysis 2.5) and
diastolic blood pressure (MD -4.00 mmHg, 95% CI -13.41 to
5.41, Analysis 2.6).
Other secondary outcomes (health-related quality of life,
attitudes to diets, satisfaction)
None of the studies reported on health-related quality of life. Two
studies (Armendariz-Anguiano 2011; Bellisle 2007) reported on
behaviour change, both studies reported no difference between the
intervention and control (see Analysis 1.7). In the study by Bellisle
2007, both the 12 week low GI and the control diet produced a
similar increase in dietary restraint, and a similar decrease in dis-
inhibition, hunger sensations, emotionality and externality. In the
study by Armendariz-Anguiano 2011, there was no no significant
change in physical activity observed.
Five studies (Bellisle 2007; Juanola-Falgarona 2014; Melanson
2012; Philippou 2008; Sichieri 2007) reported on hunger/desire
to eat parameters (see Analysis 1.8). In one study (Bellisle 2007)
participants in the low GI group had significantly lower intensity
of hunger (P < 0.001) and desire to eat than participants of the
control group (P < 0.001). In one study (Juanola-Falgarona 2014),
the low GI group reported lower hunger sensation in comparison
to the control. Philippou 2009a and Sichieri 2007 reported no
evidence of a difference in hunger/fullness between the lowGI and
the control groups after the intervention (four, six and 18 months
respectively).
Three studies (Bellisle 2007; DiOGenes 2011a high protein;
DiOGenes 2011 low protein) reported on participants satisfaction
(see Analysis 1.9). In one study (Bellisle 2007) participants of both
the low GI and the control group were equally satisfied with the
dietary programme and that both 12 week diets were perceived to
be equally effective but they found the low GI diet significantly
easier to follow than the control diet. The DiOGenes 2011a high
protein and DiOGenes 2011 low protein studies reported mean
scores of intervention acceptability for the overall (high protein
and low protein) lowGI group (n = 273) and the overall (high pro-
tein and low protein) high GI group (n = 255). Both low GI and
high GI groups reported similar scores and there was no difference
between groups for satisfaction with the program, convenience
of the program, ease of adherence to the program, motivation to
continue the program, and enjoying the dietary intervention.
Weight change as a potential confounder
Primary Prevention studies
Most studies reported someweight loss in both the lowandhighGI
groups. Weight loss ranged from 0.26 kg to 9.95 kg in the weight
loss studies and from a weight loss of 9 kg to a weight gain of 1.45
kg in the weight maintenance studies. In the studies with an initial
weight loss phase before a weight maintenance phase, participants
had ameanweight loss of 11.2 kg (SD 3.5) in theDiOGenes study
(DiOGenes 2011a high protein; DiOGenes 2011 low protein)
and a median weight loss of 6.1% body weight in the study by
Philippou 2009a. There was no evidence for a difference in weight
loss between the low and the high GI groups (MD -0.16 kg, 95%
CI -0.54 to 0.21, P = 0.40, 1403 participants, 14 studies, 17 com-
parisons, Analysis 1.10). There was no substantial heterogeneity.
There was also no evidence for a difference in change in recorded
BMI between low and high GI groups at the end of the interven-
tions (MD -0.0 kg/m2, 95% CI -0.26 to 0.26, P = 0.98, 525 par-
ticipants, 11 studies, 11 comparisons, Analysis 1.11). There was
no substantial heterogeneity (I2 = 0%). In the studies that could
not be included in the meta-analysis, weight change was between
+0.3 and -4 kg in the low GI groups and between -0.3 and -8.4
kg in the high GI groups. There was no evidence for a difference
between high and low GI comparison groups in weight change in
these studies. One study (Juanola-Falgarona 2014) reported sig-
nificant changes according to weight loss between the beginning
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and the end of the intervention, mostly in the high GI group that
showed a significant decrease in BMI compared to the high GI
group.
Secondary Prevention study
In the one study (Frost 2004) including participants with CHD,
there was no evidence for differences in weight loss between the
low and high GI groups (MD 0.70 kg, 95% CI -6.77 to 8.17,
55 participants, 1 study, 1 comparison, Analysis 2.7) or change
in BMI (MD 0.30 kg, 95% CI -1.75 to 2.35, 55 participants, 1
study, 1 comparison, Analysis 2.8).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Low GI versus high GI for the secondary prevention of cardiovascular disease
Patient or population: Adults with coronary heart disease
Settings: Clinical sett ing
Intervention: Low GI
Control: Healthy eat ing advice
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
High GI Low GI
Total and cardiovascu-
lar mortality
See comment See comment See comment See comment See comment The trial did not report
total and CVD mortality
for the secondary pre-
vent ion of CVD
Fatal and nonfatal my-
ocardial infarction
See comment See comment See comment See comment See comment The trial did not report
fatal and nonfatal my-
ocardial infarct ion for
the secondary preven-
t ion of CVD
Unstable angina See comment See comment See comment See comment See comment The trial did not report
unstable angina for the
secondary prevent ion of
CVD
Coronary artery bypass
graft surgery
See comment See comment See comment See comment See comment The trial did not re-
port coronary artery by-
pass graf t surgery for
the secondary preven-
t ion of CVD
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Percutaneous translu-
minal coronary angio-
plasty
See comment See comment See comment See comment See comment The trial did not report
percutaneous translumi-
nal coronary angioplasty
for the secondary pre-
vent ion of CVD
Stroke See comment See comment See comment See comment See comment The trial did not report
stroke for the secondary
prevent ion of CVD
Adverse events See comment See comment See comment See comment See comment The trial did not report
adverse events for the
secondary prevent ion of
CVD
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
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D I S C U S S I O N
Summary of main results
This systematic review summarised 21 RCTs, with 2538 ran-
domised participants, examining the effect of lowGI diets or foods
compared with higher GI diets or foods on risk factors for car-
diovascular disease over 12 weeks or more. Twenty RCTs were in
a primary prevention population and one RCT in a secondary
prevention population. None of the studies reported on mortality
(total or cardiovascular) or cardiovascular events. Risk of bias was
high, with none of the studies fulfilling more than half of the cri-
teria. Most of the studies did not have an intervention duration
of longer than six months. Difference in GI between comparison
groups varied widely from 0.6 to 42.
Overall, in the primary prevention studies, no evidence of a differ-
ence between low GI and high GI groups was seen for blood lipid
parameters and blood pressure parameters: total cholesterol (MD
-0.12 mmol/L, 95% CI -0.26 to 0.02, P = 0.10), HDL choles-
terol (MD -0.00 mmol/L, 95% CI -0.03 to 0.02, P = 0.78), LDL
cholesterol (MD -0.03 mmol/L, 95% CI -0.10 to 0.04, P = 0.46),
triglycerides (MD 0.03 mmol/L, 95% CI -0.03 to 0.09, P = 0.32),
systolic blood pressure (MD 0.52 mmHg, 95% CI -1.21 to 2.25,
P = 0.55), and diastolic blood pressure (MD -0.23 mmHg, 95%
CI -1.42 to 0.96, P = 0.90). Similarly, no differences were seen
in body weight or BMI (as a potential confounder): weight (MD
0.16 kg, 95%CI -0.54 to 0.21, P = 0.40), BMI (MD -0.00 kg/m2,
95% CI -0.26 to 0.26, P = 0.98). Hunger or satiety, or both, were
only reported by five studies and evidence of a difference in favour
of the low GI group was only reported by one of these studies.
In the secondary prevention study, no evidence of any differences
were observed between low and high GI groups on any reported
outcomes of this review.
Overall completeness and applicability of
evidence
The GI of compared diets varied considerably between compari-
son groups for the included studies from 2.5 to 42 (see Analysis
1.1). It is unclear therefore whether the apparent lack of effect
on CVD risk factors was due to small differences in GI between
intervention and control groups. Most diets were energy-reduced
(with associated weight loss) and followed some form of healthy
eating recommendations. We examined the effects of the diets on
weight and BMI as potential confounders and, whilst no differ-
ences were seen between low GI and comparison groups, the small
sample sizes and short follow-up periods may not have allowed
the separation of the true effect of low GI foods compared to the
effects produced by weight loss and general healthy eating, espe-
cially in view of the fact that, in some studies, GI differences were
very small.
It should be noted that the GI of the low and high GI diets were
measured in most of the studies by food diaries and showed con-
siderable variation. The method of measuring the GI of individ-
ual foods was standardised in 1997 (FAO/WHO 1997), and all
included trials were published after that date. There is some de-
bate about the accurate measurement of GI in the diet. Most of
the low GI diets used in the studies in this review were based
on mixed meals. It has been demonstrated that the GI of mixed
meals predicted by table values does not predict the measured GI,
and that the fat and protein content, or energy content of mixed
meals are more strongly correlated with the GI of mixed meals
than carbohydrate content (Flint 2004). Additionally, it has been
reported that most current food frequency questionnaires are not
constructed for the purpose of measuring GI and have not been
validated for this purpose (Barclay 2006).
Quality of the evidence
The unclear risk of bias (according to Cochrane criteria) of most
of the included studies makes overall interpretation of the data
difficult. Sample sizes were small and durations of follow-up were
short and many trials had a large number of dropouts. Adverse
events (including useful information about how easy it was to
make the dietary changes) were generally not reported.Differences
between studies in measuring the GI of the diets consumed may
also have contributed some bias (Du 2006).
We aimed to assess the overall quality of the evidence for each
primary outcome according to the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) approach
which takes into account issues not only related to internal va-
lidity (risk of bias, inconsistency, imprecision, publication bias)
but also to external validity such as directness of results. We pre-
sented two tables; for the primary prevention of CVD and the sec-
ondary prevention of CVD. For the primary prevention of CVD,
the majority of the included randomised controlled trials did not
report the primary outcomes (n = 6) of this review, therefore we
could not assess the overall quality (Summary of findings for the
main comparison). Adverse events (one of the primary outcomes)
was downgraded by one level for risk of bias because of a high
attrition rate, adverse events not reported consistently and poten-
tially underpowered studies. Adverse events was downgraded by
one level for imprecision because of the small number of partic-
ipants and included studies. Overall, inconsistency was difficult
to evaluate because the majority of the domains were not appli-
cable (Appendix 2). For the secondary prevention of CVD, there
was one included study which did not measure primary outcomes
(Summary of findings 2).
Potential biases in the review process
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The inclusion criteria for this update were expanded to include all
cardiovascular disease and not just coronary heart disease. We also
included studies with healthy participants to capture a primary
prevention subset. As there are other Cochrane reviews which ex-
amine the effect of low GI diets in obesity (Thomas 2007) and
diabetes (Thomas 2009), studies were only included if they re-
ported blood lipids or blood pressure, or both, and studies in par-
ticipants with diabetes were excluded. We also excluded studies
reporting weight-related outcomes, but if studies reported weight
change and blood lipids and/or blood pressure, we abstracted this
information since weight change is a potential confounder. We
chose to include studies of at least 12 weeks duration and therefore
excluded many short-term studies. However, by selecting studies
of longer duration, we were able to determine if these effects were
sustained, which is more relevant for public health interventions.
There was substantial heterogeneity in the composition of diets
between studies so what drives the effects of low GI across studies
might be different; for example, if the intake of fibre was con-
trolled, this might make a difference to the outcome. LowGI diets
are often characterised by a higher fibre content which may con-
found the effect of low GI per se, although data have shown that
the effects of low GI diets can be seen in the absence of difference
in fibre content (Bjorck 2003). Where reported, the studies in-
cluded in this review had no significant difference in fibre content
when comparing the high and the low GI diets. The inclusion cri-
teria required a similar dietary composition between the interven-
tion and control groups with the exception of low GI within each
study, but the composition of diets between studies varied widely
and studies were variable in the level of detail provided. There may
also be different effects seen for advice to consume low GI foods
and provision of low GI foods. Currently, there were insufficient
studies included in the review to explore this in subgroup analyses.
Agreements and disagreements with other
studies or reviews
Thomas 2007 summarised six RCTs (duration five weeks to six
months) of the effects of low GI diets in overweight or obese
participants (n = 202). They found a significantly greater weight
loss in low GI groups (WMD -1.1 kg, 95% CI: -2.0, -0.2, P <
0.05, n = 163) and also a significantly greater decrease in total
cholesterol (WMD -0.22 mmol/L, 95% CI: -0.43, -0.02, P <
0.05) and LDL cholesterol (WMD -0.24mmol/L, 95%CI: -0.44,
-0.05, P < 0.05). However, the comparison diets in this review
were not matched for macronutrient composition, and so other
dietary factors may have contributed to the effect seen.
Goff 2013 assessed the effects of low GI diets on blood lipids in
28 RCTs lasting at least four weeks (n = 1272). Studies compar-
ing intended macronutrient differences of diets were excluded but
differences in fibre content were allowed. The authors also found
a significant reduction in total (WMD -0.13 mmol/L, 95% CI:
-0.22, -0.04, P < 0.004, n = 1441) and LDL cholesterol (WMD
-0.16 mmol/L, 95% CI: -0.24, -0.08, P < 0.0001, n = 1281) in
the low GI groups. This may have been due to the larger number
of short term studies included in that review; the meta-analyses
suggest that few of the individual trials found significant differ-
ences in cholesterol levels.
The review by Kristo 2013 focused on controlled feeding studies
(i.e. all food and drinks provided throughout the study) of low
versus high GI diets (with similar macronutrient composition).
They included five studies lasting between four and 12 weeks and
reported inconsistent results regarding the effects of the diets on
blood lipids.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is currently no evidence available regarding the effect of
low GI diets on cardiovascular disease events. Moreover, there is
currently no convincing evidence that low GI diets have a clear
beneficial effect on blood lipids or blood pressure parameters.
Implications for research
There is a need for well-designed, adequately powered, long-term
(follow-up at one year or more) RCTs to assess the effects of low
GI diets on cardiovascular risk factors. Measurement of GI and
desirable GI differences between diets should be standardised.
Studies are needed assessing the effects of low GI diets on hard
cardiovascular outcomes (to reduce the power requirements, this
may be best done in populations with an increased cardiovascular
risk, such as in patients with existing cardiovascular disease or type
2 diabetes mellitus).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Armendariz-Anguiano 2011
Methods Setting: Mexico; single centre; details of setting not reported.
Design: individual randomisation, parallel group.
Dates: trial dates not reported.
Intervention duration: 6 months.
Follow-up: no postintervention follow-up.
Focus: to compare the effects of different glycaemic load diets on biochemical data and
body composition in overweight and obese participants
Participants N: 54 (16/27 completers in the intervention group and 8/27 in the control group)
Inclusion criteria: overweight or obese adults.
Exclusion criteria: pregnancy, diabetes, cancer, psychiatric disorders, physical disabilities
Age (years) (mean (SD)): intervention: 36.9 (SD 9.0) (22 to 57); control: 33.8 (SD 8.
2) (21 to 53)
Sex (% men): intervention: 33.4%; control: 32.2%.
Ethnicity: Mexican.
Cardiovascular risk status (mean (SD)):
BMI (kg/m2): intervention: 30.7 (SD 4.0) (24 to 42); control: 32.5 (SD 5.9) (26 to 46).
Total cholesterol (mmol/L): intervention: 5.5 (SD 1.2); control: 6.1 (SD 3.0).
HDL cholesterol (mmol/L): intervention: 1.6 (SD 0.4); control: 1.7 (SD 0.4).
LDL cholesterol (mmol/L): intervention: 3.8 (SD 0.8); control: 4.4 (SD 2.7).
Blood pressure (mmHg): not reported.
Medications used: not reported.
Interventions Low GI group (n = 27): low glycaemic load diet.
Control (n = 27): high glycaemic load diet.
Description of dietary intervention: high and low glycaemic load diets were designed
according to the food habits ofMexicans living in the Tijuana area; GI values of each food
were estimated from the tables by Foster-Powell 2002; participants were given menus
with the high or low glycaemic load diets at the start of the intervention; a research
assistant was available by phone or mail for questions during the whole intervention;
emails were sent as reminders and diet reinforcements every 2 weeks
Incentives: not reported.
Cointerventions in both groups: none.
Assessment of dietary adherence: 3-day dietary records (2 weekdays and one weekend
day); only participants who completed these were included in the analysis
Was the diet energy-reduced? yes.
Comparability of diet composition: yes, see Table 2.
Change in diet over time: both groups significantly decreased their caloric intake by
468 to 500 kcal/day from baseline to 6 months, no significant difference between groups
Outcomes Outcomes (not clearly divided into primary and secondary): waist circumference,
BMI, fat mass, serum glucose, serum insulin, insulin resistance (HOMA), total choles-
terol, HDL cholesterol, LDL cholesterol, triglycerides; physical activity (International
Physical Activity Questionnaire), adverse events
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Armendariz-Anguiano 2011 (Continued)
Funding / conflict of interest Not reported.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Allocation method not reported.
Allocation concealment (selection bias) Unclear risk Allocation method not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding method not reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk Large number of dropouts/losses to follow-
up, reasons not given, imbalance between
groups
Loss to follow-up/drop-outs:
Low GI group: 11/27 (40.7%).
Control: 19/27 (70.4%).
Intention-to-treat analysis High risk No, only completers analysed.
Selective reporting (reporting bias) Unclear risk Not enough detail to judge.
Groups comparable at baseline Low risk With respect to demographic variables,
body composition and biochemical mark-
ers
Other bias High risk Power analysis (80% power to detect a
change in waist circumference with 30 par-
ticipants per group, i.e. study was under-
powered)
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Bellisle 2007
Methods Setting: France; 16 Weight Watchers classes in Paris; visits of the Hotel-Dieu hospital
for anthropometric and biochemical assessments
Design: cluster randomisation (Weight Watchers classes randomised), parallel group
Dates: classes attended January to March 2004.
Intervention duration: 12 weeks.
Follow-up: no postintervention follow-up.
Focus: to assess whether the Weight Watchers weight loss system could be improved by
encouraging dieters to select low GI, high carbohydrate foods
Participants N: 96 (35/51 completers in the intervention group and 30/45 in the control group)
Inclusion criteria: female, age 18 years or over, BMI > 25 kg/m2; recruited among first
time applicants to the Weight Watchers programme
Exclusion criteria: chronic disease (diabetes mellitus, eating disorders, psychiatric dis-
orders), pharmacological treatment
Age (years) (mean (SE)): intervention: 46.1 (SE 2.3); control: 45.3 (SE 2.2).
Sex: intervention: 100% women; control: 100% women.
Ethnicity: not reported.
Cardiovascular risk status (mean (SE)):
BMI (kg/m2): intervention: 30.2 (SE 0.7); control: 30.4 (SE 0.8).
Total cholesterol (mmol/L): intervention: 5.64 (SE 0.19); control: 5.88 (SE 0.16).
HDL cholesterol (mmol/L): intervention: 1.9 (SE 0.07); control: 1.81 (SE 0.09).
LDL cholesterol (mmol/L): intervention: 3.56 (SE 0.19); control: 3.91 (SE 0.14).
Blood pressure (mmHg): intervention: systolic 120.6 (SE 2.5), diastolic 74.1 (SE 1.8);
control: systolic 118.6 (SE 3.0), diastolic 72.8 (SE 2.2).
Medications used: not reported.
Interventions Low GI group (n = 51): standard Weight Watchers POINTS Weight Loss System
plus additional information about the GI of foods based on the International Table of
Glycaemic Index and Glycaemic Load Values (Foster-Powell 2002); Weight Watchers
booklets modified to emphasise low GI foods, participants encouraged to include at least
one low GI food (GI < 55) at each meal
Control (n = 45): standard Weight Watchers POINTS Weight Loss System with ad-
ditional information about the French National Nutrition and Health Programme, not
specifically dealing with GI (advice similar to that of Weight Watchers programme)
Description of dietary intervention: booklets with information on food selection,
weekly Weight Watchers class, increased consumption of fruit and vegetables, Ca and
carbohydrate, reduced total fat, increased daily physical activity; special training for class
leaders
Incentives: all costs associated with hospital visits were covered; participants were offered
three coupons for one free weekly attendance at Weight Watchers classes
Cointerventions in both groups: none.
Assessment of dietary adherence: food choice checklist completed for 3 days during a
randomly selected week of the 12 week programme (2 weekdays and one weekend day)
Was the diet energy-reduced? yes.
Comparability of diet composition: no details of diet composition, difference in food
selection based on GI reported, see Table 2.
Change in diet over time: diets of both groups tended to be rich in lowGI foods (mainly
fruit and vegetables), but the low GI group included fewer high GI choices
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Bellisle 2007 (Continued)
Outcomes Outcomes (not clearly divided into primary and secondary): weight (basis of power
analysis), BMI, blood pressure, fasting glucose, insulin, blood lipids, insulin sensitivity
(HOMA); behavioural and motivational questionnaires (Three Factor Eating Question-
naire, Dutch Eating Questionnaire); hunger (VAS), desire to eat (VAS)
Funding / conflict of interest Research grant by Weight Watchers International.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Classes were randomised, but method not
stated.
Allocation concealment (selection bias) Unclear risk Allocation method not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding method not reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk High attrition rate; reasons included lack
of time, pregnancy, illness, personal rea-
sons; no difference in anthropometric
and biochemical parameters between com-
pleters and non-completers but women
were younger in the non-completers
Loss to follow-up / drop-outs:
Low GI group: 16/51 (31.4%).
Control: 15/45 (33.3%).
Intention-to-treat analysis High risk Not explicitly reported, but probably not
as results were only reported for completers
Selective reporting (reporting bias) Unclear risk Not enough detail to judge.
Groups comparable at baseline Unclear risk With respect to demographic variables,
body composition and biochemical mark-
ers but only study completers reported
Other bias Unclear risk Power analysis (90% power to detect a
change in weight with 18 participants per
group); randomised as clusters but this was
not considered in the analysis
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Buscemi 2013
Methods Setting: Italy; medical centre.
Design: individual randomisation, parallel group.
Dates: study period November 2010 to February 2012.
Intervention duration: 3 months.
Follow-up: intervention phase followed by 12 month weight maintenance phase, but
results not reported
Focus: to assess the effects of hypocaloric diets with different glycaemic indexes and
glycaemic loads on endothelial function and glycaemic variability in nondiabetic partic-
ipants at increased cardiovascular risk
Participants N: 47 (19/22 completers in the intervention group and 21/25 in the control group)
Inclusion criteria: age 18 to 60 years, BMI 25.0 to 49.9 kg/m2, presence of ≥ 2
metabolic syndrome diagnostic criteria: waist circumference > 80 cm for women and 94
cm for men, serum triglycerides >150 mg/dL, serum HDL-cholesterol < 50 mg/dL for
women or 40 mg/dL for men, blood pressure > 130 mmHg for systolic or > 85 mmHg
for diastolic blood pressure, fasting plasma glucose ≥ 100 mg/dL; recruited through
announcement posted at medical centre
Exclusion criteria: diabetes mellitus, gastrointestinal or connective diseases, chronic
pancreatitis, liver or kidney disease, use of acetylsalicylic acid or other antiplatelet drugs,
statins or fibrates, oral hypoglycaemic drugs, nitrates, nonsteroidal anti-inflammatory
drugs, corticosteroids, drugs interfering with coagulation, supplementation with vita-
mins and/or antioxidants, pregnancy or lactation in the last six months, regular sports
activity
Age (years) (mean (SD)): intervention: 51 (SD 8) (20 to 60); control: 49 (SD 8) (21 to
59).
Sex (% men): intervention: 52.6%; control: 42.9%.
Ethnicity: not reported.
Cardiovascular risk status (mean (SD)):
BMI (kg/m2): intervention: 34.3 (SD 6.6) (25.1 to 49.6); control: 34.5 (SD 5.1) (27.6
to 47.5).
Total cholesterol (mmol/L): intervention: 5.48 (SD 1.01); control: 5.69 (SD 1.11).
HDL cholesterol (mmol/L): intervention: 1.23 (SD 0.31); control: 1.44 (SD 0.43).
LDL cholesterol (mmol/L): intervention: 3.88 (SD 0.96); control: 3.49 (SD 0.88).
Blood pressure (mmHg): intervention: systolic 128 (SD15), diastolic 77 (SD8); control:
systolic 124 (SD 13), diastolic 76 (SD 11).
Smokers: intervention: 10.5%; control: 14.3%.
Prediabetes: intervention: 42.1%; control: 38.1%.
Hypertension: intervention: 42.1%; control: 42.9%.
Medications used: intervention: 26.3% ACE inhibitors/angiotensin receptor blockers,
15.8% β-blockers, 10.5% Ca channel blockers, 5.3% α-blockers, 15.3% diuretics; con-
trol: 14.3% ACE inhibitors/angiotensin receptor blockers, 19.0% β-blockers, 4.8% Ca
channel blockers, 0% α-blockers, 23.8% diuretics
Interventions Low GI group (n = 22): hypocaloric low GI diet.
Control (n = 25): hypocaloric high GI diet.
Description of dietary intervention: diets were designed using lists of food high or low
in GI with participants receiving about 20 kcal per kg of body weight up to 2000 kcal/
day (1400, 1600, 1800, and 2000 kcal/day); after the initial 3 month intervention phase,
participants were assigned to a weight maintenance phase with the same Mediterranean
diet for 12 months (results not reported)
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Buscemi 2013 (Continued)
Incentives: no incentives.
Cointerventions in both groups: none.
Assessment of dietary adherence: participants met with a registered dietitian weekly
(maximum of 2 missed visits per participant allowed), received nutritional counselling,
and compiled a 3-day food diary (Friday, Saturday and Sunday) every 2 weeks; adherence
with prescribed diets was > 90% for both groups
Was the diet energy-reduced? yes.
Comparability of diet composition: yes, see Table 2.
Change in diet over time: prescribed diet.
Outcomes Outcomes (not clearly divided into primary and secondary):flow-mediated dilatation
(basis of power analysis), body composition and fat distribution, carotid intima thickness,
renal ultrasound analysis, 48-h continuous subcutaneous glucosemonitoring, lipid levels,
uric acid, plasma glucose, plasma insulin, HbA1c, insulin resistance (HOMA)
Funding / conflict of interest No funding, authors declared that they had no financial or other conflict of interest
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random list.
Allocation concealment (selection bias) Unclear risk Not reported, randomnumber list was gen-
erated by one of the investigators
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Staff members who obtained outcome
measurements were not informed of the
diet group assignment and intervention
staff members who delivered the interven-
tion did not take outcome measurements
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reasons for non-completion not reported.
Loss to follow-up / drop-outs:
Low GI group: 3/22 (13.6%).
Control: 4/25 (16%).
Intention-to-treat analysis High risk Not explicitly reported, results were only
reported for completers
Selective reporting (reporting bias) Low risk All outcomes stated in protocol reported.
Groups comparable at baseline Unclear risk With respect to demographic variables,
body composition, biochemical markers,
medication, comorbidities, but only study
completers reported
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Buscemi 2013 (Continued)
Other bias Unclear risk Power analysis (80% power to detect a
change in flow-mediated dilatation with 17
participants per group)
DiOGenes 2011 low protein
Methods Setting: 8 European countries (Netherlands, Denmark, UK, Greece, Spain, Germany,
Bulgaria, Czech Republic); research centres
Design: cluster randomisation (by family), parallel group.
Dates: enrolment November 2005 to April 2007.
Intervention duration: 26 weeks, extension to 1 year in 2 centres (Copenhagen, Maas-
tricht)
Follow-up: no postintervention follow-up.
Focus: to examine the effects of weight loss or diets varying in protein content and GI
without further changes in body weight on cardiovascular risk factors
Participants N: 773 adults (95/150 analysed in the low GI/low protein group, 84/155 high GI/low
protein, 108/159 low GI/high protein, 96/155 high GI/high protein, 104/154 control
(not considered here))
Inclusion criteria: generally healthy families (two parents or single parent) with at least
1 parent overweight (BMI ≥ 27 kg/m2) and aged < 65 years and with at least 1 child
aged between 5 and 18 years
Exclusion criteria: (for adults) BMI > 45 kg/m2, liver or kidney diseases, cardiovascular
diseases, diabetes mellitus, special diets/eating disorders, systemic infections/chronic dis-
eases, cancer within the last 10 years, weight change > 3 kg within the previous 3 months,
other clinical disorders or use of prescription medication that might interfere with the
outcome of the study, planned major changes in physical activity, pregnancy/lactation,
individuals following special diet; recruitment through various strategies (referrals from
GPs, flyers and posters, radio, TV, newspapers, internet)
Age (years) (mean (SD)): low GI/low protein: 42.1 (SD 5.8); high GI/low protein: 41.
6 (SD 5.9); low GI/high protein: 42.6 (SD 6.3); high GI/high protein:42.2 (SD 5.6) (all
numbers based on study completers).
Sex (%men): low GI/low protein: 34.7%; high GI/low protein:32.2%; low GI/high protein:
35.8%; high GI/high protein: 38.7% (all numbers based on ITT group).
Ethnicity: not reported.
Cardiovascular risk status (mean (SD)):
BMI (kg/m2): 32.5 to 36.1 (only reported for centres), total group 33.8.
Total cholesterol (mmol/L): low GI/low protein: 4.14 (SD 0.91); high GI/low protein: 4.
12 (SD 0.92); low GI/high protein: 4.17 (SD 0.87); high GI/high protein: 4.21 (SD 0.98)
.
HDL cholesterol (mmol/L): low GI/low protein: 1.13 (SD 0.28); high GI/low protein: 1.
17 (SD 0.25); low GI/high protein: 1.16 (SD 0.29); high GI/high protein: 1.14 (SD 0.27)
.
LDL cholesterol (mmol/L): low GI/low protein: 2.54 (SD 0.76); high GI/low protein: 2.
42 (SD 0.79); low GI/high protein: 2.54 (SD 0.81); high GI/high protein: 2.56 (SD 0.81)
.
Blood pressure (mmHg): low GI/low protein: systolic 118.6 (SD 9.4), diastolic 73.9 (SD
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DiOGenes 2011 low protein (Continued)
13.7); high GI/low protein: systolic 115.5 (SD 13.9), diastolic 71.4 (SD 9.2); low GI/high
protein: systolic 118.8 (SD 13.3), diastolic 73.5 (SD 9.6); high GI/high protein: systolic
120.1 (SD 15.0), diastolic 73.4 (SD 10.3).
Medications used: not reported.
Interventions Low GI/low protein (n = 150): low GI (difference 15 points between high and low GI
diets), low protein diet (10 to 15% energy from protein, 57 to 62% from carbohydrate)
High GI/low protein (n = 155): high GI, low protein diet (10 to 15% energy from
protein, 57 to 62% from carbohydrate)
Low GI/high protein (n = 159): low GI, high protein diet (23 to 28% energy from
protein, 45 to 50% from carbohydrate)
High GI/high protein (n = 155): high GI, high protein diet (23 to 28% energy from
protein, 45 to 50% from carbohydrate)
(Control diet (n = 154): control diet according to accepted national guidelines (12 to
15% energy from protein, 55 to 63% from carbohydrate) (not considered here)).
Description of dietary intervention: eligible adults followed an 8-week low calorie diet
(800 kcal/day, Modifast); about 200 g (up to 400 g) of additional raw vegetables per day
were allowed; the families of adults achieving a weight loss of≥ 8% (mean weight loss 11.
2 (SD 3.5 kg)) were randomised to one of the 5 ad libitum diets above; participants were
instructed to maintain weight loss during ad libitum phase; the average amount of plant
protein intake of total protein was 36%; dietary counselling every 2 weeks during first 6
weeks (with children, where possible), thenmonthly; families were providedwith recipes,
cooking and behavioural advice; point-based system to achieve desired macronutrient
composition; in 2 centres (’shop centres’, Copenhagen and Maastricht), adherence to
dietary compositions (food lists) was optimised during the first 6 months by providing
> 80% of all relevant foods for each of the diet groups at no cost through a lab-based
shop system
Incentives: free food in ’shop centres’.
Cointerventions in both groups: none.
Assessment of dietary adherence: (adults) 3-day food diaries (2 weekdays, 1 weekend
day) before study visit 1, 2 to 4 weeks after randomisation and before study visits 3 and
4
Was the diet energy-reduced? no.
Comparability of diet composition: yes, see Table 2.
Change in diet over time: energy reduced in all groups.
Outcomes Primary outcomes: weight, body composition, proportion maintaining > 5% or > 10%
of initial weight loss, dropout rate
Secondary outcomes: abdominal fat mass, risk factors for type 2 diabetes and cardio-
vascular disease (including blood lipids, blood pressure), appetite and satiety hormones,
physical activity, fat tissue mRNA, certain blood peptide and protein biomarkers; genetic
profiles, measurements of basal metabolic rate, free-living energy expenditure; psycho-
logical features (appetite and food preferences, health promoting behaviour, attitudes
towards eating, social support)
Funding / conflict of interest Funding by European Commission Food Quality and Safety Priority of the 6th Frame-
work Programme (contract FP6-2005-513946); local sponsors made financial contribu-
tions to the shop centres and local food manufacturers provided a number of foods free
of charge (but had no influence on the selection of foods found in the two shops, nor
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DiOGenes 2011 low protein (Continued)
were they in any other way involved in the study)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Web-based randomisation programme;
block randomisation with stratification ac-
cording to centre, number of eligible par-
ents within the family, number of parents
with BMI > 34 kg/m2.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The investigators who performed the statis-
tical analysis had not been in contact with
the participants; but blinding of outcome
assessment unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Slightly different numbers given in differ-
ent papers, following numbers according
to Larsen et al. 2010 NEJM; reasons for
dropout not given
Loss to follow-up/dropouts:
Low GI/low protein: 44/150 (29.3%).
High GI/low protein: 58/155 (37.4%).
Low GI/high protein: 35/159 (22.0%).
High GI/high protein: 48/155 (31.0%).
(Control diet: 40/154 (26.0%))
Intention-to-treat analysis Low risk ’intention-to-treat analyseswere performed
including...’
Selective reporting (reporting bias) Unclear risk Not enough information to judge.
Groups comparable at baseline Unclear risk With respect to demographic variables,
body composition, biochemical markers,
but only study completers reported
Other bias Unclear risk Power analysis (97% power to detect a
change in weight with 918 participants;
slightly underpowered)
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DiOGenes 2011a high protein
Methods See previous - study has two independent relevant comparisons
Participants
Interventions
Outcomes
Funding / conflict of interest
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk See above - study has two independent rel-
evant comparisons.
Allocation concealment (selection bias) Unclear risk See above.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk See above.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk See above.
Intention-to-treat analysis Low risk See above.
Selective reporting (reporting bias) Unclear risk See above.
Groups comparable at baseline Low risk See above.
Other bias Unclear risk See above.
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Frost 2004
Methods Setting: UK; Hammersmith Hospital, London.
Design: individual randomisation, parallel group.
Dates: unclear, patients entered on a cardiac intervention database for coronary bypass
grafting or cardiac angioplasty in 1997 and 1998 were selected and received a letter of
invitation to participate
Intervention duration: 12 weeks.
Follow-up: no postintervention follow-up.
Focus: to assess whether low GI diets improve the metabolic profile of patients having
undergone coronary artery bypass grafting (CABG)
Participants N: 57 (55/57 completed the study).
Inclusion criteria: age 30 to 70 years with coronary heart disease (myocardial infarction,
unstable angina, or angiographically proven coronary artery disease)
Exclusion criteria: cardiomyopathy, serious organ disease, systemic illness, chronic alco-
hol abuse, serious psychiatric illness, poor compliance with food diaries or failed medical
screening
Age (years) (mean (SD)): intervention: 63.6 (SD 9.4); control: 61.8 (SD 9.0).
Sex (% men): intervention: 88.5%; control: 86.2%.
Ethnicity: not reported.
Cardiovascular risk status (mean (SD or SE)):
BMI (kg/m2): intervention: 26.9 (SD 3.3); control: 28.7 (SD 4.6).
Total cholesterol (mmol/L): intervention: 4.77 (SE 0.15); control: 4.94 (SE 0.20).
HDL cholesterol (mmol/L): intervention: 1.11 (SE 0.04); control: 1.09 (SE 0.05).
LDL cholesterol (mmol/L): intervention: 2.89 (SE 0.13); control: 3.04 (SE 0.16).
Blood pressure (mmHg): intervention: systolic 141 (SE 6), diastolic 81 (SE 5); control:
systolic 140 (SE 4), diastolic 80 (SE 2).
Smokers: intervention: 38.5% never, 53.8% ex-smoker, 7.7% smoker; control: 31.0%
never, 62.1% ex-smoker, 6.9% smoker.
CABG: intervention: 84.6%; control: 89.7%.
Angioplasty: intervention: 7.7%; control: 6.9%.
CABG and angioplasty: intervention: 7.7%; control: 3.4%.
Length of diagnosis CABG (years) (mean (SD)): intervention: 7.0 (SD 6.5); control:
6.5 (SD 6.5).
Medications used: intervention: 58% statins, 23% ACE inhibitors, 19% diuretics, 73%
aspirin; control: 86% statins, 28% ACE inhibitors, 28% diuretics, 100% aspirin
Interventions Low GI group (n = 26): healthy eating advice emphasising low GI carbohydrates (GI
< 85)
Control (n = 29): healthy eating advice only.
Description of dietary intervention: one-to-one nutritional counselling, participants
supported by regular visits to the unit (weeks 0, 4 and 8) and telephone calls; advice based
on current health education guidelines advocated by the COMA panel; aim to provide
a diet with 50% carbohydrate and 35% of total energy as fat; unrefined high cereal fibre
carbohydrates were encouraged and fat content specified to be < 10% saturated fat, 10%
polyunsaturated fat and 15% monounsaturated fat; daily target of five portions of fruit
and vegetables; all patients with BMI > 28 kg/m2 were given advice to lose weight with
target 1 kg weight loss permonth. LowGI also at least 1 lowGI food at eachmeal. Liberal
use of carbohydrates (pasta, basmati rice, wholegrains foods, granary breads, whole fruit,
beans, vegetables, pulses or milk)
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Frost 2004 (Continued)
Incentives: not reported.
Cointerventions in both groups: none.
Assessment of dietary adherence: participants were asked to keep a 7-day diet diary on
four occasions during the study period
Was the diet energy-reduced? weight loss targeted in participants with BMI > 28 kg/
m2.
Comparability of diet composition: significant difference in daily energy, seeTable 2.
Change in diet over time: intervention:GI decreased, fibre increased, sucrose decreased;
control: reduced energy intake (P = 0.04 versus low GI) and sugar and GI
Outcomes Outcomes (not clearly divided into primary and secondary): total cholesterol (basis
of power analysis), weight, BMI, HbA1c, fasting glucose, insulin, HOMA, fasting lipids,
blood pressure
Funding / conflict of interest Not reported.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation by random numbers.
Allocation concealment (selection bias) Unclear risk Method not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not clearly reported, stated that 57 patients
met the inclusion criteria and55 completed
the study, no further detail
Intention-to-treat analysis High risk Not explicitly reported, but probably not
as results were only reported for completers
Selective reporting (reporting bias) Unclear risk Not enough information to judge.
Groups comparable at baseline High risk Significantly fewer participants in the low
GI group took a statin (58% versus 86%,
P = 0.02) and aspirin (73% versus 100%,
P = 0.01)
Other bias Unclear risk Power analysis based on total cholesterol,
but unclear if the study had adequate power
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Ghani 2014 low insulin
Methods Setting: not clear.
Design: individual randomisation (1:1 ratio).
Dates: not reported (all GDM deliveries registered in the institution between January
and September were screened for eligibility)
Intervention duration: 1 year.
Follow-up: no follow-up (end of intervention).
Focus: the effects of a lowering glycaemic index diet on fasting blood glucose , serum
lipids, body weight and composition of post-GDM women with varying fasting insulin
levels
Participants N: 77 (39 in the low GI group, 38 in the conventional dietary recommendations group)
Inclusion criteria: BMI > 23 kg/m2, WC > 80 cm, increased risk of T2DM, dysgly-
caemia, 20 to 40 year old Asian women, previous history of GDM after a lapse of at least
2 months of their last GDM delivery, family history of diabetes
Exclusion criteria: current diagnosis of diabetes, BMI > 40 kg/m2, BMI < 19 kg/m2,
enrolled in weight loss programmes, underlying health complications or those on drugs
altering study outcomes, subjects who became pregnant during trial
Age (years) (mean (SD)): intervention (low fasting insulin): 31.2 (SD 4.2), intervention
(high fasting insulin): 31.5 (SD 5.2); control (low fasting insulin): 31.0 (SD 3.8); control
(low fasting insulin): 31.8 (SD 5.1).
Sex: intervention: 100% women; control: 100% women.
Ethnicity: not reported.
Cardiovascular risk status (mean (SD)):
Total cholesterol (mmol/L): intervention (low fasting insulin): 5.0 (SD 0.98), intervention
(high fasting insulin): 5.2 (SD 0.7); control (low fasting insulin): 5.3 (SD 0.81), control
(low fasting insulin): 5.2 (SD 0.77).
HDL cholesterol (mmol/L): intervention (low fasting insulin): 1.5 (SD 0.4), intervention
(high fasting insulin): 1.2 (SD 0.3); control (low fasting insulin): 1.5 (SD 0.5), control (high
fasting insulin): 1.3 (SD 0.2).
LDL cholesterol (mmol/L): intervention (low fasting insulin): 3.2 (SD 1.0), intervention
(high fasting insulin): 3.4 (SD 0.8); control (low fasting insulin): 3.3 (SD 0.7), control (high
fasting insulin): 3.3 (SD 0.7).
Triglyceride (mmol/L): intervention (low fasting insulin): 0.7 (SD0.2), intervention (high
fasting insulin): 1.3 (SD 0.5) ; control (low fasting insulin): 0.93 (SD 2.8), control (high
fasting insulin): 1.1 (SD 0.5).
Weight (kg): intervention (low fasting insulin): 61.7 (SD 10.2), intervention (high fasting
insulin): 71.1 (SD 11.3); control (low fasting insulin): 57.9 (SD 10.1), control (high fasting
insulin): 72.1 (SD 10.6).
Medications used: not reported.
Interventions Low-GI education + conventional dietary recommendations: emphasis on reducing
GI intake along with nutrition education to lower CVD and T2DM was provided
Conventional dietary recommendations: nutrition education to lower CVD and
T2DM was provided. They provided a sample high GI menu
Description of dietary intervention: received GI education to substitute high GI foods
with low GI options. Substituting high GI staple food (rice, bread, breakfast cereal) with
low GI such as Basmati or brown rice and low GI multigrain bread. Restricting rice
consumption to once per day, opting for low GI staple options like noodles or spaghetti
and increasing consumption of legumes. Foods were classified as high, moderate and low
GI to enable easy comprehension
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Ghani 2014 low insulin (Continued)
Energy intake was individually calculated and a 500 calorie deficit was carried out.
Prescribed diets were provided. Vouchers for low GI breads were provided. Nutrition
education to lower CVD and T2DM was provided (minimise salt, sugar, and oil and
more fruit and vegetables). Take home educational material was provided. Frequency of
contact between the two groups was kept similar
Incentives: not reported.
Cointerventions in both groups: none.
Assessment of dietary adherence: not reported.
Was the diet energy-reduced? individually calculated with a 500 calorie deficit carried
out
Comparability of diet composition: not clear, see Table 2.
Change in diet over time: GI was significantly lower in the intervention group in
comparison to the control
Outcomes Outcomes (not clearly divided into primary and secondary): total cholesterol, triglyc-
eride, fasting lipids, blood pressure
Funding / conflict of interest Noncommercial.
Notes Outcomes were stratified by insulin levels (low fasting insulin INS < 2 µIU ml, high
fasting insulin INS ≥ µIU ml)
Author contacted on 24.06.2016 for risk of bias, CVD outcomes and further details on
control. Author reply provided published paper
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “eligible subjects were randomised accord-
ing to an allocation list (allocation 1:1) gen-
erated using randomisation software from
John Hopkins Division of Biostatics”
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Laboratory technicians and physicians re-
viewing the subjects were blinded to the
randomisation”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Outcome data available for all randomized
participants (n = 77). However, in an ear-
lier investigation (part of the 1-year study)
authors stated attrition rate and reported
different numbers (n = 60) to the 1-year
study:
Intervention group (low LGI): 7/30 (23%)
.
Control group (conventional healthy di-
etary recommendations): 5/30 (17%)
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Ghani 2014 low insulin (Continued)
Intention-to-treat analysis Unclear risk Not stated.
Selective reporting (reporting bias) Low risk Reported outcomes that they intended to
measure.
Groups comparable at baseline Low risk With respect to demographic variables, an-
thropometric and biochemical markers
Other bias Unclear risk “Individual effect size values were calcu-
lated for changes in outcomes for each of
the two diet groups and compared. ES val-
ues between 0.2 to 0.5, 0.5 to 0.8 and > 0.
8 were taken to denote ‘small’, ‘moderate’
and ‘large’ changes in outcomes”. Did not
report how many participants required to
reach this effect size
Ghani 2014a high insulin
Methods See previous - study stratified analysis by fasting insulin levels
Participants
Interventions
Outcomes
Funding / conflict of interest
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk See above.
Allocation concealment (selection bias) Unclear risk See above.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk See above.
Intention-to-treat analysis Unclear risk See above.
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Ghani 2014a high insulin (Continued)
Selective reporting (reporting bias) Low risk See above.
Groups comparable at baseline Low risk See above.
Other bias Unclear risk See above.
Hönemann 2010
Methods Setting: Germany; Institute of Nutritional Psychology, Göttingen.
Design: individual randomisation, parallel group.
Dates: not reported.
Intervention duration: 6 months.
Follow-up: no postintervention follow-up.
Focus: to assess the effects of several popular nutritional weight-reducing strategies on
cardiovascular risk factors
Participants N: 160 (31/53 completers in the low GI/low fat group, 27/54 in the low fat group, 26/
53 in the low CHO group)
Inclusion criteria: female, age 25 to 70 years, BMI 25 to 42 kg/m2, no serious comor-
bidities; recruited through newspaper advertisements
Exclusion criteria: dieting attempts/weight reduction in the past 6 months, extreme
low fat or low carbohydrate nutrition before the start of the study
Age (years) (mean (SD)): intervention: 51.1 (SD 8.6); control: 49.6 (SD 11.4).
Sex: intervention: 100% women; control: 100% women.
Ethnicity: not reported.
Cardiovascular risk status (mean (SD)):
Weight (kg): intervention: 84.1 (SD 9.8); control: 83.0 (SD 10.8).
Total cholesterol (mmol/L): intervention: 5.35 (SD 0.77); control: 5.38 (SD 1.00).
HDL cholesterol (mmol/L): intervention: 1.45 (SD 0.24); control: 1.48 (SD 0.33).
LDL cholesterol (mmol/L): intervention: 3.59 (SD 0.66); control: 3.54 (SD 0.86).
Blood pressure (mmHg): intervention: systolic 129.8 (SD 18.4), diastolic 82.9 (SD 8.
7); control: systolic 127.7 (SD 16.7), diastolic 82.7 (SD 9.4).
Medications used: not reported.
Interventions Low GI group (n = 53): low fat and reduction of glycaemic load, maximum 30 g fat
per day in first 4 weeks, then maximum 45 g fat per day for 5 months; maximum 50 g
carbohydrates with high glycaemic load
Control (n = 54): low fat only,maximum30 g fat per day in first 4 weeks, thenmaximum
45 g fat per day for 5 months
(Low CHO group (n = 53):maximum 30 g carbohydrates per day in first 4 weeks, then
maximum 60 g carbohydrates per day for 5 months (not considered here)).
Description of dietary intervention: written information about the different diets
according to study group; written instructions for behaviour change including increase
in physical activity; other macronutrients could be consumed ad libitum
Cointerventions in both groups: none.
Assessment of dietary adherence: weekly appointments for weight control, analysis
of consumption using computer system at time 0, 1 month and 6 months; adherence
intervention 69.8%, control 64.8%
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Hönemann 2010 (Continued)
Was the diet energy-reduced? not reported.
Comparability of diet composition: unclear, see Table 2.
Change in diet over time: intervention: carbohydrate increased, fat decreased, small
increase in fibre (+ 3.8 (SD 10.6) g/day); control: carbohydrate increased, fat decreased.
Outcomes Outcomes (not clearly divided into primary and secondary): weight (basis of power
analysis), blood pressure, blood lipids, blood glucose, B vitamins, homocysteine
Funding / conflict of interest Funded by Stifterverband für die DeutscheWissenschaft; authors declared that they had
no conflicts of interest
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Allocation method not reported.
Allocation concealment (selection bias) Unclear risk Allocation method not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk High attrition rate, reasons for discontin-
uation not reported; 59/160 (36.9%) dis-
continued, 17/160 were excluded (12 due
to high sensitive reactive C-protein eleva-
tion > 8 mg/L, 2 due to lack of adherence)
Loss to follow-up/dropouts:
Low GI group: 22/53 (41.5%);
Control: 27/54 (50%).
(Low CHO group: 27/53 (50.9%)).
Intention-to-treat analysis High risk Per-protocol analysis; weight reductionwas
also analysed in an intention-to-treat anal-
ysis
Selective reporting (reporting bias) Low risk Reported outcomes that the authors in-
tended to measure.
Groups comparable at baseline High risk With respect to demographic variables,
most biochemical markers; triglycerides
were significantly lower in the lowGI group
at baseline than in the control group
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Hönemann 2010 (Continued)
Other bias Low risk Power analysis (80% power to detect a
change in weight with 16 participants per
group)
Juanola-Falgarona 2014
Methods Setting: Spain, community-dwelling, setting not clearly reported.
Design: Parallel group design.
Dates: Recruitment from 2010 to 2012. Enrolment: completed at the end of May 2012
Intervention duration: 6 months, February 2010 to November 2012.
Follow-up:No follow-up (end of intervention at 6 months).
Focus: to assess the efficacy of 2 moderate-carbohydrate diets and an LF diet with
different GIs on weight loss and the modulation of satiety, inflammation, and other
metabolic risk markers
Participants N: 121 (37/41 completers in the low GI group, 36/41 completers in the high GI group,
31/40 completers in the low fat group)
Inclusion criteria: community-dwelling, females and males, age 30 to 60 years, BMI
between 27 and 35 kg/m2.
Exclusion criteria: noncontrolled type 2 diabetes defined as glycated hemoglobin 8%,
systolic blood pressure 159 mm Hg or diastolic blood pressure 99 mm Hg, plasma
LDL cholesterol concentration 160 mg/dL, plasma triglyceride concentration 400 mg/
dL, suspicion of secondary obesity, presence of any inflammatory or chronic obstructive
pulmonary disease, infection, active neoplastic, endocrine, or hematologic disease at the
time of the study, blood leukocyte count ≥ 11 × 106 cells, use of anti-inflammatory
drugs, steroids, hormones or antibiotics that could affect the variables analysed in the
study, changes in medication for lipid profile, diabetes, or hypertension in the previous 3
months, active alcoholism or drug dependence, excluding tobacco use, a restrictive diet
3 months before the study or weight loss 0.5 kg in the previous 3 months, any medical
condition that advised against being included in the study, problems understanding the
study or anticipated difficulty in making dietary changes according to the Prochaska and
DiClemente model
Age (years) (mean (SE)): low GI group: 42.5 (SE 1.1); high GI group: 44 (SE 1.3).
Sex (% men): low GI group: 19%; high GI group: 17%.
Ethnicity: not reported.
Cardiovascular risk status (mean (SE)):
Weight (kg): low GI group: 82.7 (SE 1.5); high GI group: 82.7 (SE 1.6).
BMI (kg/m2): low GI group: 31.2 (SE 0.3); high GI group: 30.8 (SE 0.3).
Total cholesterol (mmol/L): low GI group: 4.99 (SE 0.13); high GI group: 5.13 (SE 0.
13).
HDL cholesterol (mmol/L): low GI group: 1.45 (SE 0.05); high GI group: 1.47 (SE 0.
05).
LDL cholesterol (mmol/L): low GI group: 3.05 (SE 0.11); high GI group: 3.15 (SE 0.
10).
Blood pressure (mmHg): low GI group: systolic 128.0 (SE 2.7), diastolic 80.2 (SE 1.7);
high GI group: systolic 128.0 (SE 2.4), diastolic 81.2 (SE 1.5).
Medications used: not reported.
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Juanola-Falgarona 2014 (Continued)
Interventions Low GI group (n = 41): encouraged to eat whole grain cereals and pulses as the base
of their diet, avoid rice and potatoes, and were also recommended to select specific type
of fruit (apple, orange, peach) and vegetables (courgette, tomato, onion) with low GI,
avoiding the ripe pieces. They were advised to reduce the time cooking of carbohydrate-
rich foods in order to maintain the low GI of the foods. The principal animal protein
sources of the diet were white fish and white meat.
High GI group (n = 41): encouraged to eat refined grain cereals, fruits (banana, kiwi,
melon) and vegetables (carrot, green bean, cabbage) with high GI, and avoid pulses.
Were advised to increase the time cooking in order to raise the GI of the foods. In this
intervention group, intake of white fish and white meat were the main animal sources
of protein
(Low fat group (n = 40):maintain a high-GI diet but with lower fat content. They were
encouraged to avoid redmeat andblue fish due its high fat content and also recommended
to eat low-fat dairy products.(not considered here)).
Description of dietary intervention: a booklet, biweekly menus and seasonal receipts.
Cointerventions in both groups: diets were designed at 1500, 1700, 2000, and 2500
kcal/d, and all participants were categorized as having one of the 4 categories of dietary
energy content after subtracting 500 kcal/d of the total estimated energy intake to achieve
a desired weight loss
Assessment of dietary adherence: not reported.
Was the diet-energy reduced? subtracting 500 kcal/d of the total estimated energy
intake to achieve a desired weight loss
Comparability of diet composition: not clear, see Table 2.
Change in diet over time: low GI: energy, % of energy from carbohydrates, % of energy
from fat and GI decreased; % of energy from protein and fibre increased. high GI: energy
and % of energy from fat decreased; % of energy from carbohydrates, % of energy from
protein, fibre, and GI increased
Outcomes Primary outcome: weight loss (power calculations based on body weight).
Funding / conflict of interest Grant from the Institut d’Investigació Sanitaria Pere Virgili (PV11059S) and Fondo
de Investigación Sanitaria (PI120153). None of the authors had a personal or financial
conflict of interest
Notes Author contacted on 15.08.2016 to clarify risk of bias. Author did not reply
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Subjects fulfilling the inclusion criteria
were randomly assigned to three equally
sized different dietary intervention groups,
by using a computer generated random-
number sequence’
Allocation concealment (selection bias) Unclear risk Not reported.
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Juanola-Falgarona 2014 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Laboratory technicians and statisticians
were blinded to group assignments’
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up/dropouts:
Low GI group: 4/41 (9.8%);
High GI group: 5/41 (12.2%).
Intention-to-treat analysis Low risk “All statistical analyses were conducted by
both intention-to-treat (ITT) and per pro-
tocol (PP) approaches. The ITTanalysis in-
cluded all randomly assigned participants.
The last observation carried forward was
used for handling missing data”
Selective reporting (reporting bias) High risk Blood pressure parameters were not re-
ported postintervention. Physical activity
was assessed but not reported
Groups comparable at baseline Low risk With respect to demographic variables, an-
thropometric and biochemical markers
Other bias Unclear risk Power calculations based on body weight
not outcomes of interest for this review;
so the study may be underpowered for the
outcomes of interest, i.e. lipids and blood
pressure
McMillan-Price 2006 high CHO
Methods Setting: Australia; setting not clearly reported.
Design: individual randomisation, parallel group.
Dates: screening July 2002 to July 2004.
Intervention duration: 12 weeks.
Follow-up: no postintervention follow-up.
Focus: to assess the relative effects of low GI and high protein diets on weight loss and
cardiovascular risk factors
Participants N: 129 (30/32 completers in the low GI/high CHO group, 27/32 in the high GI/high
CHOgroup, 28/33 in the lowGI/high protein group, 31/32 in the highGI/high protein
group)
Inclusion criteria: 18 to 40 years, BMI ≥ 25 kg/m2, body weight < 150 kg, weight
fluctuations < 5 kg in past 2 months, willing to eat red meat and maintain current
physical activity; recruited using notice boards and newspaper advertisements
Exclusion criteria: chronic illness, regular medication other than birth control pills,
eating disorders, special diets, pregnancy, food allergy, and insufficient command of
English
Age (years) (mean (SE)): low GI/high CHO: 30.5 (SE 1.4); high GI/high CHO: 31.8
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McMillan-Price 2006 high CHO (Continued)
(SE 1.7); low GI/high protein: 34.6 (SE 1.5); high GI/high protein: 30.2 (SE1.5).
Sex (% men): low GI/high CHO: 28%; high GI/high CHO: 22%; low GI/high protein:
21%; high GI/high protein: 25%.
Ethnicity: not reported.
Cardiovascular risk status (mean (SE)):
BMI (kg/m2): low GI/high CHO: 30.6 (SE 0.8; high GI/high CHO: 30.9 (SE 0.6); low
GI/high protein: 32.1 (SE 0.9); high GI/high protein: 31.3 (SE 0.8).
Total cholesterol (mmol/L): low GI/high CHO: 4.71 (SE 0.19); high GI/high CHO: 4.
79 (SE 0.19); low GI/high protein: 4.83 (SE 0.14); high GI/high protein: 5.15 (SE 0.18).
HDL cholesterol (mmol/L): low GI/high CHO: 1.17 (SE 0.05); high GI/high CHO: 1.
29 (SE 0.07); low GI/high protein: 1.36 (SE 0.08); high GI/high protein: 1.16 (SE 0.05).
LDL cholesterol (mmol/L): low GI/high CHO: 2.90 (SE 0.14); high GI/high CHO: 2.
87 (SE 0.16); low GI/high protein: 2.89 (SE 0.14); high GI/high protein: 3.33 (SE 0.15).
Blood pressure (mmHg): not reported.
Medications used: none.
Interventions LowGI/high CHO (n = 32): high carbohydrate (55% of energy), average protein (15%
of energy), based on low GI foods
High GI/high CHO (n = 32): high carbohydrate (55% of energy), average protein
(15% of energy), based on high GI wholegrains
Low GI/high protein (n = 33): higher protein (25% of energy), reduced carbohydrate
(45% of energy), based on lean red meat and low GI foods
High GI/high protein (n = 32): higher protein (25% of energy), reduced carbohydrate
(45% of energy), based on lean red meat and high GI wholegrains
Description of dietary intervention: reduced energy, reduced fat (30% of energy),
moderate fibre (30 g/day) eating plans; eating plans were devised to achieve the desired
macronutrients and to provide 1400 kcal/day for women and 1900 kcal/day for men;
additional lists of appropriatemeals and snacks provided; all key carbohydrate andprotein
foods and some prepared meals were provided using a colour-coded ’shop’ system where
participants could collect the respective food each week; participants met with a dietitian
on the same day who encouraged adherence and answered queries
Incentives: as above.
Cointerventions in both groups: none.
Assessment of dietary adherence: 3-day food diaries (2 weekdays, 1 weekend day) kept
at baseline and during weeks 4 and 8
Was the diet energy-reduced? yes.
Comparability of diet composition: yes, see Table 2.
Change in diet over time: change in energy and nutrient intake, as intended.
Outcomes Outcomes:weight, fatmass, blood lipids, blood glucose, blood insulin, insulin sensitivity
(HOMA), leptin
Funding / conflict of interest Funded by the National Heart Foundation and Meat and Livestock Australia
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Stratified according to weight (< 80 kg, 80
to 100 kg, > 100 kg) and sex; allocation
method not reported
Allocation concealment (selection bias) Unclear risk Allocation method not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for discontinuation only reported
overall (1 pregnancy, 1 failed to complete
the final analysis, 2 moved away, 9 were
disappointed with weight loss)
Loss to follow-up/dropouts:
Low GI/high CHO: 2/32 (6.3%);
High GI/high CHO: 5/32 (16.6%).
Low GI/high protein: 5/33 (15.2%).
High GI/high protein: 1/32 (3.1%).
Intention-to-treat analysis Low risk Last observation carried forward.
Selective reporting (reporting bias) Unclear risk Not enough information to assess.
Groups comparable at baseline Low risk With respect to demographic variables, an-
thropometric and biochemical markers
Other bias Unclear risk Power analysis (90% power to detect a
change in weight with 30 participants per
group; but considering dropouts, the study
may be underpowered)
McMillan-Price 2006 high protein
Methods See previous - study had two independent relevant comparisons
Participants
Interventions
Outcomes
Funding / conflict of interest
Notes
Risk of bias
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McMillan-Price 2006 high protein (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk See above - study had two independent rel-
evant comparisons.
Allocation concealment (selection bias) Unclear risk See above.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk See above.
Incomplete outcome data (attrition bias)
All outcomes
Low risk See above.
Intention-to-treat analysis Low risk See above.
Selective reporting (reporting bias) Unclear risk See above.
Groups comparable at baseline Low risk See above
Other bias Unclear risk See above.
Melanson 2012
Methods Setting: USA; setting not reported.
Design: individual randomisation, parallel group.
Dates: not reported.
Intervention duration: 12 weeks.
Follow-up: no postintervention follow-up.
Focus: to assess the effects of multidisciplinary weight loss programmes on chronic
disease prevention
Participants N: 157 (49/59 completers in the low GI group, 41/41 in the portion control group, 45/
57 in the low energy density group)
Inclusion criteria: age 25 to 50 years, BMI 27 to 35 kg/m2, sedentary (< 150 min
physical activity per week), weight stable; recruited through newspaper advertisements
Exclusion criteria: taking prescription medication or over-the-counter supplements
for weight loss; diabetes, uncontrolled hypertension, orthopaedic limitations, eating
disorders, pregnancy or lactation, surgical medical conditions, recent weight loss, excess
alcohol intake, serious medical conditions; current enrolment in commercial weight loss
programme
Age (years) (mean (SD)): low GI: 39.1 (SD 7.1); portion control: 37.9 (SD 7.0).
Sex (% men): low GI: 11.9%; portion control: 12.2%.
Ethnicity: not reported.
Cardiovascular risk status (mean (SD)):
BMI (kg/m2): low GI: 31.13 (SD 2.50); portion control: 31.83 (SD 2.18).
Total cholesterol (mmol/L): low GI: 5.22 (SD 1.05); portion control: 5.29 (SD 1.29).
HDL cholesterol (mmol/L): low GI: 1.42 (SD 0.33); portion control: 1.44 (SD 0.31).
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LDL cholesterol (mmol/L): low GI: 3.07 (SD 0.76); portion control: 3.32 (SD 1.27).
Blood pressure (mmHg): low GI: systolic 113.02 (SD 10.11), diastolic 72.42 (SD 7.13)
; portion control: systolic 112.39 (SD 8.69), diastolic 71.12 (SD 7.27).
Medications used: none.
Interventions LowGI group (n = 59): followed a dietary plan based on foods from the Low Glycaemic
Index Pyramid; no prescription of specific portions or food tracking; encouraged to eat
unrefined grains; instructions to eat prior to getting too hungry and stopping before
feeling too full
Portion control (n = 41): instructed on an approach assigning point values to foods
based on energy content, dietary fibre, total fat in defined serving sizes; individual target
amount of point values to consume assigned to each participant, based on current weight
and a target weight loss of about 0.5 to 1 kg/week; participants kept track of the point
values of foods consumed, to assure that their daily intake was within their points limit;
guidelines regarding food choices to ensure nutritional adequacy provided
(Low energy density (n = 57): instructed to follow a plan based on wholesome low
energy density foods; guidelines aboutmaking food choices encouraging balanced intake;
instructions to eat prior to getting too hungry and stopping before feeling too full (not
considered here as GI not different from low GI group)).
Description of dietary intervention: participation in Weight Watchers programme
with weekly meetings to encourage regular physical activity, cognitive skills; weekly one-
hour meetings included weigh-ins, social support, discussions, education; at baseline, all
groups received individual counselling from a registered dietitian on how to follow the
assigned dietary plans, including education materials; distribution of recipes, shopping
lists, and other guidelines specific to the respective diets; adherence to diets emphasised
Incentives: not reported.
Cointerventions in both groups: none.
Assessment of dietary adherence: 3-day food diaries (2 weekdays, 1 weekend day)
before baseline and week 12 visit
Was the diet energy-reduced? not reported.
Comparability of diet composition: yes, see Table 2.
Change in diet over time: all groups significantly decreased their energy intake.
Outcomes Outcomes (not clearly divided into primary and secondary): weight (basis of power
analysis), BMI, body composition, waist circumference, blood pressure, blood lipids,
blood glucose, blood insulin, insulin sensitivity (HOMA), hunger/satiety (VAS)
Funding / conflict of interest Funding not reported; one author had received consulting fees and research grants from
Weight Watchers International
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Allocation method not reported.
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Allocation concealment (selection bias) Unclear risk Allocation method not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reasons for discontinuation not reported.
Loss to follow-up/dropouts:
Low GI group: 10/59 (17%);
Portion control: 41/41 (0%);
(Low energy density: 12/57 (21%))
Intention-to-treat analysis High risk Not explicitly reported, but probably not
as results were only reported for completers
Selective reporting (reporting bias) Unclear risk Unclear, total cholesterol and LDL choles-
terol only reported narratively, no data pro-
vided
Groups comparable at baseline High risk With respect to demographic variables, an-
thropometric variables, most biochemical
markers; significantly higher blood triglyc-
erides, significantly lower fibre intake and
significantly lower blood glucose in the low
GI group compared to the portion control
group at baseline
Other bias Unclear risk Power analysis (based onweight, but details
not reported).
Philippou 2008
Methods Setting: UK; setting not reported.
Design: individual randomisation, parallel group.
Dates: not reported.
Intervention duration: 12 weeks.
Follow-up: no postintervention follow-up.
Focus: to assess the effects of two energy-restricted health diets with or without low GI
on heart disease risk factors in participants at risk of heart disease
Participants N: 18 (13/18 completers, not reported for comparison groups).
Inclusion criteria: age 35 to 65 years, at least one recognised heart disease risk factor
(BMI 27 to 35 kg/m2, waist circumference ≥ 88 cm for women and ≥ 94 cm for men,
total cholesterol:HDL ratio ≥ 5.0 mmol/L, blood pressure systolic > 130 mmHg or
diastolic > 85 mmHg)
Exclusion criteria: major illnesses, lipid lowering, and weight loss medication
Age (years): intervention: 54 (49 to 58); control: 45 (39 to 50).
Sex (% men): intervention: 42.9%; control: 33.3%.
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Ethnicity: not reported.
Cardiovascular risk status:
BMI (kg/m2): intervention: 28.6 (28.1 to 29.8); control: 33.2 (28.2 to 34.2).
Total cholesterol (mmol/L, median, IQR): intervention: 5.7 (4.9 to 6.1); control: 5.3
(5.0 to 6.1).
HDL cholesterol (mmol/L, median, IQR): intervention: 1.5 (1.1 to 1.6); control: 1.3
(1.2 to 1.4).
LDL cholesterol (mmol/L, median, IQR): intervention: 3.7 (3.0 to 4.3); control: 3.4 (3.
1 to 3.9).
Blood pressure (mmHg): not reported.
Medications used: not reported.
Interventions Low GI group (n = 7): healthy eating advice plus advice to have one low GI food with
meals and snacks from a list of food choices
Control (n = 6): healthy eating advice plus advice to have one high GI food with meals
and snacks from a list of food choices
Description of dietary intervention: individual advice on healthy eating for heart dis-
ease prevention aiming for 50 to 55% of energy intake from carbohydrates, < 30% energy
from total fat (of which < 10% saturated fat, replacing saturated fats bymonounsaturated
fats, consuming oily fish twice a week), and limiting alcohol and salt intake; overweight
participants were advised on weight loss by aiming for a 500 kcal/day energy deficit
Incentives: not reported.
Cointerventions in both groups: none.
Assessment of dietary adherence: regular visits, telephone calls, 7-day food diaries.
Was the diet energy-reduced? yes, for overweight participants.
Comparability of diet composition: yes, see Table 2.
Change in diet over time: energy intake decreased in both groups.
Outcomes Outcomes (not clearly divided into primary and secondary): weight, fasting glucose,
fasting blood lipids.
Funding / conflict of interest Funding not reported.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Allocation method not reported.
Allocation concealment (selection bias) Unclear risk Allocation method not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
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Incomplete outcome data (attrition bias)
All outcomes
High risk High attrition rate, reasons for discontin-
uation not reported; 4 discontinued, 1 ex-
cluded due to high alcohol intake and
triglycerides > mean + 2SD
Loss to follow-up/drop-outs: only re-
ported for whole group, 5/18 (27.8%).
Intention-to-treat analysis Unclear risk Not reported.
Selective reporting (reporting bias) Unclear risk Not enough information to judge.
Groups comparable at baseline Low risk With respect to demographic variables, an-
thropometric variables, biochemical mark-
ers
Other bias High risk No power analysis, small sample size.
Philippou 2009
Methods Setting: UK; setting not reported.
Design: individual randomisation, parallel group.
Dates: not reported.
Intervention duration: 6 months.
Follow-up: no postintervention follow-up.
Focus: to assess the effects of altering GI, in addition to healthy eating and weight loss
advice, on heart disease risk factors
Participants N: 56 (38/56 completers, not reported for comparison groups).
Inclusion criteria: men, age 35 to 65 years, at least one recognised heart disease risk
factor (BMI 27 to 35 kg/m2, waist circumference ≥ 94 cm, total cholesterol:HDL ratio
≥ 5.0 mmol/L, raised blood pressure to a maximum of 140/90 mmHg); in good health
Exclusion criteria: medication use.
Age (years): not reported.
Sex (% men): all men.
Ethnicity: not reported.
Cardiovascular risk status (mean (SD)):
BMI (kg/m2): intervention: 20/22 had BMI > 25 kg/m2; control: all had BMI > 25 kg/
m2; no further details.
Total cholesterol (mmol/L): intervention: 5.61 (SD 0.79); control: 5.19 (SD 0.91).
HDL cholesterol (mmol/L, median, IQR): intervention: 1.1 (1.01 to 1.26); control: 1.
1 (0.96 to 1.37).
LDL cholesterol (mmol/L): intervention: 3.62 (SD 0.63); control: 3.34 (SD 0.80).
Blood pressure (mmHg): intervention: systolic 130 (SD15), diastolic 81 (SD11); control:
systolic 132 (SD 13), diastolic 81 (SD 10).
Medications used: not on medication.
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Interventions Low GI group (n = 22): healthy eating advice plus advice to have one low GI food with
meals and snacks
Control (n = 16): healthy eating advice plus advice to have one high GI food with meals
and snacks
Description of dietary intervention: advice on healthy eating for heart disease preven-
tion and weight loss if BMI > 25 kg/m (energy reduced by 500 kcal with respect to
the estimated needs); supported by behavioural techniques; groups were asked to avoid
foods of the opposite GI; dietetic consultations and anthropometric measurements were
carried out monthly
Incentives: not reported.
Cointerventions in both groups: none.
Assessment of dietary adherence: monthly 3-day food diaries.
Was the diet energy-reduced? yes, for overweight participants.
Comparability of diet composition: significant difference in carbohydrate, fat/protein/
fibre not reported but stated that no other difference in dietary composition; see Table
2.
Change in diet over time: energy intake decreased in both groups.
Outcomes Outcomes (not clearly divided into primary and secondary): arterial compliance
(pulse wave velocity), 24-h blood pressure, fasting blood lipids, fasting glucose and
insulin, weight
Funding / conflict of interest Funded by the British Heart Foundation.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Allocation method not reported.
Allocation concealment (selection bias) Unclear risk Allocation method not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk High attrition rate, reasons for discontinu-
ation not reported
Loss to follow-up/dropouts: only re-
ported for whole group 18/56 (32.1%).
Intention-to-treat analysis Unclear risk Not reported.
Selective reporting (reporting bias) Unclear risk Not enough detail to judge.
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Groups comparable at baseline Low risk With respect to biochemical and anthropo-
morphic variables.
Other bias Unclear risk No power analysis.
Philippou 2009a
Methods Setting: UK; Hammersmith Hospital, London.
Design: individual randomisation, parallel group.
Dates: not reported.
Intervention duration: 4 months.
Follow-up: no postintervention follow-up.
Focus: to assess the effects of altering diet GI on weight loss maintenance
Participants N: 42 completers (not reported how many started the study).
Inclusion criteria: age 18 to 65 years, BMI 27 to 45 kg/m2, good health status assessed
by blood tests, medical examination and ECG
Exclusion criteria: not reported.
Age (years): not reported.
Sex (% men): not reported.
Ethnicity: not reported.
Cardiovascular risk status (mean (SD)):
BMI (kg/m2): intervention: 32.5 (SD 4.8); control: 31.3 (SD 4.8).
Total cholesterol (mmol/L): intervention: 4.67 (SD 0.93); control: 4.87 (SD 0.67).
HDL cholesterol (mmol/L): intervention: 1.26 (SD 0.21); control: 1.19 (SD 0.16).
LDL cholesterol (mmol/L): intervention: 3.01 (SD 0.81); control: 3.21 (SD 0.58).
Blood pressure (mmHg): not reported.
Medications used: not reported.
Interventions Low GI group (n = 23): low GI diet.
Control (n = 19): high GI diet.
Description of dietary intervention: the study consisted of a nonrandomised weight
loss phase which was the prerequisite to being randomised to a low or high GI diet for
weight maintenance; the weight loss phase aimed to achieve a 500 to 1000 kcal/day
deficit and a 5% reduction in body weight (including use of Slimfast); participants who
lost 5% body weight were then randomised to the second part of the study (median
weight loss achieved was 6.1 (IQR 5.2 to 7.1)% body weight); during the randomised
phase, participants were asked to include at least one low or high GI food with each of
their meals or snacks; participants were asked to eat to satisfy their appetite and follow
healthy eating guidelines (e.g. avoid high fat foods, consume 5 portions of fruit and
vegetables a day) and continue exercising for at least half and hour a day
Cointerventions in both groups: none.
Assessment of dietary adherence: participants seen monthly for dietetic assessment;
adherence assessed using semiquantitative 3-day food diaries
Was the diet energy-reduced? no, weight maintenance after weight loss.
Comparability of diet composition: yes; see Table 2.
Change in diet over time: not reported with respect to weight loss phase or study start
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Outcomes Primary outcome: weight change during weight maintenance phase.
Secondary outcomes:BMI,waist circumference,%body fat, fasting blood lipids, fasting
blood glucose and insulin, insulin sensitivity (HOMA), appetite/hunger/fullness (VAS)
Funding / conflict of interest Not reported; Slimfast used during the weight loss phase provided by Unilever; one of
the authors was a consultant to Unilever
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Allocation method not reported.
Allocation concealment (selection bias) Unclear risk Allocation method not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Only reported howmanyparticipants com-
pleted the study, not how many partici-
pants started the study
Intention-to-treat analysis High risk Only participants completing the study
were analysed.
Selective reporting (reporting bias) Unclear risk Not enough detail to judge.
Groups comparable at baseline Low risk No significant difference in any of the out-
comes at randomisation; age and sex not
reported
Other bias Unclear risk No power analysis.
Raatz 2005
Methods Setting: USA; research centre.
Design: individual randomisation, parallel group.
Dates: not reported.
Intervention duration: 36 weeks (two phases of 12 and 24 weeks).
Follow-up: no postintervention follow-up.
Focus: to assess the effects of a reduced GI hypocaloric diet on weight loss
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Participants N: 29 in second phase (6/10 completers in low GI group, 8/9 in high GI group)
Inclusion criteria: age 18 to 70 years, BMI 30 to 40 kg/m2, habitually consumed regular
diets with no food restrictions
Exclusion criteria: taking prescription medication, existing medical conditions, preg-
nancy
Age (years): not reported.
Sex (% men): low GI: 30%; high GI: 22.2%.
Ethnicity: not reported.
Cardiovascular risk status:
BMI (kg/m2) (mean (SE)): low GI: 36.5 (SE 1.8); high GI: 34.6 (SE 1.4).
Total cholesterol (mmol/L): not reported.
HDL cholesterol (mmol/L): not reported.
LDL cholesterol (mmol/L): not reported.
Blood pressure (mmHg): not reported.
Medications used: no prescription medication.
Interventions Low GI group (n = 10): hypocaloric low GI diet.
High GI group (n = 9): hypocaloric high GI diet.
(High fat group (n = 10): hypocaloric high fat diet (not considered here)).
Description of dietary intervention: two phases: 12-week feeding phase where indi-
vidualised energy-restricted diets were prepared by Metabolic Kitchen and participants
were required to eat all foods provided and consume no additional foods; in the sec-
ond phase (weeks 13 to 24), diet assignment was maintained but participants prepared
their own meals, receiving intensive dietary instructions regarding their assigned dietary
regimen and sample menus and recipes; ongoing nutrition counselling every 2 weeks;
energy levels designed to promote weight loss 0.7 kg/week for each participant; fatty acid
distribution of the diets was 1:1:1 for the ratio of polyunsaturated to monounsaturated
to saturated fatty acids; cholesterol content constant at 100 g/4184 kJ
Incentives: as above.
Cointerventions in both groups: none.
Assessment of dietary adherence: daily questionnaires during first 12 weeks; 5-day food
diaries at weeks 24 and 26
Was the diet energy-reduced? yes.
Comparability of diet composition: yes, data only given for the first 12 weeks, no
numeric data for the 24 weeks participants prepared their own meals (only significance
levels for GI); see Table 2.
Change in diet over time: prescribed diets.
Outcomes Primary outcome: weight.
Secondary outcomes:, BMI, % body fat, lean body mass, serum insulin, plasma glucose,
plasma triglycerides, insulin sensitivity (HOMA)
Funding / conflict of interest Funding by National Institutes of Health and Allan Foundation of Midland, MI
Notes
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Allocation method not reported.
Allocation concealment (selection bias) Unclear risk Allocation method not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk 42 participants started the study, 13 left
the study before completion of the first 12
weeks (31%), 29 started the second phase
Loss to follow-up/dropouts during 2nd
phase:
Low GI group: 4/10 (40%);
High GI control: 1/9 (11.1%);
(High fat group: 2/10 (20%)).
Intention-to-treat analysis High risk Only participants completing the first
phase were analysed (n = 29) but not stated
how non-completers of the second phase
were handled
Selective reporting (reporting bias) High risk Only very limited reporting of outcomes
after phase 2.
Groups comparable at baseline Low risk For participants completing the first phase,
with respect to anthropometric and bio-
chemical variables
Other bias High risk No power analysis, probably underpow-
ered.
Randolph 2014
Methods Setting: USA; setting not reported.
Design: parallel group design.
Dates: recruitment July 2008 to June 2010.
Intervention duration: 12-week intervention.
Follow-up: no postintervention follow-up.
Focus: assess the role of glycemic index on measures of body weight, body composition,
andmetabolic indices in a free-living overweight population and to assess the compliance
of prescribed diets based on the GI system in free-living individuals
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Participants N: 90 (24/31 completers for the low GI group, 25/30 completers for the high GI group,
24/29 completers for the control group)
Inclusion criteria: females and males, age over 18 years, BMI 25 to 37 kg/m2, light
to moderate exercise, normal fasting plasma glucose, able to meet the time and effort
requirements required for study participation
Exclusion criteria: total cholesterol not greater than 300 mg/dL, fasting triglyceride not
greater than 300 mg/dL, LDL cholesterol (LDL-C) not greater than 180 mg/dL, smok-
ers, female subjects who were pregnant or lactating, subjects taking any medications that
would interfere with outcomes of the study, subjects with unusual dietary habits (eg.
pica), subjects who were actively losing weight or trying to lose weight, subjects who
were addicted to drugs or alcohol or who are < 1 y in a recovery program, subjects who
presented with significant psychiatric or neurological disturbances, subjects with known
allergy or intolerance to potato products, subjects with documented atherosclerotic dis-
ease, inflammatory disease, diabetes mellitus, uncontrolled hypertension ( 140/90 mm
Hg), chronic lung, renal or liver disease, presence of other health problems requiring
ongoing intervention by their personal physician, excessive exercisers or trained athletes,
intolerance to potatoes
Age (years) (mean SD)): low GI group: 47.8 (SD 14.1), high GI group: 51.4 ( SD14.
7)
Sex (% men): 18.9% male over both intervention and control group.
Ethnicity: not reported.
Cardiovascular risk status (mean (SD)):
BMI (kg/m2): low GI group: 29.5 (SD 4.1), high GI group: 29.7 (SD 4.0).
Total cholesterol (mg/dL): low GI-energy restricted group: 192.8 (SD 38.5), high GI-
energy restricted group: 189.1 (SD 31.9).
HDL cholesterol (mg/dL): low GI-energy restricted group: 50.5 (SD 11.9), high GI-energy
restricted group: 53.8 (SD 15.2).
LDL cholesterol (mg/dL): low GI-energy restricted group: 122.9 (SD 35.8), high GI-
energy restricted group: 118.5 (SD 28.1).
Blood pressure (mmHg): low GI-energy restricted group: systolic 121.6 (SD 2.9), diastolic
77.1 (SD 2.0); high GI-energy restricted group: systolic 119.3 (SD 2.4), diastolic 75.4
(SD 1.2).
Medications used: not reported.
Interventions Low GI, energy-restricted group (n = 31): the targeted average GI was 30 for the
low GI energy-restricted group. They were provided with potatoes (6 russet and 3 red
potato varieties) on a weekly basis. Customized food lists of low GI foods were provided.
Received a customized recipe booklet for potato preparation, cooking methods, and
specific recipes to comply with low GI dietary preparation
High GI, energy-restricted (n = 30): the targeted average GI was 80 for the high GI
energy-restricted group. Customized food lists of high GI foods were provided. Received
a customized recipe booklet for potato preparation, cooking methods and specific recipes
to comply with high GI dietary preparation
(Control diet (n = 29): prescribed for weight maintenance with no energy reduction
(not considered here)).
Description of dietary intervention: weekly counselling visits by a registered dietitian
for the first 6 weeks, then every other week until week 12
Cointerventions in both groups:They were provided with potatoes (6 russet and 3 red
potato varieties) on a weekly basis. They were required 5 to 7 servings of potatoes each
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week such as one medium potato or ½ cup of cooked potato, providing approximately
110 kcal of potato/serving
Assessment of dietary adherence: weekly potato consumption was based on review of
food records and verbal interview
Was the diet energy-reduced? Diets were energy-restricted (~ 500 kcal deficit/d) for
weight loss. Participants received a new energy prescription with each 5 kg drop in weight
Comparability of diet composition: yes; see Table 2.
Change in diet over time: energy, carbohydrates and fat intakes significantly decreased
in the low GI, energy-restricted group
Outcomes Primary outcome: weight loss.
Secondary outcomes: glucose tolerance, blood pressure, and body composition.
Funding / conflict of interest Funding for this project was provided by the United States Potato Board
Notes Author was contacted on 15.08.2016 to clarify risk of bias and blood pressure measure-
ments
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Author response ’Randomization was com-
puter generated’.
Allocation concealment (selection bias) Unclear risk Author response ’Allocation was blinded to
subjects in the sense that the arms were
coded/named with nonidentifying titles as
to what diets they would follow. The co-
ordinator of subject schedules and alloca-
tion was not blinded and held the key in
sealed envelope. After subject was random-
ized this information was given to RD to
carry out counselling’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Author response ’Nurses, staff, statistician
were blinded since everything was coded’
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up/dropouts:
Low GI, energy-restricted group: 7/31
(22%).
High GI,energy-restricted group: 5/30
(16%).
Intention-to-treat analysis High risk ’Body weight missing data were replaced
with the last known value for the ITT anal-
ysis. All other results are based on the per
protocol data set, which includes only those
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subjects who completed both 0 and 12
week procedures’
Selective reporting (reporting bias) Unclear risk Not all lipids reported at baseline were
reported at follow-up (only triglycerides)
. However, they reported all primary and
secondary outcomes
Groups comparable at baseline Low risk With respect to anthropomorphic and bio-
chemical baseline values for low and high
GI groups
Other bias Unclear risk Power calculations based on body weight
(80% power to detect 2 kg change in
weight) not on the outcomes of interest
for this review i.e. lipids and blood pres-
sure. So, the study may be underpowered
for these outcomes
RISCK 2010 high MUFA
Methods Setting: UK; clinic at five research centres (Reading, Imperial College, Surrey, Cam-
bridge, Kings College)
Design: individual randomisation, parallel group.
Dates: baseline assessments made between August 2004 and April 2006
Intervention duration: 24 weeks (after 4 week run-in).
Follow-up: no postintervention follow-up.
Focus: to assess the effects of replacing saturated fatty acids with monounsaturated fatty
acids or carbohydrates and of lowering GI on insulin sensitivity and other cardiovascular
risk factors in participants at risk of developing a metabolic syndrome
Participants N: 720 (116/144 completers in MUFA/low GI group, 111/145 in MUFA/high GI
group, 121/149 in low fat/low GI group, 116/145 in low fat/high GI group, 85/137 in
control group)
Inclusion criteria: age 30 to 70 years, BMI 30 to 40 kg/m2; a score of ≥ 4 was required
for entry, according to the following point system: fasting glucose concentration > 5.5
mmol/L or insulin concentration > 40 pmol/L = 3 points; BMI > 30 kg/m2 or waist >
102 cm for men and > 88 cm for women = 2 points; BMI of 25 to 30 kg/m2 or waist >
94 cm for men and > 80 cm (women) = 1 point; treated hypertension = 2 points; systolic
blood pressure > 140 mmHg = 1 point; diastolic blood pressure > 90 mmHg = 1 point;
HDL cholesterol concentration < 1.0 mmol/L for men and < 1.3 mmol/L for women
= 2 points; and serum triacylglycerol concentration > 1.3 mmol/L = 1 point; recruited
from the general population (undefined)
Exclusion criteria: history of ischaemic heart disease; a > 30% 10-year risk of car-
diovascular disease; diabetes mellitus; cancer, pancreatitis, cholestatic liver disease, re-
nal disease; use of lipid-lowering drugs, systemic corticosteroids, androgens, phenytoin,
erythromycin, or drugs for regulating haemostasis (excluding aspirin); exposure to any
investigational agent 30 days before the study; presence of gastrointestinal disorder or
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use of a drug likely to alter gastrointestinal motility or nutrient absorption; history of
substance misuse or alcoholism; pregnancy, planned pregnancy, or given birth in the
past 12 months; allergy or intolerance to intervention foods; unwillingness to follow the
protocol or to give informed consent; weight change of > 3 kg in the 2 months before
the study; intake of > 1 g eicosapentaenoic and docosahexaenoic acids/day, smoking >
20 cigarettes/day
Age (years) (mean (SD)): men: 52 (SD 10); women: 51 (SD 9).
Sex (% men): 42%.
Ethnicity: men: 83.5%White, 9.1% South Asian, 5.2% Black, 2.2% other; women: 78.
3% White, 9.7% South Asian, 8.8% Black, 3.2% other.
Cardiovascular risk status (mean (SD)):
BMI (kg/m2): men: 28.3 (SD 3.8); women: 28.6 (SD 5.3).
Smoking: men: 7.8%; women: 5.6%.
Total cholesterol (mmol/L): men: 5.5 (SD 0.9); women: 5.5 (SD 1.0).
HDL cholesterol (mmol/L): men: 1.2 (SD 0.3); women: 1.5 (SD 0.4).
LDL cholesterol (mmol/L): not reported.
Blood pressure (mmHg): men: systolic 138 (SD 16), diastolic 84 (SD 10); women:
systolic 129 (SD 17), diastolic 80 (SD 9.3).
Medications used: men: 19.1% on blood pressure medication; women: 16.3% on blood
pressure medication.
Baseline values only reported for men and women, not for separate comparison groups
Interventions MUFA/low GI (n = 144): high monounsaturated fatty acids and low GI diet.
MUFA/high GI (n = 145): high monounsaturated fatty acids and high GI diet.
Low fat/low GI (n = 149): low fat and low GI diet.
Low fat/high GI (n = 145): low fat and low GI diet.
(High SFA/high GI (n = 137): high saturated fatty acids and high GI diet (control)
(not considered here)).
Description of dietary intervention: run-in with a diet of high saturated fatty acids and
high GI; intervention: provision of key sources of fat (spreads, cooking oils, margarine)
and carbohydrates (bread, pasta, rice, cereals)with additional dietary information tailored
to study group (given in writing and reinforced by counselling at 12 individual study
visits); target for total fat intakes was 38% of energy in the MUFA groups and 28%
of energy in the low fat groups with carbohydrate intakes of 45% and 55% of energy,
respectively; saturated fatty acids were reduced to 10% of energy with a planned MUFA
intake of 20% of energy in the high MUFA group and 12% in the low fat group; the
target difference in GI was about 11 points in the MUFA comparison and 13 points
in the low fat comparison; dietary targets were achieved using a food exchange model;
participants were offered sufficient quantities of study foods for their whole household
on a fortnightly basis
Incentives: see below.
Cointerventions in both groups: advice to engage in exercise, avoid alcohol.
Assessment of dietary adherence: unweighed 4-day food records (3 weekdays and 1
weekend day) before run-in and during the 3rd and the final month of the intervention;
a small remuneration was given for participation
Was the diet energy-reduced? no, participants were told that diets were designed for
weight maintenance
Comparability of diet composition: yes; see Table 2.
Change in diet over time: decrease in reported energy intake.
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RISCK 2010 high MUFA (Continued)
Outcomes Primary outcome: insulin sensitivity.
Secondary outcomes: blood lipids, blood pressure, weight.
Funding / conflict of interest Funding by UK Food Standards Agency (project NO2031); foods supplied by Unilever
Food and Health Research Institute, Cereal Partners UK, Grampian, Weetabix Ltd,
Sainsbury’s Supermarkets Ltd
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-based minimisation procedure
to balance assignment by age, sex, waist cir-
cumference, HDL cholesterol
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Relatively high attrition rate, reasons for
loss to follow-up not reported
MUFA/low GI: 28/144 (19.4%).
MUFA/high GI: 34/145 (23.4%).
Low fat/low GI: 28/149 (18.8%).
Low fat/high GI: 29/145 (20.0%).
(High SFA/high GI: 52/137 (38.0%)).
Intention-to-treat analysis Unclear risk Probably not, stated that 548/549 partici-
pants were analysed (of 720 randomised)
Selective reporting (reporting bias) Unclear risk Not enough detail to judge.
Groups comparable at baseline Unclear risk Baseline data only given for men and
women, not for different comparison
groups
Other bias Unclear risk Power analysis (80% power to detect a
change in insulin sensitivity with 113 par-
ticipants per group)
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RISCK 2010 low fat
Methods See previous - study had two independent relevant comparisons
Participants
Interventions
Outcomes
Funding / conflict of interest
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk See above - study had two independent rel-
evant comparisons.
Allocation concealment (selection bias) Unclear risk See above.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk See above.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk See above.
Intention-to-treat analysis Unclear risk See above.
Selective reporting (reporting bias) Unclear risk See above.
Groups comparable at baseline Unclear risk See above.
Other bias Unclear risk See above.
Shikany 2005
Methods Setting: USA; University of Alabama Division of Preventive Medicine clinic and class-
rooms
Design: individual randomisation, parallel group.
Dates: not reported.
Intervention duration: 12 weeks.
Follow-up: no postintervention follow-up.
Focus: to assess the effects of a low fat/low GI diet on serum lipids
Participants N: 62 (57/62 completers, distribution by comparison group not reported)
Inclusion criteria: age 19 to 70 years, serum LDL-C ≥ 160 mg/dL with less than two
heart disease risk factors or ≥ 130 mg/dL with two or more heart disease risk factors
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Shikany 2005 (Continued)
Exclusion criteria: serum triglycerides ≥ 400 mg/dL; use of cholesterol-lowering med-
ications; use of low-fat or other specialised diets; ≥ 8 meals per week consumed away
from home; history of serious illness, including coronary heart disease, stroke, diabetes,
cancer, severe renal or liver disease
Age (years): intervention: 29%: 19 to 39 yrs, 25.8%: 40 to 49 yrs, 45.2%: 50 to 69 yrs;
control: 11.5%: 19 to 39 yrs, 34.6%: 40 to 49 yrs, 53.8%: 50 to 69 yrs
Sex (% men): intervention: 61.3%; control: 65.4%.
Ethnicity: intervention: 71.0% White, 22.6% African American, 6.5% Asian, 0 Native
American; control: 76.9%White, 15.4% African American, 0 Asian, 7.7%Native Amer-
ican
Cardiovascular risk status (mean (SD)):
BMI (kg/m2): intervention: 30.1 (SE 1.0); control: 30.4 (SE 1.1).
Current smoker: intervention: 9.7%; control: 0.
Total cholesterol (mmol/L): intervention: 6.13 (SE 0.10); control: 6.26 (SE 0.10).
HDL cholesterol (mmol/L): intervention: 1.14 (SE 0.05); control: 1.14 (SE 0.05).
LDL cholesterol (mmol/L): intervention: 4.19 (SE 0.10); control: 4.32 (SE 0.10).
Blood pressure (mmHg): not reported.
Medications used: not reported.
Interventions Low GI group (n = 31): low fat/low GI diet; National Cholesterol Education Program
TLC diet, replacement of high GI carbohydrates with low carbohydrate alternatives
(including information on factors influencing GI such as food processing and cooking
time), encouraged to increase intake in fruit, vegetables and legumes; low GI cookbook
provided
High GI group (n = 26): low fat only diet; National Cholesterol Education Program
TLC diet, no recommendations on types of carbohydrate to consume
Description of dietary intervention: 7 sessions held over a 12 week period; the first
4 sessions were held weekly, then biweekly over the final 8 weeks; all sessions were
conducted by registered dietitians and were 60 mins long for the low fat only group
and 90 min for the low fat plus low GI group; sessions included group instruction and
individual counselling; participants who missed sessions were mailed session materials
and offered individual advice by person or over the phone; session topics included goal
setting, label reading, food shopping, challenges associated with dining out
Incentives: not reported.
Cointerventions in both groups: none.
Assessment of dietary adherence: food diaries completed for a minimum of 5 days a
week throughout 12 weeks; reviewed by dietitian at each session who gave individual
feedback; additional 3-day food records at baseline, 4 weeks and 12 weeks
Was the diet energy-reduced? unclear.
Comparability of diet composition: yes; see Table 2.
Change in diet over time: total energy intake, carbohydrate intake, fat intake reduced
significantly in both groups, but no significant difference between groups
Outcomes Primary outcomes: serum lipids.
Secondary outcomes: BMI, serum glucose, serum insulin, HbA1c.
Funding / conflict of interest Funding by the American Heart Association.
Notes
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Shikany 2005 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Allocation method not reported.
Allocation concealment (selection bias) Unclear risk Allocation method not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reasons for discontinuation/exclusiononly
reported overall (5 did not complete the 4-
week dietary and/or the 12 week session)
Loss to follow-up/dropouts:not reported
by comparison group, 5/62 (8.1%) overall.
Intention-to-treat analysis High risk Only completers included in the analysis.
Selective reporting (reporting bias) Unclear risk Not enough detail to judge.
Groups comparable at baseline Low risk With respect to demographic, anthropo-
morphic and biochemical baseline values
Other bias Unclear risk No power analysis.
Sichieri 2007
Methods Setting: Brazil; primary care centres.
Design: individual randomisation, parallel group.
Dates: recruitment October 2003 to September 2004.
Intervention duration: 18 months.
Follow-up: no postintervention follow-up.
Focus: to investigate the long term effect of a low GI diet compared with a high GI diet,
with all other dietary components being equal, on weight and satiety
Participants N: 203 (61/101 completers in the intervention group and 46/102 in the control group)
Inclusion criteria: healthy women; overweight (BMI 23 to 29.9 kg/m2), age 25 to 45
years, not pregnant or breastfeeding, with at least one child
Exclusion criteria: physician-diagnosed thyroid disease; diabetes; menopausal women;
not being able to eat beans on a daily basis or having a particular dislike for them
Age (years) (mean (SD)): intervention: 37.2 (SD 5.4); control: 37.5 (SD 5.6).
Sex: intervention: 100% women; control: 100% women.
Ethnicity: intervention: 54.5% White, 19.8% Black, 25.7% Mulatto; control: 52.0%
White, 15.0% Black, 33.0% Mulatto.
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Sichieri 2007 (Continued)
Cardiovascular risk status (mean (SD)):
BMI (kg/m2): intervention: 26.9 (SD 1.8); control: 26.7 (SD 2.1).
Total cholesterol (mmol/L): intervention: 4.88 (SD 0.90); control: 5.02 (SD 0.96).
HDL cholesterol (mmol/L): intervention: 1.11 (SD 0.4); control: 1.12 (SD 0.41).
LDL cholesterol (mmol/L): intervention: 3.30 (SD 0.85); control: 3.44 (SD 0.95).
Blood pressure (mmHg): not reported.
Medications used: not reported.
Interventions Low GI group (n = 101): low GI diet.
Control (n = 102): high GI diet.
Description of dietary intervention: study started with a 6 week run-in phase (2
weeks low GI diet, 4 weeks high GI diet) after completion of which participants were
randomised to intervention or control; main intervention: dietary counselling based on a
small energy restriction (100 to 300 kcal/day), skipping the diet 1 day/week was allowed;
individual nutritional counselling every month with menus and exchange lists; both
diets designed with 26% to 28% of energy as fat; low GI diets for each meal designed
to maintain an average difference of 40 GI units compared to high GI diet (major
determinant was sticky rice versus parboiled rice and amount of beans); participants
were instructed to eat 3 meals and 3 snacks per day according to a 6 day menu plan;
instructions also included limiting to a minimum all candies, added sugar, sodas, except
for the weekly day free of diet; portions of staple foods were reduced monthly if the
participants reported that they were prescribed too much food
Incentives: see above.
Cointerventions in both groups: none.
Assessment of dietary adherence: food frequency questionnaire at the beginning of the
run-in and 3, 6, 12 and 18 months after the start of the intervention; adherence in the
low GI group was greater than in the high GI group (61% versus 46%, P = 0.0006)
Was the diet energy-reduced? yes.
Comparability of diet composition: yes, see Table 2.
Change in diet over time: energy reduced in both groups, no significant difference.
Outcomes Outcomes (not clearly divided into primary and secondary): BMI (basis of power
analysis), serum lipids, fasting serum glucose, fasting serum insulin, insulin sensitivity
(HOMA), hunger/satiety. Abstract suggested weight change was the primary outcome
and yet this was not reported
Funding / conflict of interest Funding by National Institutes of Health and Brazilian Research Council; authors stated
that they had no conflicts of interest
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation list
with blocking.
Allocation concealment (selection bias) Unclear risk Not reported.
77Low glycaemic index diets for the prevention of cardiovascular disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sichieri 2007 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk Reasons for non-completion: interven-
tion: n = 39 withdrawn, n = 13 tired of the
diet, n = 4 pregnancy, n = 6 moving away,
n = 1 death, n = 9 other reasons; control: n
= 41 withdrawn, n = 20 tired of the diet, n
= 1 pregnancy, n = 5 moving away, n = 15
other reasons
Loss to follow-up/dropouts:
Low GI group: 40/101 (39.6%) non-com-
pleters; 38/101 (37.6%) did not return for
the last visit
Control: 56/102 (54.9%) non-completers;
42/102 (41.2%) did not return for the last
visit
Intention-to-treat analysis Low risk
Selective reporting (reporting bias) Unclear risk BMI at follow-up not reported.
Groups comparable at baseline Low risk With respect to demographic, anthropo-
metric and biochemical variables
Other bias Unclear risk Power analysis (90% power to detect a
change in BMI with 206 participants, al-
lowing for 20% loss during follow-up -
but more participants did not complete the
study, so the studywas probably underpow-
ered)
Solomon 2010
Methods Setting: USA; setting not reported.
Design: individual randomisation, parallel group.
Dates: not reported.
Intervention duration: 12 weeks.
Follow-up: no postintervention follow-up.
Focus: to assess the effects of exercise training with a low or high GI diet on metabolic
syndrome severity
Participants N: 24 (10/12 completers in the intervention group (11 in Malin 2012) and 12/12 in
the control group (10 in Malin 2012))
Inclusion criteria: older (mean age 66 years) obese (BMI = 35.5 kg/m2) (34.4 in
Solomon) adults meeting the National Cholesterol Education Program Adult Treatment
Panel (ATP) III criteria for metabolic syndrome; non-smokers, sedentary, weight-stable
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Solomon 2010 (Continued)
(< 2 kg weight change in previous 6 months); recruited through advertisements
Exclusion criteria: heart, kidney, liver, thyroid, intestinal, pulmonary disease; taking
medications affecting the primary outcomes; contraindications to increments in physical
activity (based on exercise ECG)
Age (years) (mean (SE)): intervention: 67 (SE 2); control: 64 (SE 1).
Sex (% men): intervention: 30%; control: 41.7%.
Ethnicity: not reported.
Cardiovascular risk status (mean (SE)):
BMI (kg/m2): intervention: 34.9 (SE 1.1); control: 34.1 (SE 1.1).
Total cholesterol (mmol/L): intervention: 5.55 (SE 0.29); control: 5.36 (SE 0.21).
HDL cholesterol (mmol/L): intervention: 1.38 (SE 0.09); control: 1.29 (SE 0.11).
LDL cholesterol (mmol/L): intervention: 3.32 (SE 0.24); control: 3.40 (SE 0.17).
Blood pressure (mmHg): intervention: systolic 127 (SE 3,) diastolic 76 (SE 3); control:
systolic 133 (SE 5), diastolic 79 (SE 3).
Medications used: not reported.
Interventions Low GI group (n = 12): low GI diet (GI 40) plus exercise.
Control (n = 12): high GI (GI 80) diet plus exercise.
Description of dietary intervention: measurements of resting metabolic rate to ascer-
tain caloric requirements; all meals, snacks, and beverages were provided to participants
on a daily basis; diets designed by a registered dietitian and isocaloric to the individ-
ual requirements of participants; dietary macronutrient composition (including fibre)
matched between groups
Incentives: as above.
Cointerventions in both groups: 60 min of aerobic exercise 5 days/week (treadmill
walking and cycle ergometry) at about 85% of the maximum heart rate obtained during
an incremental maximal aerobic-exercise test; sessions supervised by exercise physiologist
Assessment of dietary adherence: daily food-container weigh backs; weekly counselling
session with a research dietitian; adherence 98% (SE 1) low GI group, 96% (SE 1)
control group
Was the diet energy-reduced? no.
Comparability of diet composition: yes, see Table 2.
Change in diet over time: prescribed diet.
Outcomes Outcomes (not clearly divided into primary and secondary): body composition,
aerobic fitness, insulin sensitivity, plasma lipids, plasma insulin, plasma glucose, HbA1c,
metabolic syndrome severity (Z-score)
Funding / conflict of interest Funding byNational Institutes ofHealthGrants RO1AG-12834 andNational Institutes
of Health National Center for Research Resources 1UL1RR024989; authors stated that
they had no financial or other conflicts of interest
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Solomon 2010 (Continued)
Random sequence generation (selection
bias)
Unclear risk Allocation method not reported.
Allocation concealment (selection bias) Unclear risk Allocation method not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 24 participants in Solomon 2010, 21 in
Malin 2012.
2 exclusions in the low GI group (failure
to comply with diet and exercise, refusal of
repeated testing)
Loss to follow-up/dropouts:
Low GI group: 2/12 (16.7%) (11 com-
pleters in Malin 2012).
Control: 0/12 (0%) (10 completers inMa-
lin 2012).
Intention-to-treat analysis High risk Not explicitly reported, but probably not
as results were only reported for completers
Selective reporting (reporting bias) Unclear risk Different papers reporting different out-
comes - unclear what the primary/sec-
ondary outcomes of the overall study were
Groups comparable at baseline Low risk Not specifically reported, but study char-
acteristics table suggests that there were
no significant differences between groups
in demographic, anthropometric and bio-
chemical variables at baseline
Other bias Unclear risk No power analysis reported.
Venn 2010
Methods Setting: New Zealand; setting not reported.
Design: individual randomisation, parallel group.
Dates: not reported.
Intervention duration: 18 months.
Follow-up: no postintervention follow-up.
Focus: to compare weight loss, metabolic outcomes, and nutrient intakes in obese people
assigned to a diet rich in pulses and wholegrains or to a control diet
Participants N: 108 (43/53 completers in the intervention group and 30/55 in the control group)
Inclusion criteria: BMI ≥28 kg/m2.
Exclusion criteria: pregnancy, lactation; chronic disease (diabetes mellitus, cancer, coro-
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nary heart disease)
Age (years) (mean (SD)): intervention: 42 (SD 11.2); control: 42 (SD 10.3).
Sex (% men): intervention: 16%; control: 12%.
Ethnicity: not reported.
Cardiovascular risk status (mean (SD)):
BMI (kg/m2): intervention: 36.1 (SD 6.5); control: 34.7 (SD 4.6).
Total cholesterol (mmol/L): intervention: 5.3 (SD 1.0); control: 5.2 (SD 1.0).
HDL cholesterol (mmol/L): intervention: 1.2 (SD 0.3); control: 1.3 (SD 0.3).
LDL cholesterol (mmol/L): intervention: 3.3 (SD 0.8); control: 3.2 (SD 0.8)
Blood pressure (mmHg): intervention: systolic 132 (SD 15.4), diastolic 83 (SD 8.7);
control: systolic 133 (SD 13.2), diastolic 83 (SD 9.0).
Hypertension: intervention: 10%; control: 12%.
Medications used: not reported.
Interventions Low GI group (n = 53): diet emphasising pulses and wholegrains; similar advice as
given to the control group below but specifically instructed to consume 2 servings of
pulses as a substitute for 2 servings of breads and cereals and all other breads were to be
wholegrain
Control (n = 55): diet based on guidelines produced by the National Heart Foundation
of New Zealand (see below)
Description of dietary intervention: diet based on guidelines produced by theNational
Heart Foundation of New Zealand: instructions to eat each day 3 servings of vegetables
and 2 servings of fruit, at least 6 servings of breads and cereals; 1 to 2 servings of protein-
rich foods; 1 to 2 tablespoons of monounsaturated fats and oil products; small amounts
of nuts and seeds; instructed to stay within the portion size guidelines of the National
Heart Foundation of New Zealand; counselling sessions in pairs every 2 weeks for the
first 6 months and provision of key foods, followed by 12 months with monthly contacts
with study investigators; cooking classes and supermarket tours during first 6 months,
as well as dietary advice and recipe cards
Incentives: as above.
Cointerventions in both groups: encouraged to exercise half an hour a day and given
a pedometer
Assessment of dietary adherence: daily dietary check sheets discussed with the dietitian
every 2 weeks during the first 6 months; 3-day weighed diet records (2 weekdays and 1
weekend day) recorded by participants on 4 occasions (before randomisation, 2, 6, 12
months)
Was the diet energy-reduced? no (based onNational Heart Foundation of NewZealand
guidelines of 7.2 MJ/day)
Comparability of diet composition: yes, see Table 2.
Change in diet over time: energy reduced in both groups, no significant difference.
Outcomes Outcomes (not clearly divided into primary and secondary): weight (basis of power
analysis), BMI, waist circumference, plasma lipids, fasting glucose, blood pressure
Funding / conflict of interest Funding by New Zealand Foundation for Research, Science and Technology and the
Lifestyle foods programme; the authors declared that they had no conflicts of interest
Notes
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Allocation method not reported.
Allocation concealment (selection bias) Unclear risk Allocation method not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk High attrition rate, especially in the control
group.
Reasons for non-completion: interven-
tion: n = 1 moved away, n = 1 achieved
their weight loss goals, n = 1 illness, n = 3
family reasons, n = 4 failed to meet their
expectations; control: n = 3 moved away, n
= 3 achieved their weight loss goals, n = 5
illness/injury, n = 3 family reasons, n = 11
failed to meet their expectations
Loss to follow-up/drop-outs:
Low GI group: 10/53 (18.9%).
Control: 25/55 (45.5%).
Intention-to-treat analysis Low risk “The datawere analyzed according tomod-
ified intention to treat....”
Selective reporting (reporting bias) Unclear risk Not enough detail to judge.
Groups comparable at baseline Low risk With respect to demographic, anthropo-
metric and biochemical variables
Other bias Low risk Power analysis (80% power to detect a dif-
ference in weight loss with 40 participants
per group)
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Wolever 2002
Methods Setting: Canada; setting not reported.
Design: individual randomisation, parallel group.
Dates: not reported.
Intervention duration: 4 months.
Follow-up: no postintervention follow-up.
Focus: to examine the optimal amount and source of dietary carbohydrate for managing
insulin resistance
Participants N: 37 (13/13 completers in the low GI group and 11/13 in the high GI group)
Inclusion criteria: age 30 to 65 years, impaired glucose tolerance, BMI < 40 kg/m2,
serum triacylglycerol < 10 mmol/L.
Exclusion criteria: pregnancy.
Age (years) (mean (SE)): low GI: 55.2 (SE 3.0); high GI: 58.8 (SE 4.0).
Sex (% men): low GI: 23%; high GI: 18%.
Ethnicity: not reported.
Cardiovascular risk status (mean (SE)):
BMI (kg/m2): low GI: 29.7 (SE 1.2); high GI: 29.3 (SE 2.2).
Total cholesterol (mmol/L): whole study population: 5.24 (SE 0.16).
HDL cholesterol (mmol/L): whole study population: 1.21 (SE 0.06).
LDL cholesterol (mmol/L): whole study population: 3.18 (SE 0.13).
Blood pressure (mmHg): low GI: systolic 129 (SE 4), diastolic 80 (SE 2); high GI:
systolic 126 (SE 6), diastolic 78 (SE 3).
Medications used: thiazide diuretics were used by one high GI participant; β-blockers
were taken by one low GI participant at stable doses throughout the study
Interventions Low GI group (n = 13): high carbohydrate, low GI (at least one serving of low GI food
at each meal)
High GI group (n = 11): high carbohydrate, high GI (at least one serving of high GI
food at each meal)
(MUFA group (n = 11): low carbohydrate, high monounsaturated fatty acid (MUFA)
(not considered here)).
Description of dietary intervention: weight-maintaining ad libitum diet; baseline 3-
day food records were used as a basis for individualised dietary advice; high carbohydrate
diets contained 55% of energy from carbohydrate and 30% from fat; lists of high and
low GI foods provided, along with specified foods to be used in the diet
Cointerventions in both groups: none.
Assessment of dietary adherence: participants were seen monthly for consultation with
the dietitian and to hand in 3-day food records
Was the diet energy-reduced? no.
Comparability of diet composition: significantly more protein (% of energy) in the
low GI group, see Table 2.
Change in diet over time: small decrease in energy intake in the low GI group.
Outcomes Outcomes (not clearly divided into primary and secondary): insulin sensitivity (basis
of power analysis), body weight, fasting lipids, blood pressure, fasting plasma glucose,
HbA1c, glucose effectiveness, pancreatic responsivity, glucose disposition index, post-
prandial plasma glucose, insulin
Funding / conflict of interest Funding by the Canadian Diabetes Association and the International Olive Oil Council
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Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Coin toss; stratification by age, sex, BMI.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reasons for discontinuation not reported;
1 person participated in 2 arms of the study
(MUFA and high GI)
Loss to follow-up/drop-outs:
Low GI group: 0/13 (0%).
High GI group: 2/13 (15.4%).
MUFA group: 1/12 (8.3%).
Intention-to-treat analysis High risk Not explicitly reported, but probably not
as results were only reported for completers
Selective reporting (reporting bias) Unclear risk Selective reporting of numeric values, data
mainly reported in graphical form
Groups comparable at baseline Low risk With respect to demographic, anthropo-
metric and biochemical variables
Other bias Unclear risk Power analysis (90% power to detect a dif-
ference in insulin sensitivity with 12 par-
ticipants per group, i.e. slightly underpow-
ered)
ACE:Angiotensin−converting−enzyme;ATP :Adenosinetriphosphate;BMI :Bodymassindex;Ca:Calcium;CHO :Carbohydrates;CV D:Cardiovasculardisease;ECG:Electrocardiogram
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abbasi 2000 Participants not diagnosed with CHD or at risk of CHD.
GI of the diet not reported or compared.
Intervention < 12 weeks.
Abete 2008 Intervention duration < 12 weeks.
Agus 2000 Intervention duration < 12 weeks.
Alfenas 2005 Intervention duration < 12 weeks.
Participants not diagnosed with CHD or at risk of CHD.
Participants not free-living.
Alfenas 2012 Intervention duration < 12 weeks.
Amano 2007 Participants with type 2 diabetes.
Argiana 2011 Participants with type 2 diabetes.
Aston 2008 No relevant outcomes reported (primary and/or secondary outcomes)
Bahadori 2005 Not an RCT.
Barakatun 2010 Participants with type 2 diabetes.
Barkoukis 2002 Participants not diagnosed with CHD or at risk of CHD.
Intervention duration < 12 weeks.
Bouche 2002 Intervention duration < 12 weeks.
Brand 1991 Participants with type 2 diabetes.
Brynes 2003 Intervention duration < 12 weeks.
Calle-Pascual 1988 Participants with diabetes mellitus.
Carels 2005 No relevant outcomes reported (primary and/or secondary outcomes)
Chanteleau 1985 Intervention duration < 12 weeks.
Cheong 2009 Participants with type 2 diabetes.
Chiavaroli 2016 Participants with type 2 diabetes.
Clapp 1998 Participants not diagnosed with CHD or at risk of CHD.
Participants pregnant.
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Colagiuri 1986 Intervention duration < 12 weeks.
GI of diets not reported or compared.
Collier 1986 Comparison not between diets with similar overall energy and macronutrient contents.
Intervention duration < 12 weeks.
CHD mortality, morbidity or risk factor outcomes not reported
Collier 1988 Intervention in children.
Coulston 1984 Intervention duration < 12 weeks.
Crapo 1981 GI of diets not reported or compared.
Participants not free-living.
Intervention duration < 12 weeks.
De Rougemont 2007 Intervention duration < 12 weeks.
Dumesnil 2001 Comparison not between diets with similar energy and macronutrient contents.
Participants not free-living.
Intervention duration < 12 weeks.
Ebbeling 2003 Comparison not between diets with similar energy and macronutrient contents
Ebbeling 2005 Comparison not between diets with similar energy and macronutrient contents
Fontvielle 1988 Intervention duration < 12 weeks.
Fontvielle 1992 Participants with diabetes mellitus.
Frost 1994 Participants with type 2 diabetes.
Frost 1996 Intervention duration < 12 weeks.
Frost 1998a Intervention duration < 12 weeks.
Frost 1998b Not a dietary intervention.
Frost 1999 Not an RCT or CCT.
Fuh 1990 Participants not free-living.
GI of diets not reported or compared.
Comparison not between diets with similar overall energy and macronutrient levels.
Intervention duration < 12 weeks.
Garg 1988 GI of diets not reported or compared.
Participants not free-living.
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Garg 1992 GI of diets not reported or compared.
Comparison not between diets with similar overall energy and macronutrient intakes.
Participants not free-living.
Intervention duration < 12 weeks.
Garg 1994 GI of diets not reported or compared.
Giacco 2000 Participants with type 1 diabetes.
Gilbertson 2001 Participants were children.
Gilbertson 2003 Study did not report CHD risk factors or outcomes.
Golay 1992 Intervention duration < 12 weeks.
Grant 2010 Pregnant women, gestational hyperglycaemia.
Gutschall 2009 Participants with type 2 diabetes.
Heilbronn 2002 Participants with type 2 diabetes.
Herrmann 2001 Participants not diagnosed with CHD or at risk of CHD.
Intervention duration < 12 weeks.
Hollenbeck 1985 GI of diets not reported or compared.
Comparisons not between diets with similar overall energy and macronutrient levels
Jarvi 1995 Intervention duration < 12 weeks.
Jarvi 1999 Intervention duration < 12 weeks.
Jenkins 1985 Not RCT or CCT.
Jenkins 1987a Participants not diagnosed with CHD or at risk of CHD.
Intervention duration < 12 weeks.
Jenkins 1987b Not RCT or CCT.
Jenkins 1988 Intervention duration < 12 weeks.
Jenkins 2002a GI of diets not reported or compared.
Participants not free-living.
Jenkins 2002b Intervention duration < 12 weeks.
Jenkins 2008 Participants with type 2 diabetes.
Jensen 2008 Intervention duration < 12 weeks.
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(Continued)
Jeppesen 1997 Participants not diagnosed with CHD or at risk of CHD.
GI of diets not reported or compared.
Comparisons not between diets with similar overall energy and macronutrient contents.
Intervention duration < 12 weeks.
Jimenez-Cruz 2003a Participants with type 2 diabetes.
Jiminez-Cruz 2003b Intervention duration < 12 weeks.
Jiminez-Cruz 2004 Intervention duration < 12 weeks.
Kabir 2002 Participants with type 2 diabetes.
Kelly 2011 No relevant outcomes reported (primary and/or secondary outcomes)
Kendall 2012 Participants with type 2 diabetes.
Kiens 1996 Participants not diagnosed with CHD or at risk of CHD.
Komindr 2001 Participants with type 2 diabetes.
Krog-Mikkelsen 2011 Intervention duration < 12 weeks.
Kwak 2012 Intervention duration < 12 weeks.
Lafrance 1998 Intervention duration < 12 weeks.
LaHaye 2005 Not an RCT.
Laitinen 1993 GI of diets not reported or compared.
Leinonen 2000 GI of diet not reported or compared.
Lerman-Garber 1995 GI of diets not reported or compared.
Comparison not between diets with similar overall energy and macronutrient contents
Lieberman 2003 Not an RCT.
Liu 2000 Not RCT or CCT.
Liu 2002 Not RCT or CCT.
Ludwig 1999 Participants were children.
Lunetta 1996 Intervention duration < 12 weeks.
Participants not free-living.
Luscombe 1999 Participants with type 2 diabetes.
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(Continued)
Marsh 2010 Participants with polycystic ovary syndrome.
Morales 1997 Not RCT or CCT.
Participants were children.
Nazare 2010 Intervention duration < 12 weeks.
Pacy 1984 GI of diets not reported or compared.
Comparison not between diets with similar overall energy and macronutrient contents
Patel 2004 Intervention duration < 12 weeks.
Patel 2011a Intervention duration < 12 weeks.
Percheron 1997 Comparison not between diets with similar energy and macronutrient levels.
Participants not free-living.
Intervention duration < 12 weeks.
Pereira 2002 GI of diets not reported or compared.
Pereira 2004 Comparison not between diets with similar energy and macronutrient levels
Perichart-Perera 2012 Pregnant women with diabetes or gestational diabetes.
Pittas 2005 Comparison not between diets with similar energy and macronutrient levels
Poppitt 2002 GI of the diets not reported or compared.
Rabasa-Lhoret 1999 Comparison not between diets with similar overall energy and macronutrient levels..
Participants not free-living.
Intervention duration < 12 weeks.
Rasmussen 1993 GI of diets not reported or compared.
Comparison not between diets with similar overall energy and macronutrient contents
Runchey 2012 Intervention duration < 12 weeks.
Runchey 2013 Intervention duration < 12 weeks.
Sacks 2013 Intervention duration < 12 weeks.
Salmeron 1997 Not an RCT or CCT.
Santacroce 1990 GI of diets not reported or compared.
Scholz 2003 Intervention duration < 12 weeks.
Sciarrone 1993 Participants not diagnosed with CHD or at risk of CHD.
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(Continued)
Sharafetdinov 1997 Intervention duration < 12 weeks.
Shikany 2009 Intervention duration < 12 weeks.
Shyam 2013 No relevant outcomes reported (primary and/or secondary outcomes)
Singh 1991 GI of the diets not reported or compared.
Comparison not between diets of similar energy and macronutrient intake
Slabber 1994 GI of the diets not reported or compared.
Sloth 2004 Intervention duration < 12 weeks.
Spieth 2000 Participants were children.
Taghrid 2004 Participants with type 2 diabetes.
Tovar 2012 Intervention duration < 12 weeks.
Tsihlias 2000 Participants with type 2 diabetes.
Van Horn 1991 GI of diets not reported or compared.
Visek 2011 Participants with type 2 diabetes.
Vrolix 2010 Intervention duration < 12 weeks.
Wolever 1992a Participants with type 2 diabetes and overweight/obese.
Wolever 1992b Intervention duration < 12 weeks.
Wolever 1995 Participants not diagnosed with CHD or at risk of CHD.
Intervention duration < 12 weeks.
Wolever 2008 Participants with type 2 diabetes.
Yang 2002 Not an RCT.
Yusof 2009 Participants with type 2 diabetes.
Zhang 2010 Intervention duration < 12 weeks.
CHD:Coronaryheartdisease;GI :Glycaemicindex
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Characteristics of studies awaiting assessment [ordered by study ID]
Boyadjieva 2015
Methods RCT.
Participants 30 obese adults (males and females).
Interventions 16 weeks dietary intervention: low GI vs high GI.
Outcomes Plasma ghrelin, leptin, and anthropometric parameters.
Notes Not clear if they collected CVD outcomes.
Contacted authors (23.06.2016) to clarify the measurement of CVD outcomes. Authors did not respond
Cayanan 2015
Methods RCT.
Participants 44 obese adults with obstructive sleep apnea.
Interventions Low glycaemic index high protein diet.
Outcomes Cardio-metabolic markers (such as blood pressure).
Notes Diet composition not clear.
Contacted authors (18.08.2016) to clarify intervention and control diet composition. Authors did not respond
Giroux 2015
Methods Design not clear.
Participants 26 rural adults with prediabetes.
Interventions 6-month lifestyle education program.
Outcomes Eating behaviour and anthropometric measures.
Notes Study design and CVD outcomes are not clear.
Contacted authors (23.06.2106) to clarify study design and measured outcomes. Author did not respond
Karl 2015
Methods RCT
Participants 91 obese adults.
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Karl 2015 (Continued)
Interventions 17 weeks of four food provided diets: moderate carbohydrate/low GI; moderate carbohydrate/high GI; high carbo-
hydrate/low GI; high carbohydrate/low GI
Outcomes Anthropometric measures and metabolic adaptation.
Notes CVD outcomes not available.
Weinhold 2015
Methods RCT.
Participants Employees 18 to 65 years old with prediabetes.
Interventions Intervention: 16-week group based lifestyle intervention adapted from the Diabetes Prevention Program
Control: usual care.
Outcomes Weight loss, glucose control, blood pressure, and food intake
Notes Library unable to locate.
RCT :Randomisedcontrolledtrial;GI :Glycaemicindex;CVD:Cardiovasculardisease
Characteristics of ongoing studies [ordered by study ID]
Brand-Miller 2013
Trial name or title PREVIEW.
Methods RCT.
Participants 2500 adults and children, overweight (BMI ≥ 25.0 kg/m2) and prediabetic will be recruited
Interventions 3 years high-protein, low-glycaemic index diet vs a high-carbohydrate, medium-glycaemic index diet in
combination with moderate or high intensity physical activity
Outcomes Incidence of type 2 diabetes and related outcomes including CVD outcomes
Starting date 2013
Contact information Author response ’Indeed the PREVIEW intervention study is ongoing, and the data will not be analysed for
the whole data set until late 2018. We are including CVD risk factors”
Notes 6-year EU project (2013-2018).
RCT :Randomisedcontrolledtrial;BMI :Bodymassindex;CVD:Cardiovasculardisease;EU :EuropeanUnioin
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D A T A A N D A N A L Y S E S
Comparison 1. Low GI versus control (primary prevention)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total cholesterol (mmol/L)
change
17 1277 Mean Difference (IV, Random, 95% CI) -0.12 [-0.26, 0.02]
2 HDL Cholesterol (mmol/L)
change
17 1329 Mean Difference (IV, Fixed, 95% CI) -0.00 [-0.03, 0.02]
3 LDL cholesterol (mmol/L)
change
17 1274 Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.10, 0.04]
4 Triglycerides (mmol/L) change 16 1252 Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.03, 0.09]
5 Systolic blood pressure (mmHg)
change
10 786 Mean Difference (IV, Fixed, 95% CI) 0.52 [-1.21, 2.25]
6 Diastolic blood pressure
(mmHg) change
10 786 Mean Difference (IV, Fixed, 95% CI) -0.23 [-1.42, 0.96]
7 Behaviour change Other data No numeric data
8 Hunger/desire to eat Other data No numeric data
9 Satisfaction Other data No numeric data
10 Weight change (kg) 20 1403 Mean Difference (IV, Fixed, 95% CI) -0.16 [-0.54, 0.21]
11 BMI change (kg/m2) 11 525 Mean Difference (IV, Fixed, 95% CI) -0.00 [-0.26, 0.26]
Comparison 2. Low GI versus control (secondary prevention)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total cholesterol (mmol/L)
change
1 55 Mean Difference (IV, Fixed, 95% CI) -0.1 [-0.59, 0.39]
2 HDL Cholesterol (mmol/L)
change
1 55 Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.18, 0.12]
3 LDL cholesterol (mmol/L)
change
1 55 Mean Difference (IV, Fixed, 95% CI) -0.06 [-0.47, 0.35]
4 Triglycerides (mmol/L) change 1 55 Mean Difference (IV, Fixed, 95% CI) -0.29 [-0.73, 0.15]
5 Systolic blood pressure (mmHg)
change
1 55 Mean Difference (IV, Fixed, 95% CI) -2.0 [-14.99, 10.99]
6 Diastolic blood pressure
(mmHg) change
1 55 Mean Difference (IV, Fixed, 95% CI) -4.0 [-13.41, 5.41]
7 Weight change (kg) 1 55 Mean Difference (IV, Fixed, 95% CI) 0.70 [-6.77, 8.17]
8 BMI change (kg.m2) 1 55 Mean Difference (IV, Fixed, 95% CI) 0.30 [-1.75, 2.35]
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Analysis 1.1. Comparison 1 Low GI versus control (primary prevention), Outcome 1 Total cholesterol
(mmol/L) change.
Review: Low glycaemic index diets for the prevention of cardiovascular disease
Comparison: 1 Low GI versus control (primary prevention)
Outcome: 1 Total cholesterol (mmol/L) change
Study or subgroup Low GI Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Sichieri 2007 101 0.29 (0.99) 102 0.38 (1.02) 7.7 % -0.09 [ -0.37, 0.19 ]
Solomon 2010 10 -0.8 (0.86) 12 -0.67 (0.79) 3.0 % -0.13 [ -0.83, 0.57 ]
McMillan-Price 2006 high CHO 32 -0.18 (0.6) 32 0.05 (0.6) 7.4 % -0.23 [ -0.52, 0.06 ]
McMillan-Price 2006 high protein 33 -0.5 (0.6) 33 0.24 (0.6) 7.5 % -0.74 [ -1.03, -0.45 ]
Philippou 2009a 23 0.39 (0.58) 19 0.46 (0.34) 7.6 % -0.07 [ -0.35, 0.21 ]
Philippou 2009 22 -0.45 (0.62) 16 0.02 (0.56) 6.1 % -0.47 [ -0.85, -0.09 ]
Buscemi 2013 19 -0.41 (0.97) 21 -0.62 (1.02) 3.6 % 0.21 [ -0.41, 0.83 ]
Armendariz-Anguiano 2011 16 -0.8 (1.13) 8 -0.4 (0.87) 2.3 % -0.40 [ -1.22, 0.42 ]
Ghani 2014a high insulin 15 -0.11 (0.73) 18 -0.11 (0.76) 4.5 % 0.0 [ -0.51, 0.51 ]
Ghani 2014 low insulin 24 -0.09 (0.85) 20 -0.18 (0.58) 5.5 % 0.09 [ -0.33, 0.51 ]
DiOGenes 2011a high protein 107 0.8 (0.75) 95 0.64 (0.66) 9.0 % 0.16 [ -0.03, 0.35 ]
DiOGenes 2011 low protein 95 0.7 (0.72) 84 0.79 (0.87) 8.4 % -0.09 [ -0.33, 0.15 ]
Venn 2010 53 -0.1 (1.11) 55 -0.5 (1.05) 5.7 % 0.40 [ -0.01, 0.81 ]
Shikany 2005 31 -0.23 (0.76) 26 0.13 (0.7) 6.1 % -0.36 [ -0.74, 0.02 ]
Juanola-Falgarona 2014 41 -0.05 (0.7) 40 0.13 (0.69) 7.3 % -0.18 [ -0.48, 0.12 ]
Bellisle 2007 8 -0.39 (0.98) 8 -0.38 (0.95) 1.9 % -0.01 [ -0.96, 0.94 ]
Ho¨nemann 2010 31 -0.27 (0.69) 27 -0.3 (0.73) 6.3 % 0.03 [ -0.34, 0.40 ]
Total (95% CI) 661 616 100.0 % -0.12 [ -0.26, 0.02 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 40.89, df = 16 (P = 0.00058); I2 =61%
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Low GI versus control (primary prevention), Outcome 2 HDL Cholesterol
(mmol/L) change.
Review: Low glycaemic index diets for the prevention of cardiovascular disease
Comparison: 1 Low GI versus control (primary prevention)
Outcome: 2 HDL Cholesterol (mmol/L) change
Study or subgroup Low GI Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sichieri 2007 101 0.21 (0.36) 102 0.24 (0.37) 6.4 % -0.03 [ -0.13, 0.07 ]
Solomon 2010 10 -0.08 (0.3) 12 -0.07 (0.35) 0.9 % -0.01 [ -0.28, 0.26 ]
Juanola-Falgarona 2014 41 0.03 (0.19) 40 0.08 (0.18) 10.0 % -0.05 [ -0.13, 0.03 ]
McMillan-Price 2006 high CHO 32 0.03 (0.2) 32 0.08 (0.2) 6.8 % -0.05 [ -0.15, 0.05 ]
McMillan-Price 2006 high protein 33 0.07 (0.2) 32 0.05 (0.2) 6.9 % 0.02 [ -0.08, 0.12 ]
Philippou 2009a 23 0.13 (0.2) 19 0.17 (0.23) 3.7 % -0.04 [ -0.17, 0.09 ]
Buscemi 2013 19 -0.01 (0.27) 21 -0.08 (0.39) 1.5 % 0.07 [ -0.14, 0.28 ]
Armendariz-Anguiano 2011 16 -0.6 (0.36) 8 -0.7 (0.36) 0.7 % 0.10 [ -0.21, 0.41 ]
Ghani 2014a high insulin 15 0.1 (0.18) 18 0.01 (0.31) 2.3 % 0.09 [ -0.08, 0.26 ]
Ghani 2014 low insulin 24 0.04 (0.3) 20 0.04 (0.2) 2.9 % 0.0 [ -0.15, 0.15 ]
DiOGenes 2011 low protein 95 0.23 (0.21) 84 0.23 (0.26) 13.3 % 0.0 [ -0.07, 0.07 ]
DiOGenes 2011a high protein 107 0.21 (0.24) 96 0.2 (0.21) 17.0 % 0.01 [ -0.05, 0.07 ]
Melanson 2012 49 -0.11 (0.2) 41 -0.05 (0.16) 11.8 % -0.06 [ -0.13, 0.01 ]
Venn 2010 53 0 (0.3) 55 -0.1 (0.3) 5.1 % 0.10 [ -0.01, 0.21 ]
Shikany 2005 31 -0.03 (0.29) 26 -0.13 (0.26) 3.2 % 0.10 [ -0.04, 0.24 ]
Bellisle 2007 8 -0.15 (0.4) 8 -0.19 (0.46) 0.4 % 0.04 [ -0.38, 0.46 ]
Ho¨nemann 2010 31 -0.02 (0.21) 27 -0.02 (0.16) 7.1 % 0.0 [ -0.10, 0.10 ]
Total (95% CI) 688 641 100.0 % 0.00 [ -0.03, 0.02 ]
Heterogeneity: Chi2 = 12.71, df = 16 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
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Analysis 1.3. Comparison 1 Low GI versus control (primary prevention), Outcome 3 LDL cholesterol
(mmol/L) change.
Review: Low glycaemic index diets for the prevention of cardiovascular disease
Comparison: 1 Low GI versus control (primary prevention)
Outcome: 3 LDL cholesterol (mmol/L) change
Study or subgroup Low GI Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sichieri 2007 101 -0.05 (0.88) 102 -0.03 (0.97) 7.6 % -0.02 [ -0.27, 0.23 ]
Juanola-Falgarona 2014 41 0.03 (0.51) 40 0.14 (0.5) 10.2 % -0.11 [ -0.33, 0.11 ]
Solomon 2010 10 -0.45 (0.77) 12 -0.39 (0.66) 1.3 % -0.06 [ -0.67, 0.55 ]
McMillan-Price 2006 high CHO 32 -0.17 (0.6) 32 0.04 (0.6) 5.7 % -0.21 [ -0.50, 0.08 ]
McMillan-Price 2006 high protein 33 -0.04 (0.5) 32 0.26 (0.6) 6.8 % -0.30 [ -0.57, -0.03 ]
Philippou 2009a 23 0.24 (0.45) 19 0.26 (0.31) 9.2 % -0.02 [ -0.25, 0.21 ]
Philippou 2009 22 -0.22 (0.49) 16 -0.11 (0.73) 2.9 % -0.11 [ -0.52, 0.30 ]
Buscemi 2013 19 0.34 (0.97) 21 0.44 (0.87) 1.5 % -0.10 [ -0.67, 0.47 ]
Armendariz-Anguiano 2011 16 0 (0.79) 8 0.3 (0.79) 1.1 % -0.30 [ -0.97, 0.37 ]
Ghani 2014a high insulin 15 -0.1 (0.54) 18 -0.21 (0.57) 3.4 % 0.11 [ -0.27, 0.49 ]
Ghani 2014 low insulin 24 -0.23 (0.66) 20 -0.18 (0.41) 4.8 % -0.05 [ -0.37, 0.27 ]
DiOGenes 2011 low protein 93 0.4 (0.53) 83 0.52 (0.74) 13.3 % -0.12 [ -0.31, 0.07 ]
DiOGenes 2011a high protein 108 0.5 (0.63) 95 0.37 (0.6) 17.1 % 0.13 [ -0.04, 0.30 ]
Venn 2010 53 0 (0.85) 55 -0.3 (0.85) 4.8 % 0.30 [ -0.02, 0.62 ]
Shikany 2005 31 0.21 (0.66) 26 0.05 (0.7) 3.9 % 0.16 [ -0.20, 0.52 ]
Bellisle 2007 8 -0.26 (1.01) 8 -0.24 (0.92) 0.5 % -0.02 [ -0.97, 0.93 ]
Ho¨nemann 2010 31 -0.35 (0.5) 27 -0.37 (0.61) 5.9 % 0.02 [ -0.27, 0.31 ]
Total (95% CI) 660 614 100.0 % -0.03 [ -0.10, 0.04 ]
Heterogeneity: Chi2 = 16.75, df = 16 (P = 0.40); I2 =4%
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Low GI versus control (primary prevention), Outcome 4 Triglycerides (mmol/L)
change.
Review: Low glycaemic index diets for the prevention of cardiovascular disease
Comparison: 1 Low GI versus control (primary prevention)
Outcome: 4 Triglycerides (mmol/L) change
Study or subgroup Low GI Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sichieri 2007 101 0.28 (0.59) 102 0.35 (0.61) 12.9 % -0.07 [ -0.24, 0.10 ]
Solomon 2010 10 -0.6 (0.81) 12 -0.46 (0.67) 0.9 % -0.14 [ -0.77, 0.49 ]
Raatz 2005 10 -0.4 (0.9) 9 -0.5 (0.6) 0.8 % 0.10 [ -0.58, 0.78 ]
McMillan-Price 2006 high CHO 32 -0.05 (0.4) 32 -0.14 (0.4) 9.1 % 0.09 [ -0.11, 0.29 ]
McMillan-Price 2006 high protein 33 -0.19 (0.4) 32 -0.18 (0.4) 9.3 % -0.01 [ -0.20, 0.18 ]
Buscemi 2013 19 -0.06 (0.57) 21 -0.26 (0.59) 2.7 % 0.20 [ -0.16, 0.56 ]
Armendariz-Anguiano 2011 16 -0.5 (1.39) 8 -0.5 (1.57) 0.2 % 0.0 [ -1.28, 1.28 ]
Ghani 2014a high insulin 15 -0.26 (0.55) 18 0.19 (0.54) 2.5 % -0.45 [ -0.82, -0.08 ]
Ghani 2014 low insulin 24 0.16 (0.43) 20 -0.08 (0.34) 6.8 % 0.24 [ 0.01, 0.47 ]
DiOGenes 2011a high protein 107 0.19 (0.51) 94 0.14 (0.38) 23.0 % 0.05 [ -0.07, 0.17 ]
DiOGenes 2011 low protein 93 0.13 (0.53) 82 0.13 (0.52) 14.4 % 0.0 [ -0.16, 0.16 ]
Melanson 2012 49 -0.06 (0.85) 41 -0.06 (0.48) 4.5 % 0.0 [ -0.28, 0.28 ]
Venn 2010 53 -0.2 (0.75) 55 -0.2 (0.7) 4.7 % 0.0 [ -0.27, 0.27 ]
Randolph 2014 24 -0.1 (0.97) 25 -0.2 (1) 1.2 % 0.10 [ -0.45, 0.65 ]
Shikany 2005 31 -0.08 (0.8) 26 0.09 (0.83) 1.9 % -0.17 [ -0.60, 0.26 ]
Ho¨nemann 2010 31 0.01 (0.39) 27 -0.23 (0.58) 5.3 % 0.24 [ -0.02, 0.50 ]
Total (95% CI) 648 604 100.0 % 0.03 [ -0.03, 0.09 ]
Heterogeneity: Chi2 = 16.50, df = 15 (P = 0.35); I2 =9%
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours Low GI Favours High GI
97Low glycaemic index diets for the prevention of cardiovascular disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.5. Comparison 1 Low GI versus control (primary prevention), Outcome 5 Systolic blood pressure
(mmHg) change.
Review: Low glycaemic index diets for the prevention of cardiovascular disease
Comparison: 1 Low GI versus control (primary prevention)
Outcome: 5 Systolic blood pressure (mmHg) change
Study or subgroup Low GI Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Solomon 2010 10 -9 (8.37) 12 -14 (15.88) 2.8 % 5.00 [ -5.37, 15.37 ]
Philippou 2009 22 -5 (10) 16 -10 (10) 7.2 % 5.00 [ -1.44, 11.44 ]
Buscemi 2013 19 -10 (13.23) 21 -2 (13.53) 4.3 % -8.00 [ -16.30, 0.30 ]
DiOGenes 2011a high protein 105 4.24 (14.27) 93 2.72 (13.39) 20.1 % 1.52 [ -2.33, 5.37 ]
DiOGenes 2011 low protein 92 4.47 (12.81) 80 5.12 (10.67) 24.3 % -0.65 [ -4.16, 2.86 ]
Melanson 2012 44 -0.05 (12.08) 41 -3.71 (13.13) 10.4 % 3.66 [ -1.72, 9.04 ]
Venn 2010 53 -10 (14.71) 55 -10 (15.39) 9.3 % 0.0 [ -5.68, 5.68 ]
Randolph 2014 24 -1.4 (8.32) 25 0.2 (7.5) 15.2 % -1.60 [ -6.04, 2.84 ]
Bellisle 2007 8 -2.4 (16.13) 8 -5.3 (15.88) 1.2 % 2.90 [ -12.79, 18.59 ]
Ho¨nemann 2010 31 -2.5 (12.7) 27 -3.5 (16.2) 5.2 % 1.00 [ -6.57, 8.57 ]
Total (95% CI) 408 378 100.0 % 0.52 [ -1.21, 2.25 ]
Heterogeneity: Chi2 = 9.63, df = 9 (P = 0.38); I2 =7%
Test for overall effect: Z = 0.59 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Low GI versus control (primary prevention), Outcome 6 Diastolic blood
pressure (mmHg) change.
Review: Low glycaemic index diets for the prevention of cardiovascular disease
Comparison: 1 Low GI versus control (primary prevention)
Outcome: 6 Diastolic blood pressure (mmHg) change
Study or subgroup Low GI Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Solomon 2010 10 -3 (8.37) 12 -8 (10.4) 2.3 % 5.00 [ -2.84, 12.84 ]
Philippou 2009 22 -2 (9) 16 -5 (7) 5.5 % 3.00 [ -2.09, 8.09 ]
Buscemi 2013 19 -3 (8) 21 -4 (10.54) 4.2 % 1.00 [ -4.77, 6.77 ]
DiOGenes 2011a high protein 105 1.94 (8.01) 93 0.96 (7.99) 28.4 % 0.98 [ -1.25, 3.21 ]
DiOGenes 2011 low protein 92 1.01 (7.89) 80 3.55 (7.68) 26.0 % -2.54 [ -4.87, -0.21 ]
Melanson 2012 44 1.91 (12.15) 41 -2.29 (9.37) 6.7 % 4.20 [ -0.40, 8.80 ]
Venn 2010 53 -4 (9.13) 55 -3 (10.09) 10.7 % -1.00 [ -4.63, 2.63 ]
Randolph 2014 24 -0.5 (7.83) 25 1.1 (5.5) 9.8 % -1.60 [ -5.40, 2.20 ]
Bellisle 2007 8 -2.8 (11.98) 8 -4.4 (12) 1.0 % 1.60 [ -10.15, 13.35 ]
Ho¨nemann 2010 31 -4.5 (10.1) 27 -0.8 (9.8) 5.4 % -3.70 [ -8.83, 1.43 ]
Total (95% CI) 408 378 100.0 % -0.23 [ -1.42, 0.96 ]
Heterogeneity: Chi2 = 14.43, df = 9 (P = 0.11); I2 =38%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Low GI versus control (primary prevention), Outcome 7 Behaviour change.
Behaviour change
Study Low GI group Control group P
Armendariz-Anguiano 2011 diet as per menu plans diet as per menu plans NS
Armendariz-Anguiano 2011 no significant change in physical
activity observed
no significant change in physical
activity observed
NS
Bellisle 2007 increase in dietary restraint; de-
crease in disinhibition, hunger
sensations, emotionality, and ex-
ternality
increase in dietary restraint; de-
crease in disinhibition, hunger
sensations, emotionality and ex-
ternality
NS
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Behaviour change (Continued)
Bellisle 2007
Analysis 1.8. Comparison 1 Low GI versus control (primary prevention), Outcome 8 Hunger/desire to eat.
Hunger/desire to eat
Study Low GI group Control group P
Bellisle 2007 Participants in the low GI group
had significantly lower intensity of
hunger and desire to eat than par-
ticipants of the control group
< 0.0001 for both
Juanola-Falgarona 2014 - 4.13 (SE 0.46) hunger sensation - 2.52 (SE 0.45) hunger sensation 0.048 between the two groups
Melanson 2012 Hunger and satiety ratings only
reported for low GI and low en-
ergy density groups, no significant
difference between groups after 12
weeks
Philippou 2009a No significant difference between
groups for hunger and fullness
0.8 for both
Sichieri 2007 -1.31 (SD 6.3) on hunger scale -0.98 (SD 4.3) on hunger scale 0.74
Analysis 1.9. Comparison 1 Low GI versus control (primary prevention), Outcome 9 Satisfaction.
Satisfaction
Study Outcome Low GI group Control group P
Bellisle 2007 Satisfaction with
programme (VAS)
73.2 (SE 1.2) 69.1 (SE 1.2) NS
Bellisle 2007 Perception of effectiveness
(VAS)
71.5 (SE 1.2) 70.4 (SE 1.0) NS
Bellisle 2007 Ease of following diet
(VAS)
70.2 (SE 1.3) 65.1 (SE 1.3) 0.0048
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Analysis 1.10. Comparison 1 Low GI versus control (primary prevention), Outcome 10 Weight change (kg).
Review: Low glycaemic index diets for the prevention of cardiovascular disease
Comparison: 1 Low GI versus control (primary prevention)
Outcome: 10 Weight change (kg)
Study or subgroup Low GI Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sichieri 2007 101 -0.41 (2.9) 102 -0.26 (3.6) 17.6 % -0.15 [ -1.05, 0.75 ]
Solomon 2010 10 -7.8 (14.45) 12 -9 (14.73) 0.1 % 1.20 [ -11.03, 13.43 ]
Raatz 2005 10 -9.95 (4.4) 9 -9.3 (3.9) 1.0 % -0.65 [ -4.38, 3.08 ]
McMillan-Price 2006 high CHO 32 -4.8 (2.8) 32 -3.7 (2.8) 7.5 % -1.10 [ -2.47, 0.27 ]
McMillan-Price 2006 high protein 33 -4.4 (2.9) 32 -5.3 (2.8) 7.4 % 0.90 [ -0.49, 2.29 ]
Philippou 2009a 23 -0.7 (2.9) 19 0.3 (1.9) 6.7 % -1.00 [ -2.46, 0.46 ]
Philippou 2009 22 -2.2 (3.6) 16 -3 (4.2) 2.2 % 0.80 [ -1.75, 3.35 ]
Buscemi 2013 19 -8.3 (16.87) 21 -7.1 (13.71) 0.2 % -1.20 [ -10.79, 8.39 ]
Armendariz-Anguiano 2011 16 -3.6 (12.53) 8 -2.4 (12.53) 0.1 % -1.20 [ -11.83, 9.43 ]
Ghani 2014a high insulin 15 -1.7 (3.8) 18 -0.2 (2.9) 2.6 % -1.50 [ -3.84, 0.84 ]
Ghani 2014 low insulin 24 -0.6 (4.3) 20 -0.2 (2.7) 3.3 % -0.40 [ -2.49, 1.69 ]
DiOGenes 2011a high protein 108 -0.38 (6.28) 96 0.36 (5.41) 5.5 % -0.74 [ -2.34, 0.86 ]
DiOGenes 2011 low protein 95 0.27 (5.01) 84 1.45 (5.34) 6.1 % -1.18 [ -2.70, 0.34 ]
Wolever 2002 13 -0.19 (1.4) 11 -0.49 (1) 15.3 % 0.30 [ -0.66, 1.26 ]
Melanson 2012 49 -3.39 (2.76) 41 -3.73 (2.84) 10.5 % 0.34 [ -0.82, 1.50 ]
Venn 2010 53 -5 (21.83) 55 -3 (19.97) 0.2 % -2.00 [ -9.90, 5.90 ]
Randolph 2014 24 -1.5 (2.4) 25 -2.3 (3) 6.2 % 0.80 [ -0.72, 2.32 ]
Juanola-Falgarona 2014 41 -7.18 (3.74) 40 -7.05 (5.16) 3.7 % -0.13 [ -2.10, 1.84 ]
Bellisle 2007 8 -4 (13) 8 -4.5 (13) 0.1 % 0.50 [ -12.24, 13.24 ]
Ho¨nemann 2010 31 -6.8 (3.5) 27 -6.3 (3.9) 3.9 % -0.50 [ -2.42, 1.42 ]
Total (95% CI) 727 676 100.0 % -0.16 [ -0.54, 0.21 ]
Heterogeneity: Chi2 = 13.06, df = 19 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.40)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
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Analysis 1.11. Comparison 1 Low GI versus control (primary prevention), Outcome 11 BMI change (kg/m2).
Review: Low glycaemic index diets for the prevention of cardiovascular disease
Comparison: 1 Low GI versus control (primary prevention)
Outcome: 11 BMI change (kg/m
2
)
Study or subgroup Low GI Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Solomon 2010 10 -2.8 (3.84) 12 -3.2 (4.01) 0.6 % 0.40 [ -2.89, 3.69 ]
Raatz 2005 10 -3.91 (1.6) 9 -3 (1.2) 4.3 % -0.91 [ -2.17, 0.35 ]
Philippou 2009a 23 -0.3 (1.1) 19 0.1 (0.7) 22.6 % -0.40 [ -0.95, 0.15 ]
Buscemi 2013 19 -2.8 (6.28) 21 -2.6 (4.96) 0.5 % -0.20 [ -3.73, 3.33 ]
Armendariz-Anguiano 2011 16 -1.3 (4.33) 8 -1 (5.06) 0.4 % -0.30 [ -4.40, 3.80 ]
Melanson 2012 49 -1.11 (1.04) 41 -1.32 (1.03) 37.0 % 0.21 [ -0.22, 0.64 ]
Venn 2010 53 -2 (7.01) 55 -1.3 (5.6) 1.2 % -0.70 [ -3.10, 1.70 ]
Randolph 2014 24 -0.5 (0.97) 25 -0.8 (1) 22.4 % 0.30 [ -0.25, 0.85 ]
Shikany 2005 31 -0.6 (5.6) 26 -0.3 (5.6) 0.8 % -0.30 [ -3.22, 2.62 ]
Bellisle 2007 8 -1.5 (4.1) 8 -1.7 (4.4) 0.4 % 0.20 [ -3.97, 4.37 ]
Ho¨nemann 2010 31 -2.3 (1.5) 27 -2.2 (1.7) 9.9 % -0.10 [ -0.93, 0.73 ]
Total (95% CI) 274 251 100.0 % 0.00 [ -0.26, 0.26 ]
Heterogeneity: Chi2 = 6.61, df = 10 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Low GI versus control (secondary prevention), Outcome 1 Total cholesterol
(mmol/L) change.
Review: Low glycaemic index diets for the prevention of cardiovascular disease
Comparison: 2 Low GI versus control (secondary prevention)
Outcome: 1 Total cholesterol (mmol/L) change
Study or subgroup Low GI Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Frost 2004 26 -0.13 (0.8) 29 -0.03 (1.05) 100.0 % -0.10 [ -0.59, 0.39 ]
Total (95% CI) 26 29 100.0 % -0.10 [ -0.59, 0.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
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Analysis 2.2. Comparison 2 Low GI versus control (secondary prevention), Outcome 2 HDL Cholesterol
(mmol/L) change.
Review: Low glycaemic index diets for the prevention of cardiovascular disease
Comparison: 2 Low GI versus control (secondary prevention)
Outcome: 2 HDL Cholesterol (mmol/L) change
Study or subgroup Low GI Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Frost 2004 26 -0.01 (0.26) 29 0.02 (0.3) 100.0 % -0.03 [ -0.18, 0.12 ]
Total (95% CI) 26 29 100.0 % -0.03 [ -0.18, 0.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
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Analysis 2.3. Comparison 2 Low GI versus control (secondary prevention), Outcome 3 LDL cholesterol
(mmol/L) change.
Review: Low glycaemic index diets for the prevention of cardiovascular disease
Comparison: 2 Low GI versus control (secondary prevention)
Outcome: 3 LDL cholesterol (mmol/L) change
Study or subgroup Low GI Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Frost 2004 26 -0.1 (0.7) 29 -0.04 (0.85) 100.0 % -0.06 [ -0.47, 0.35 ]
Total (95% CI) 26 29 100.0 % -0.06 [ -0.47, 0.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
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Analysis 2.4. Comparison 2 Low GI versus control (secondary prevention), Outcome 4 Triglycerides
(mmol/L) change.
Review: Low glycaemic index diets for the prevention of cardiovascular disease
Comparison: 2 Low GI versus control (secondary prevention)
Outcome: 4 Triglycerides (mmol/L) change
Study or subgroup Low GI Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Frost 2004 26 -0.19 (0.72) 29 0.1 (0.95) 100.0 % -0.29 [ -0.73, 0.15 ]
Total (95% CI) 26 29 100.0 % -0.29 [ -0.73, 0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
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Analysis 2.5. Comparison 2 Low GI versus control (secondary prevention), Outcome 5 Systolic blood
pressure (mmHg) change.
Review: Low glycaemic index diets for the prevention of cardiovascular disease
Comparison: 2 Low GI versus control (secondary prevention)
Outcome: 5 Systolic blood pressure (mmHg) change
Study or subgroup Low GI Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Frost 2004 26 -6 (26.99) 29 -4 (21.5) 100.0 % -2.00 [ -14.99, 10.99 ]
Total (95% CI) 26 29 100.0 % -2.00 [ -14.99, 10.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours Low GI Favours High GI
Analysis 2.6. Comparison 2 Low GI versus control (secondary prevention), Outcome 6 Diastolic blood
pressure (mmHg) change.
Review: Low glycaemic index diets for the prevention of cardiovascular disease
Comparison: 2 Low GI versus control (secondary prevention)
Outcome: 6 Diastolic blood pressure (mmHg) change
Study or subgroup Low GI Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Frost 2004 26 -8 (22.23) 29 -4 (10.8) 100.0 % -4.00 [ -13.41, 5.41 ]
Total (95% CI) 26 29 100.0 % -4.00 [ -13.41, 5.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.40)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 2.7. Comparison 2 Low GI versus control (secondary prevention), Outcome 7 Weight change (kg).
Review: Low glycaemic index diets for the prevention of cardiovascular disease
Comparison: 2 Low GI versus control (secondary prevention)
Outcome: 7 Weight change (kg)
Study or subgroup Low GI Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Frost 2004 26 -1.4 (12.23) 29 -2.1 (15.96) 100.0 % 0.70 [ -6.77, 8.17 ]
Total (95% CI) 26 29 100.0 % 0.70 [ -6.77, 8.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.85)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 2.8. Comparison 2 Low GI versus control (secondary prevention), Outcome 8 BMI change (kg.m2).
Review: Low glycaemic index diets for the prevention of cardiovascular disease
Comparison: 2 Low GI versus control (secondary prevention)
Outcome: 8 BMI change (kg.m
2
)
Study or subgroup Low GI Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Frost 2004 26 -0.4 (3.1) 29 -0.7 (4.57) 100.0 % 0.30 [ -1.75, 2.35 ]
Total (95% CI) 26 29 100.0 % 0.30 [ -1.75, 2.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
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A D D I T I O N A L T A B L E S
Table 1. Glycaemic index values for food types
Food type Glycaemic index
White bread 100
Wholemeal bread 100
Weetabix 100
Cornflakes 119
Porridge 87
Baked beans 69
Digestive biscuits 84
Apple 52
Table 2. Comparibility of diets achieved
Study ID Dietary component Low GI Control P
Armendariz-Anguiano
2011
Energy (kJ/day) 5690 (SE 1255) kJ/day 6460 (SE 2489) kJ/day NS
Carbohydrate (g/day) 173 (SE 41) g/day 197 (SE 82) g/day NS
Fat (g/day) 48 (SE 22) g/day 49 (SE 39) g/day NS
Protein (g/day) 67 (SE 18) g/day 82 (SE 31) g/day NS
Fibre (g/day) 23 (SE 12) g/day 14 (SE 7) g/day NS
GI 51 (SE 7) 59 (SE 5) 0.008
Bellisle 2007 Energy (kJ or kcal/day) NR NR
Carbohydrate (g/day or
% energy)
NR NR
Fat (g/day or % energy) NR NR
Protein (g/day or % en-
ergy)
NR NR
High GI foods selected
over 3 days (n)
5.8 (SE 0.7) 10.7 (SE 1.5) 0.002
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Table 2. Comparibility of diets achieved (Continued)
Low GI foods selected
over 3 days (n)
19.6 (SE 1.3) 17 (SE 1.3) 0.18
Buscemi 2013 Energy (kJ/day) set to about 20 kcal/
kg BW (83.7 kJ) (1400,
1600, 1800 or 2000
kcal/day (5858, 6694,
7531, 8368 kJ/day)),
data below for 1600
kcal/day (6694 kJ/day)
set to about 83.7 kJ/kg
BW (5858, 6694, 7531,
8368kJ/day), data below
for 6694 kJ/day (1600
kcal/day)
Carbohydrate (g/day or
% energy)
218 g/day
55% of energy
230 g/day
57% of energy
Fat (g/day or % energy) 45 g/day
25% of energy
43 g/day
24% of energy
Protein (g/day or % en-
ergy)
81 g/day
20% of energy
74 g/day
19% of energy
Fibre (g/day) 32 g/day 33 g/day
GI 43.8 54.1
DiOGenes 2011 low
protein
Energy (kJ/day) screening: 9075 (SD
3388) kJ/day
week 26: -2218 (SD
3734) kJ/day
screening: 9752 (SD
3529) kJ/day
week 26: -2046 (SD
3210) kJ/day
Carbohydrate (% en-
ergy)
screening: 42.2 (SD 9.0)
% of energy
week 26: +9.0 (SD 8.6)
% of energy
screening: 44.7 (SD 8.6)
% of energy
week 26: +6.0 (SD 10.1)
% of energy
Fat (% energy) screening: 37.4 (SD 7.8)
% of energy
week 26: -7.7 (SD 8.8)
% of energy
screening: 36.3 (SD 7.4)
% of energy
week 26: -5.5 (SD 10.4)
% of energy
Protein (% energy) screening: 18.3 (SD 5.2)
% of energy
week 26: -0.3 (SD 4.7)
% of energy
screening: 17.0 (SD 4.0)
% of energy
week 26: -0.7 (SD 4.9)
% of energy
Fibre (g/day) screening: 19.3 (SD 8.9)
g/day
week 26: +1.7 (SD 14.7)
g/day
screening: 18.7 (SD 8.2)
g/day
week 26: +1.6 (SD 10.4)
g/day
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Table 2. Comparibility of diets achieved (Continued)
GI screening: 61.0 (SD 5.7)
week 26: -4.7 (SD 6.8)
screening: 60.7 (SD 4.7)
week 26: +0.3 (SD 5.6)
DiOGenes 2011a high
protein
Energy (kJ/day) screening: 9657 (SD
2868) kJ/day
week 26: -2259 (SD
2759) kJ/day
screening: 9492 (SD
3311) kJ/day
week 26: -2609 (SD
2603) kJ/day
Carbohydrate (% en-
ergy)
screening: 43.7 (SD 8.8)
% of energy
week 26: +1.4 (SD 10.7)
% of energy
screening: 45.2 (SD 7.3)
% of energy
week 26: +0.5 (SD 7.4)
% of energy
Fat (% energy) screening: 36.1 (SD 7.5)
% of energy
week 26: -4.9 (SD 9.6)
% of energy
screening: 36.3 (SD 6.7)
% of energy
week 26: -5.9 (SD 8.1)
% of energy
Protein (% energy) screening: 17.5 (SD 4.0)
% of energy
week 26: +4.2 (SD 4.5)
% of energy
screening: 16.0 (SD 3.6)
% of energy
week 26: +6.4 (SD 6.0)
% of energy
Fibre (g/day) screening: 19.8 (SD 8.6)
g/day
week 26: +1.6 (SD 13.5)
g/day
screening: 18.9 (SD 8.1)
g/day
week 26: +0.1 (SD 7.6)
g/day
GI screening: 61.1 (SD 5.2)
week 26: -4.9 (SD 6.9)
screening: 61.4 (SD 4.4)
week 26: +0.3 (SD 6.0)
Frost 2004 Energy (kJ/day) 8506 (SE 473) kJ/day 7360 (SE 331) kJ/day 0.04
Carbohydrate (% en-
ergy)
49 (SE 1) % of energy 47 (SE 2) % of energy 0.43
Fat (% energy) 31 (SE 1) % of energy 32 (SE 2) % of energy 0.36
Protein (% energy) 18 (SE 1) % of energy 18 (SE 1) % of energy 0.48
Fibre (g/day) 27 (SE 2) g/day 21 (SE 2) g/day 0.03
GI 71 (SE 1) 81 (SE 1) 0.0001
Ghani 2014 low insulin Energy (kcal) At 1 year: 1706 (SD351) At 1 year: 1595 (SD298) At 1 year: 0.298
Carbohydrate (g) At 1 year: 221 (SD 46) At 1 year: 221 (SD 55) At 1 year: 0.975
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Table 2. Comparibility of diets achieved (Continued)
Protein (g) At 1 year: 68 (SD 15) At 1 year: 60 (SD 13) At 1 year: 0.086
Fat (g) At 1 year: 59 (SD 17) At 1 year: 51 (SD 11) At 1 year: 0.093
Fibre (g) At 1 year: 17 (SD 4) At 1 year: 13 (SD 3) At 1 year: 0.004
GI At 1 year: 59 (SD 4) At 1 year: 65 (SD 4) At 1 year: <0.001
Ghani 2014a high
insulin
Energy (kcal) At 1 year: 1554 (SD292) At 1 year: 1595 (SD442) At 1 year: 0.927
Carbohydrate (g) At 1 year: 186 (SD 62) At 1 year: 208 (SD 48) At 1 year: 0.331
Protein (g) At 1 year: 70 (SD 11) At 1 year: 67 (SD 28) At 1 year: 0.259
Fat (g) At 1 year: 50 (SD 10) At 1 year:55 (SD 20) At 1 year: 0.977
Fibre (g) At 1 year: 17 (SD 4) At 1 year: 13 (SD 5) At 1 year: 0.048
GI At 1 year: 56 (SD 4) At 1 year: 62 (SD 6) At 1 year: 0.021
Hönemann 2010 Energy (kJ/day) 10769 (SD 2982) kJ/
day at baseline; -2481
(SD 2983) kJ/day at 6
months
10022 (SD 2960) kJ/
day at baseline; -1653
(SD 2958) kJ/day at 6
months
NR
Carbohydrate (% en-
ergy)
51.88% of energy 49.01% of energy NR
Fat (% energy) 32.63% of energy 33.69% of energy NR
Protein (% energy) 15.49% of energy 17.30% of energy NR
Fibre (g/day) +3.8 (SD 10.6) g/day +2.7 (SD 12.2) g/day NR
GI NR NR NR
Juanola-Falgarona
2014
Energy (kcal/day) baseline: 2076 (SE 89)
6 months: -685 (SE 94)
baseline: 2036 (SE 101)
6 months: -610 (SE 87)
NS across all three
groups
Carbohydrate (% en-
ergy)
baseline: 41.8 (SE 1.3)
6 months: -2.1 (SE 1.3)
baseline: 41.0 (SE 1.0)
6 months: 1.6 (SE 1.5)
0.001 across all 3 groups
(for 6-month change)
but not reported for low
GI vs high GI compari-
son
Fat (% energy) baseline: 39.6 (SE 1.0)
6 months: -1.5 (SE 1.3)
baseline: 38.0 (SE 0.9)
6 months: -2.9 (SE 1.2)
0.014 across all 3 groups
(for 6-month change)
but not reported for low
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Table 2. Comparibility of diets achieved (Continued)
GI vs high GI compari-
son
Protein (% energy) baseline: 17.0 (SE 0.4)
6 months: 4.2 (SE 0.7)
baseline: 18.8 (SE 0.5)
6 months: 2.8 (SE 0.8)
NS across all three
groups
Fibre (g/day) baseline: 9.0 (SE 0.7)
6 months: 4.2 (SE 0.7)
baseline: 10.0 (SE 0.7)
6 months: 2.8 (SE 0.8)
NS across all three
groups
GI baseline: 56.27 (SE 0.
87)
6 months: -7.00 (SE 1.
08)
baseline: 56.87 (SE 0.
74)
6 months: 0.50 (SE 0.
87)
0.001 across all 3 groups
(for 6-month change)
but not reported for low
GI vs high GI compari-
son
McMillan-Price 2006
high CHO
Energy (kJ) 6150 (SE 190) kJ/day 6010 (SE 240) kJ/day NS
Carbohydrate (g/day or
% energy)
200 (SE 7) g/day
56 (SE 1) % of energy
209 (SE 9) g/day
60 (SE 1) % of energy
NR
Fat (g/day or % energy) 36 (SE 2) g/day
22 (SE 1) % of energy
32 (SE 2) g/day
19 (SE 1) % of energy
NR
Protein (g/day or % en-
ergy)
69 (SE 2) g/day
19 (SE 0) % of energy
63 (SE 3) g/day
18 (SE 1) % of energy
NR
Fibre (g/day) 30 (SE 1) g/day 23 (SE 1) g/day NR
GI 45 (SE 1) 70 (SE 1) NR
McMillan-Price 2006
high protein
Energy (kJ) 5970 (SE 190) kJ/day 5950 (SE 170) kJ/day NS
Carbohydrate (g/day or
% energy)
143 (SE 7) g/day
40 (SE 2) % of energy
146 (SE 6) g/day
42 (SE 1) % of energy
NR
Fat (g/day or % energy) 48 (SE 2) g/day
29 (SE 1) % of energy
44 (SE 2) g/day
27 (SE 1) % of energy
NR
Protein (g/day or % en-
ergy)
93 (SE 3) g/day
26 (SE 1) % of energy
95 (SE 2) g/day
28 (SE 1) % of energy
NR
Fibre (g/day) 24 (SE 1) g/day 21 (SE 1) g/day NR
GI 44 (SE 1) 59 (SE 1) NR
Melanson 2012 Energy (kJ/day) -3270.2 (SD 2734.2) kJ/
day
-2608.3 (SD 2032.6) kJ/
day
NS
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Table 2. Comparibility of diets achieved (Continued)
Carbohydrate (% en-
ergy)
-0.3 (SD 8.0) % of en-
ergy
+1.3 (SD 9.6) % of en-
ergy
NS
Fat (% energy) -3.2 (SD 7.9) % of en-
ergy
-4.3 (SD 7.8) % of en-
ergy
NS
Protein (% energy) +4.4 (SD 5.7) % of en-
ergy
+3.3 (SD 5.3) % of en-
ergy
NS
Fibre (g/day) +3.6 (SD 4.5) g/day -2.4 (SD 5.6) g/day < 0.001
GI 42.43 (SD 7.35) 46.69 (SD 7.74) < 0.05
Philippou 2008 Energy (kJ/day, median,
IQR)
7418 (8661 to 10205)
kJ/day
5472 (5129 to 8133) kJ/
day
NS
Carbohydrate (%energy,
median, IQR)
46.0 (37.8 to 51.0) % of
energy
49.4 (47.8 to 51.7) % of
energy
NS
Fat (%energy, median,
IQR)
32.8 (31.3 to 37.1) % of
energy
29.2 (25.2 to 34.5) % of
energy
NS
Protein (% energy, me-
dian, IQR)
17.1 (15.7 to 17.4) % of
energy
19.6 (14.0 to 23.1) % of
energy
NS
Fibre (g/day, median,
IQR)
8.0 (7.6 to 10.1) g/day 10.0 (6.1 to 11.1) g/day NS
GI (median, IQR) 51.3 (51.0 to 52.0) 59.3 (59.2 to 64.0) < 0.05
Philippou 2009 Energy (kJ/day) -1870 (SD 2088) kJ/day
compared to baseline
-987 (SD 2644) kJ/day
compared to baseline
0.3
Carbohydrate (g/day or
% energy)
224 (SD 50) g/day 278 (SD 7) g/day < 0.001
Fat (g/day or % energy) NR NR
Protein (g/day or % en-
ergy)
NR NR
Fibre (g/day) NR NR
GI 50.6 (SD 4.6) 63.2 (SD 5.6) < 0.001
Philippou 2009a Energy (kJ/day) 6054 (SD 1590) kJ/day 6711 (SD 1439) kJ/day 0.2
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Table 2. Comparibility of diets achieved (Continued)
Carbohydrate (% en-
ergy)
47.6 (SD 6.7) % of en-
ergy
48.5 (SD 7.0) % of en-
ergy
0.6
Fat (% energy) 31.8 (SD 5.8) % of en-
ergy
30.9 (SD 9.0) % of en-
ergy
0.7
Protein (% energy) 19.5 (SD 4.2) % of en-
ergy
19.3 (SD 4.9) % of en-
ergy
0.8
Fibre (g/day) 13.2 (SD 5.7) g/day 10.8 (SD 4.7) g/day 0.2
GI 49.7 (SD 5.7) 63.7 (SD 9.4) < 0.001
Raatz 2005 Energy (kJ/day) mean daily energy level
(initial 12 weeks) for
whole population 7883
(SE 57.8) kJ/day (range
5021 to 11,297 kJ/day)
, not reported for groups
separately
Carbohydrate (g/day or
% energy)
60% of energy (initial 12
weeks)
60% of energy (initial 12
weeks)
NS
Fat (% energy) 25% of energy (initial 12
weeks)
25% of energy (initial 12
weeks)
NS
Protein (% energy) 15% of energy (initial 12
weeks)
15% of energy (initial 12
weeks)
NS
Fibre (g/day) 16.7 g/4184 kJ (initial
12 weeks)
9.1 g/4184 kJ (initial 12
weeks)
NS
GI 33 (initial 12 weeks)
at 24 weeks, low GI
group at significantly
lower GI than high GI
group (P = 0.014), no
significant difference any
more at 36 weeks (P = 0.
14)
63 (initial 12 weeks)
Randolph 2014 Energy (kcal/day) baseline: 1924.3 (SE
147.7)
mean of weeks 3, 6, 9:
1624.9 (SE 81.4)
baseline: 1712.3 (SE 76.
7)
mean of weeks 3, 6, 9:
1573.9 (SE 102.0)
NS
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Table 2. Comparibility of diets achieved (Continued)
Carbohydrate (g/day)
Carbohydrate(%
energy)
baseline: 239.2 (SE 20.
4)
mean of weeks 3, 6, 9:
219.1 (SE 10.2)
baseline: 49.7 (SE 1.8)
mean of weeks 3, 6, 9:
52.3 (SE 2.8)
baseline: 211.7 (SE 8.8)
mean of weeks 3, 6, 9:
197.4 (SE 11.2)
baseline: 50.7 (SE 2.1)
mean of weeks 3, 6, 9:
51.6 (SE 0.9)
NS
Fat (g/day)
Fat (% energy)
baseline: 73.1 (SE 7.2)
mean of weeks 3, 6, 9:
49.1 (SE 4.6)
baseline: 33.4 (SE 1.8)
mean of weeks 3, 6, 9:
26.6 (SE 1.6)
baseline: 59.9 (SE 5.1)
mean of weeks 3, 6, 9:
52.6 (SE 6.2)
baseline: 30.5 (SE 1.6)
mean of weeks 3, 6, 9:
28.8 (SE 1.4)
NS
Protein (g/d)
Protien (% energy)
baseline: 84.7 (SE 6.1)
mean of weeks 3, 6, 9:
79.2 (SE 5.7)
baseline: 18.4 (SE 1.0)
mean of weeks 3, 6, 9:
18.6 (SE 1.2)
baseline: 76.6 (SE 5.0)
mean of weeks 3, 6, 9:
73.4 (SE 4.9)
baseline: 18.0 (SE 0.8)
mean of weeks 3, 6, 9:
19.0 (SE 0.8)
NS
Fibre (g/day) baseline: 23.9 (SE 2.1)
mean of weeks 3, 6, 9:
23.8 (SE 1.5)
baseline: 25.2 (SE 1.6)
mean of weeks 3, 6, 9:
23.3 (SE 1.7)
NS
GI baseline: 52.6 (SE 1.2)
mean of weeks 3, 6, 9:
52.3 (SE 0.8)
baseline: 55.4 (SE 1.1)
mean of weeks 3, 6, 9:
53.3 (SE 0.8)
unclear
RISCK 2010 high
MUFA
Energy (kJ/day) -310 (95% CI: -760 to
+150) MJ/day
(8590 (SD 2110) for all
during run-in)
-540 (95% CI: -1000 to
-80) kJ/day
(8590 (SD 2110) for all
during run-in)
NS
Carbohydrate
(%energy)
+1.6 (95% CI: -0.2 to
+3.4) % of energy
(43.0 (SD 6.5) for all
during run-in)
+1.9 (95% CI: +0.1 to
+3.7) % of energy
(43.0 (SD 6.5) for all
during run-in)
NS
Fat (%energy) -2.2 (95% CI: -3.9 to -0.
4) % of energy
(37.9 (SD 5.3) for all
during run-in)
-2.3 (95% CI: -4.1 to -0.
5) % of energy
(37.9 (SD 5.3) for all
during run-in)
NS
Protein (g/day) +3.4 (95% CI: -1.9 to
+8.6) g/day
(80.8 (SD 20.7) for all
during run-in)
-2.2 (95%CI: -7.5 to +3.
1) g/day
(80.8 (SD 20.7) for all
NS
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Table 2. Comparibility of diets achieved (Continued)
during run-in)
Fibre (g/day) NR NR
GI -8.3 (95% CI: -9.4 to -7.
2)
(63.5 (SD 3.6) for all
during run-in)
-0.2 (95%CI: -1.3 to +1.
0)
(63.5 (SD 3.6) for all
during run-in)
< 0.05
RISCK 2010 low fat Energy (kJ/day) -1310 (95% CI: -1750
to -880) kJ/day
(8590 (SD 2110) for all
during run-in)
-830 (95% CI: -1300 to
-370) kJ/day
(8590 (SD 2110) for all
during run-in)
NS
Carbohydrate
(%energy)
+8.5 (95% CI: +6.8 to
+10.2) % of energy
(43.0 (SD 6.5) for all
during run-in)
+8.1 (95% CI: +6.3 to
+9.9) % of energy
(43.0 (SD 6.5) for all
during run-in)
NS
Fat (%energy) -11.8 (95% CI: -13.5 to
-10.1) % of energy
(37.9 (SD 5.3) for all
during run-in)
-10.4 (95% CI: -12.2 to
-8.6) % of energy
(37.9 (SD 5.3) for all
during run-in)
NS
Protein (g/day) -2.8 (95%CI: -7.8 to +2.
2) g/day
(80.8 (SD 20.7) for all
during run-in)
-0.30 (95% CI: -5.7 to
+5.1) g/day
(80.8 (SD 20.7) for all
during run-in)
NS
Fibre (g/day) NR NR
GI -7.2 (95% CI: -8.3 to -6.
1)
(63.5 (SD 3.6) for all
during run-in)
+0.9 (95% CI: -0.3 to
+2.0)
(63.5 (SD 3.6) for all
during run-in)
< 0.05
Shikany 2005 Energy (kJ/day) 5335 (SE 276) kJ/day 5565 (SE 305) kcal/day NS
Carbohydrate (g/day) 166 (SE 11) g/day 190 (SE 12) g/day NS
Fat (g/day) 37.9 (SE 2.8) g/day 40.3 (SE 3.1) g/day NS
Protein (g/day) 63.4 (SE 3.4) g/day 56.9 (SE 3.7) g/day NS
Fibre (g/day) NR NR
GI 55.2 (SE 1.0) 57.7 (SE 1.1) P < 0.05
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Table 2. Comparibility of diets achieved (Continued)
Sichieri 2007 Energy (MJ/day) 11200 (SD 7000) MJ/
day
14000 (SD9100) kJ/day NS
Carbohydrate
(%energy)
59.5 (SD 6.3) % of en-
ergy
61.6 (SD 6.2) % of en-
ergy
NS
Fat (%energy) 27.2 (SD 4.6) % of en-
ergy
26.1 (SD 4.7) % of en-
ergy
NS
Protein (%energy) NR NR NS
Fibre (g/day) 36.0 (SD 21) g/day 44.5 (SD 27) g/day NS
GI 30 (SD 54) 72 (SD 40) 0.02
Solomon 2010 Energy (kJ/day) 7364 (SE 456) kJ/day 7494 (SE 347) kJ/day NS
Carbohydrate (g/day or
% energy)
247 (SE 16) g/day
54.7 (SE 0.1) % of en-
ergy
258 (SE 12) g/day
55.6 (SE 0.2) % of en-
ergy
NS
Fat (g/day or % energy) 56.7 (SE 3.4) g/day
28.3 (SE 0.1) % of en-
ergy
57.3 (SE 2.9) g/day
27.8 (SE 0.2) % of en-
ergy
NS
Protein (g/day or % en-
ergy)
76.8 (SE 4.8) g/day
17.0 (SE 0.1) % of en-
ergy
76.7 (SE 3.5) g/day
16.6 (SE 0.1) % of en-
ergy
NS
Fibre (g/day) 28.5 (SE 1.6) g/day 26.1 (SE 1.4) g/day NS
GI 39.8 (SE 0.3) 80.0 (SE 0.6) < 0.05
Venn 2010 Energy (kJ/day, median
and IQR)
6350 (5559, 7297) kJ/
day
6508 (5845, 7311) kJ/
day
NS
Carbohydrate (% en-
ergy, median and IQR)
51 (48, 57) % of energy 52 (46, 56) % of energy NS
Fat (% energy, median
and IQR)
27 (21, 31) % of energy 26 (22, 29) % of energy NS
Protein (% energy, me-
dian and IQR)
20 (17, 22) % of energy 20 (18, 23) % of energy NS
Fibre (g/day,median and
IQR)
25 (21, 34) g/day 23 (18, 28) g/day NS
116Low glycaemic index diets for the prevention of cardiovascular disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Comparibility of diets achieved (Continued)
GI (median and IQR) 47 (43, 50) 51 (49, 54) 0.011
Wolever 2002 Energy (kJ/day) 7090 (SE 280) kJ/day 7170 (SE 390) kJ/day NS
Carbohydrate (% en-
ergy)
54.8 (SE 1.7) % of en-
ergy
52.8 (SE 2.0) % of en-
ergy
NS
Fat (% energy) 24.7 (SE 1.6) % of en-
ergy
27.9 (SE 1.9) % of en-
ergy
NS
Protein (% energy) 19.4 (SE 0.5) % of en-
ergy
17.4 (SE 0.7) % of en-
ergy
< 0.05
Fibre (g/day) 36.2 (SE 2.6) g/day 22.7 (SE 2.2) g/day < 0.05
GI 54.4 (SE 0.7) 59.3 (SE 0.6) < 0.05
KJ :kilojoules;SE:standarderror;SD:standarddeviation;g:grams;kcal:kilocalories;GI :glycaemicindex;IQR:interquartilerange;d:day;MJ :microjoule
A P P E N D I C E S
Appendix 1. Search strategies
Search update 2016
CENTRAL
#1 MeSH descriptor: [Glycemic Index] this term only
#2 glyc?emic near/3 low
#3 glyc?emic near/2 (index or indices)
#4 glyc?emic near/3 diet*
#5 #1 or #2 or #3 or #4
#6 MeSH descriptor: [Dietary Carbohydrates] explode all trees
#7 MeSH descriptor: [Carbohydrates] this term only
#8 carbohydrate*
#9 MeSH descriptor: [Starch] explode all trees
#10 starch*
#11 #6 or #7 or #8 or #9 or #10
#12 MeSH descriptor: [Cardiovascular Diseases] explode all trees
#13 heart near/2 disease*
#14 coronary near/3 disease*
#15 chd
#16 cardiovascular
#17 angina
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#18 cvd
#19 MeSH descriptor: [Cholesterol] explode all trees
#20 cholesterol
#21 blood near/2 pressure
#22 MeSH descriptor: [Blood Pressure] explode all trees
#23 MeSH descriptor: [Hypertension] explode all trees
#24 hypertensi*
#25 MeSH descriptor: [Obesity] explode all trees
#26 obes*
#27 insulin next resistan*
#28 metabolic next syndrome*
#29 MeSH descriptor: [Diabetes Mellitus] explode all trees
#30 diabet*
#31 insulin next sensitiv*
#32 glycemic near/3 control*
#33 glycaemic near/3 control*
#34 MeSH descriptor: [Hyperlipidemias] explode all trees
#35 MeSH descriptor: [Overweight] explode all trees
#36 MeSH descriptor: [Glucose Metabolism Disorders] explode all trees
#37 MeSH descriptor: [Hyperinsulinism] explode all trees
#38 cardio* near/6 risk*
#39 overweight
#40 over-weight
#41 hdl or ldl
#42 hyperlip*
#43 lipid*
#44 hyperglycem*
#45 hyperglycaem*
#46 #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20
#47 #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30
#48 #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40
#49 #41 or #42 or #43 or #44 or #45
#50 #46 or #47 or #48 or #49
#51 #11 and #50
#52 #5 or #51
MEDLINE Ovid
1. Glycemic Index/
2. (glyc?emic adj3 low).tw.
3. glyc?emic index.tw.
4. (glyc?emic adj (index or indices)).tw.
5. (glyc?emic adj3 diet$).tw.
6. or/1-5
7. exp Dietary Carbohydrates/
8. Carbohydrates/
9. carbohydrate$.tw.
10. exp Starch/
11. starch*.tw.
12. or/7-11
13. exp Cardiovascular Diseases/
14. (heart adj2 disease*).tw.
15. (coronary adj2 disease*).tw.
16. chd.tw.
17. cardiovascular.tw.
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18. angina*.tw.
19. cvd.tw.
20. exp Cholesterol/
21. exp blood pressure/
22. exp Obesity/
23. exp Hyperinsulinism/
24. exp Hyperlipidemias/
25. exp Glucose Metabolism Disorders/
26. insulin resistan*.tw.
27. insulin sensitiv*.tw.
28. (glyc?emic adj3 control).tw.
29. exp Hypertension/
30. exp Overweight/
31. (cardio* adj6 risk*).tw.
32. (blood adj2 pressure).tw.
33. overweight.tw.
34. obes*.tw.
35. over-weight.tw.
36. cholesterol.tw.
37. (hdl or ldl).tw.
38. hyperlip*.tw.
39. lipid*.tw.
40. hyperglyc?em*.tw.
41. hypertens*.tw.
42. diabet*.tw.
43. or/13-42
44. 12 and 43
45. 6 or 44
46. randomized controlled trial.pt.
47. controlled clinical trial.pt.
48. randomized.ab.
49. placebo.ab.
50. drug therapy.fs.
51. randomly.ab.
52. trial.ab.
53. groups.ab.
54. 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53
55. exp animals/ not humans.sh.
56. 54 not 55
57. 45 and 56
Embase Ovid
1. glycemic index/
2. (glyc?emic adj3 low).tw.
3. (glyc?emic adj3 diet$).tw.
4. glyc?emic index.tw.
5. (glyc?emic adj (index or indices)).tw.
6. 1 or 2 or 3 or 4 or 5
7. carbohydrate diet/
8. carbohydrate/
9. carbohydrate$.tw.
10. starch/
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11. starch*.tw.
12. or/7-11
13. exp coronary artery disease/
14. exp cardiovascular disease/
15. (heart adj2 disease*).tw.
16. (coronary adj2 disease*).tw.
17. chd.tw.
18. cardiovascular.tw.
19. angina*.tw.
20. cvd.tw.
21. exp cholesterol/
22. exp blood pressure/
23. exp Obesity/
24. exp “disorders of carbohydrate metabolism”/
25. (glyc?emic adj3 control).tw.
26. insulin resistan*.tw.
27. insulin sensitiv*.tw.
28. exp Hypertension/
29. exp Overweight/
30. (cardio* adj6 risk*).tw.
31. (blood adj2 pressure).tw.
32. overweight.tw.
33. obes*.tw.
34. over-weight.tw.
35. cholesterol.tw.
36. (hdl or ldl).tw.
37. hyperlip*.tw.
38. lipid*.tw.
39. hyperglyc?em*.tw.
40. hypertens*.tw.
41. exp hyperinsulinism/
42. exp hyperlipidemia/
43. diabet*.tw.
44. or/13-43
45. 12 and 44
46. 6 or 45
47. random$.tw.
48. factorial$.tw.
49. crossover$.tw.
50. cross over$.tw.
51. cross-over$.tw.
52. placebo$.tw.
53. (doubl$ adj blind$).tw.
54. (singl$ adj blind$).tw.
55. assign$.tw.
56. allocat$.tw.
57. volunteer$.tw.
58. crossover procedure/
59. double blind procedure/
60. randomized controlled trial/
61. single blind procedure/
62. 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61
63. (animal/ or nonhuman/) not human/
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64. 62 not 63
65. 46 and 64
66. limit 65 to embase
CINAHL
S63 S44 AND S62
S62 S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR S55 OR S56 OR S57 OR S58 OR S59
OR S60 OR S61
S61 TX cross-over*
S60 TX crossover*
S59 TX volunteer*
S58 (MH “Crossover Design”)
S57 TX allocat*
S56 TX control*
S55 TX assign*
S54 TX placebo*
S53 (MH “Placebos”)
S52 TX random*
S51 TX (doubl* N1 mask*)
S50 TX (singl* N1 mask*)
S49 TX (doubl* N1 blind*)
S48 TX (singl* N1 blind*)
S47 TX (clinic* N1 trial?)
S46 PT clinical trial
S45 (MH “Clinical Trials+”)
S44 S6 OR S43
S43 S12 AND S42
S42 S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27
OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41
S41 TI diabet* or AB diabet*
S40 TI hypertens* or AB hypertens*
S39 TI hyperglycaem* or AB hyperglycaem*
S38 TI hyperglycem* or AB hyperglycem*
S37 TI lipid* or AB lipid*
S36 TI hyperlip* or AB hyperlip*
S35 (TI hdl or ldl) or (AB hdl or ldl)
S34 TI cholesterol or AB cholesterol
S33 TI obes* or AB obes*
S32 TI over-weight or AB over-weight
S31 TI overweight or AB overweight
S30 TI blood N2 pressure or AB blood N2 pressure
S29 TI cardio* N6 risk* or AB cardio* N6 risk*
S28 (MH “Hypertension”)
S27 TI glycaemic N3 control* or AB glycaemic N3 control*
S26 TI glycemic N3 control* or AB glycemic N3 control*
S25 TI insulin N2 sensitiv* or AB insulin N2 sensitiv*
S24 TI insulin N2 resist* or AB insulin N2 resist*
S23 (MH “Metabolic Diseases+”)
S22 (MH “Obesity”)
S21 (MH “Blood Pressure+”)
S20 (MH “Cholesterol”)
S19 TI cvd or AB cvd
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S18 TI angina* or AB angina*
S17 TI cardiovascular or AB cardiovascular
S16 TI chd or AB chd
S15 (TI coronary N2 disease*) or (AB coronary N2 disease*)
S14 (TI heart N2 disease*) or (AB heart N2 disease*)
S13 (MH “Cardiovascular Diseases+”)
S12 S7 OR S8 OR S9 OR S10 OR S11
S11 (MH “Glucans”)
S10 TI starch* or AB starch*
S9 TI carbohydrate* or AB carbohydrate*
S8 (MH “Carbohydrates”)
S7 (MH “Dietary Carbohydrates+”)
S6 S1 OR S2 OR S3 OR S4 OR S5
S5 TI glyc?emic N3 diet* or AB glyc?emic N3 diet*
S4 TI “glyc?emic indices” or AB “glyc?emic indices”
S3 TI “glyc?emic index” or AB “glyc?emic index”
S2 TI glyc?emic N3 low OR AB glyc?emic N3 low
S1 (MH “Glycemic Index”)
Search strategies previous version
CENTRAL
1. glyc?emic index.tw.
2. (glyc?emic adj3 low).tw.
3. (glyc?emic adj3 diet$).tw.
4. (carbohydrate$ adj25 diet$).ab,ti.
5. (starch$ adj25 diet$).ab,ti.
6. 1 or 2 or 3 or 4 or 5
7. coronary$.ab,ti.
8. cardiovascular$.ab,ti.
9. heart$.ab,ti.
10. chd.ab,ti.
11. angina.ab,ti.
12. cvd.ab,ti.
13. ischemic$.ab,ti.
14. myocardial$.ab,ti.
15. cardiac$.ab,ti.
16. lipid$.ab,ti.
17. cholesterol$.ab,ti.
18. blood pressure.ab,ti.
19. obes$.ab,ti.
20. diabet$.ab,ti.
21. glyc?emic.ab,ti.
22. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21
23. 6 and 22
24. random$.ab,ti.
25. compar$.ab,ti.
26. control$.ab,ti.
27. study.ab,ti.
28. follow$ up.ab,ti.
29. clinic$.ab,ti.
30. blind$.ab,ti.
31. double$.ab,ti.
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32. cross?over.ab,ti.
33. 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32
34. 23 and 33
MEDLINE
1. Glycemic Index/
2. (glyc?emic adj3 low).tw.
3. glyc?emic index.tw.
4. (glyc?emic adj3 diet$).tw.
5. 1 or 2 or 3 or 4
6. exp Dietary Carbohydrates/
7. CARBOHYDRATES/
8. carbohydrate$.tw.
9. starch*/
10. or/6-9
11. exp Coronary Disease/
12. Cardiovascular Diseases/
13. heart disease$.tw.
14. coronary disease$.tw.
15. chd.tw.
16. cardiovascular.tw.
17. angina.tw.
18. cvd.tw.
19. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
20. 10 and 19
21. 5 or 20
22. randomized controlled trial.pt.
23. controlled clinical trial.pt.
24. Randomized controlled trials/
25. random allocation.sh.
26. double blind method.sh.
27. single-blind method.sh.
28. 22 or 23 or 24 or 25 or 26 or 27
29. (animal not human).sh.
30. 28 not 29
31. clinical trial.pt.
32. exp Clinical Trials/
33. (clin$ adj25 trial$).ab,ti.
34. ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).ab,ti.
35. placebos.sh.
36. placebo$.ab,ti.
37. random$.ab,ti.
38. research design.sh.
39. 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38
40. 39 not 29
41. 40 not 30
42. comparative study.sh.
43. exp Evaluation Studies/
44. follow up studies.sh.
45. prospective studies.sh.
46. (control$ or prospectiv$ or volunteer$).ab,ti.
47. 42 or 43 or 44 or 45 or 46
48. 47 not 29
49. 48 not (30 or 41)
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50. 30 or 41 or 49
51. 21 and 50
Embase
1. (glyc?emic adj3 low).tw.
2. (glyc?emic adj3 diet$).tw.
3. glyc?emic index.tw,ti.
4. 1 or 2 or 3
5. exp Carbohydrate Diet/
6. Carbohydrate/
7. carbohydrate$.tw.
8. exp STARCH/
9. 5 or 6 or 7 or 8
10. exp Ischemic Heart Disease/
11. exp Coronary Artery Disease/
12. Cardiovascular Disease/
13. heart disease$.tw.
14. coronary disease$.tw.
15. chd.tw.
16. cardiovascular.tw.
17. angina.tw.
18. cvd.tw.
19. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
20. 9 and 19
21. 4 or 20
22. Controlled Study/
23. Clinical Trial/
24. random$.ab,ti.
25. compar$.ab,ti.
26. control$.ab,ti.
27. study.ab,ti.
28. follow$ up.ab,ti.
29. clinic$.ab,ti.
30. blind$.ab,ti.
31. Double Blind Procedure/
32. double$.ab,ti.
33. 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32
34. 21 and 33
CINAHL
1. exp Glycemic Index/
2. (glyc?emic adj3 low).tw.
3. glyc?emic index.tw.
4. (glyc?emic adj3 diet$).tw.
5. 1 or 2 or 3 or 4
6. exp Dietary Carbohydrates/
7. CARBOHYDRATES/
8. carbohydrate$.tw.
9. 6 or 7 or 8
10. exp Coronary Disease/
11. Cardiovascular Diseases/
12. heart disease$.tw.
13. chd.tw.
14. cardiovascular.tw.
15. angina.tw.
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16. cvd.tw.
17. 10 or 11 or 12 or 13 or 14 or 15 or 16
18. 9 and 17
19. 5 or 18
20. clinical trial.pt.
21. exp Clinical Trials/
22. (clin$ adj25 trial$).tw.
23. ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).tw.
24. PLACEBOS/
25. placebo$.tw.
26. random$.tw.
27. exp Evaluation Research/
28. exp Prospective Studies/
29. Random Assignment/
30. Random Sample/
31. Crossover Design/
32. Comparative Studies/
33. 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32
34. 19 and 33
Appendix 2. Checklist to aid consistency and reproducibility of GRADE assessments
Adverse events
Study limitations
(risk of bias)a
1. Was random sequence generation used (i.e.
no potential for selection bias)?
Unclear
2.Was allocation concealment used (i.e. no po-
tential for selection bias)?
Unclear
3. Was there blinding of participants and per-
sonnel (i.e. no potential for performance bias)?
N/A
4. Was there blinding of outcome assessment
(i.e. no potential for detection bias)?
Unclear
5. Was an objective outcome used? Unclear
6.Weremore than80%of participants enrolled
in trials included in the analysis (i.e. no poten-
tial reporting bias)?e
No ()
7. Were data reported consistently for the out-
come of interest (i.e. no potential selective re-
porting)?
No ()
8. No other biases reported (i.e. no potential of
other bias)?
No ()
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(Continued)
9. Did the trials end up as scheduled (i.e. not
stopped early)?
No
Inconsistencyb 1. Point estimates did not vary widely? N/A
2. Towhat extent did confidence intervals over-
lap (substantial: all confidence intervals overlap
at least one of the included studies point esti-
mate;
some: confidence intervals overlap but not all
overlap at least one point estimate; no: at least
one outlier: where the confidence interval of
some
of the studies do not overlap with those of most
included studies)?
N/A
3. Was the direction of effect consistent? Yes
4. What was the magnitude of statistical het-
erogeneity (as measured by I²) - low (I² < 40%)
, moderate (I² 40% to 60%), high I² > 60%)?
N/A
5. Was the test for heterogeneity statistically
significant (P < 0.1)?
N/A
Indirectnessa 1.Were the populations in included studies ap-
plicable to the decision context?
Yes
2. Were the interventions in the included stud-
ies applicable to the decision context?
Yes
3. Was the included outcome not a surrogate
outcome?
Yes
4. Was the outcome timeframe sufficient? Yes
5. Were the conclusions based on direct com-
parisons?
Yes
Imprecisionc 1. Was the confidence interval for the pooled
estimate not consistent with benefit?
N/A
2.What is themagnitude of themedian sample
size (high: 300 participants, intermediate: 100-
300 participants, low: < 100 participants)?e
low ()
3. What was the magnitude of the number of
included studies (large: > 10 studies, moderate:
5-10 studies, small: < 5 studies)?e
small ()
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(Continued)
4. Was the outcome a common event (e.g. oc-
curs more than 1/100)?
No
Publication biasd 1. Was a comprehensive search conducted? Yes
2. Was grey literature searched? No
3. Were no restrictions applied to study selec-
tion on the basis of language?
No
4. There was no industry influence on studies
included in the review?
Unclear
5. There was no evidence of funnel plot asym-
metry?
N/A
6. There was no discrepancy in findings be-
tween published and unpublished trials?
N/A
aQuestions on risk of bias are answered in relation to the majority of the aggregated evidence in the meta-analysis rather than to
individual trials.
bQuestions on inconsistency are primarily based on visual assessment of forest plots and the statistical quantification of heterogeneity
based on I2.
cWhen judging the width of the confidence interval, it is recommended to use a clinical decision threshold to assess whether the
imprecision is clinically meaningful.
dQuestions address comprehensiveness of the search strategy, industry influence, funnel plot asymmetry, and discrepancies between
published and unpublished trials.
eDepends on the context of the systematic review area.
(): key item for possible downgrading the quality of the evidence (GRADE) as shown in the footnotes of the ’Summary of finding’
table(s); GRADE: Grading of Recommendations Assessment, Development and Evaluation; N/A: not applicable
WH A T ’ S N E W
Date Event Description
4 July 2017 New citation required and conclusions have changed 18 new studies were added and in contrast to the last version,
no changes in lipid levels were found
31 July 2016 New search has been performed The review was updated and the inclusion criteria were ex-
panded to include all cardiovascular disease (CVD) and not
just coronary heart disease. As there are other Cochrane re-
views which examine the effect of low glycaemic index diets
in obesity and diabetes, studies were only included if they
reported blood lipids and/or blood pressure, and studies in
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(Continued)
participants with diabetes were excluded. Studies in healthy
participants were included to capture both primary and sec-
ondary prevention of CVD. As more trials are available now,
we have excluded short-term studies and included only those
of at least 12 weeks duration. This means that only three
RCTs of the previous version of the review were retained and
15 new trials were added. The updated search was done in
July 2016
H I S T O R Y
Date Event Description
8 April 2008 Amended Converted to new review format.
15 May 2006 New search has been performed The search was updated to July 2006. Six new studies were identified and added
to the review. There is no change to the conclusions of the review
C O N T R I B U T I O N S O F A U T H O R S
Update:
C Clar: study selection, data extraction, update of the review text and tables, data analyses and summaries.
L Al-Khudairy: study selection, data extraction, update of the review text and tables, data analyses.
E Loveman: data extraction, checking analyses, writing results text.
L Hartley: study selection.
S Kelly: study selection, data extraction.
R Germanò: study selection.
G Frost: conceived the original idea for the review, critically read the final draft.
K Rees: project management, arbitrator for study inclusions, checking data abstraction, checking completion of final review and
critically reading drafts.
Previous review version:
S Kelly: prepared and designed the protocol. Developed and ran the search strategy. Organised the retrieval of papers and screened
papers for inclusion and exclusion. Extracted data from papers that were included and took the primary role in writing the review. For
the update of the review, ran the search strategy, organised the retrieval of papers, screened papers for inclusion and exclusion, extracted
data from included papers and took the primary role in writing the review.
G Frost: conceived the review and obtained funding. Provided a methodological, policy and clinical perspective on the data.
C Summerbell: for the original review, screened papers for inclusion and exclusion and extracted data from papers that were included
in the review for the purpose of dual data collection. Provided a methodological, policy and clinical perspective on the data.
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V Whittaker: advised on meta-analysis and quality assessment of studies. For the update of the review, extracted data from papers and
advised on statistics and quality assessment of studies.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The inclusion criteria for this review were expanded to include all cardiovascular disease and not just coronary heart disease. As there
are other Cochrane reviews which examine the effect of low GI diets in obesity and diabetes, studies were only included if they reported
blood lipids or blood pressure or both, and studies in participants with diabetes were excluded. Studies in healthy participants were
included to capture both primary and secondary prevention of CVD. As more trials are available now, we have excluded short-term
studies and included only those of at least 12 weeks duration. Only adults (age 18 or older) were included.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Glycemic Index; Blood Glucose [metabolism]; Blood Pressure; Cardiovascular Diseases [metabolism; ∗prevention & control]; Dietary
Carbohydrates [administration & dosage; ∗metabolism]; Fasting [metabolism]; Lipids [blood]; Primary Prevention; Secondary Preven-
tion; Weight Loss
MeSH check words
Adult; Aged; Humans; Middle Aged
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